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1 Introduction and aim of the study 
 
The corpus luteum (CL) is a transient endocrine gland, which plays an essential role in the 
reproductive process of the bovine species. Its main function is to produce progesterone, 
a steroidal hormone, which is necessary for the establishment and maintenance of 
pregnancy. The development of the CL begins with the ovulation of a Graafian follicle. 
This happens normally every 21 days in the cow if no implantation of an embryo occurs. 
After ovulation an active endocrine gland is formed in best time to produce progesterone, 
which can reach more than 10 ng/ml in the blood plasma (Döcke 1994). During formation 
of the CL, 50% of the cells are mitotic, primary to form new blood vessels (angiogenesis), 
which are necessary to assure an optimal support of the steroidal cells. Some researchers 
compare the angiogenesis in the corpus luteum with angiogenesis in a malignant tumor, 
but even in a highly malignant and fast growing Glioblastoma multiforme only 9% of all 
cells are mitotic. In malignant mammary gland tumors or prostata carcinomas even only 
2%. During development the CL grows from 200 mg tissue to a several grams swaying 
endocrine gland with a diameter of 1-3 cm (Augustin and Kuhn 1999). The adult CL is 
highly vasculated und consists of 53% of endothelial cells. The steroidal cells represent 
with 19% (small luteal cells) and 4% (large luteal cells) only a small contingent of the 
cellular composition. The CL consists more than 17% of fibroblast and 7% of plasma cells, 
lymphocytes and leukocytes (McCracken et al. 1999). If no embryo gives a signal to 
maintain pregnancy the luteolytic PGF2α released from the uterus reaches the CL and 
luteolysis occurs. This happens through a counter-current mechanism from the vena uteri 
to the ateria ovarica, which supports the ovary. Within 24 hours after PGF2α induced 
luteolysis the blood plasma level of progesterone drops to basal values of under 1 ng/ml 
(Schallenberger et al. 1984). This decline of progesterone is characteristic for the so 
called functional luteolysis. After 2-3 days the corpus luteum has only half of its original 
volume and after a few weeks only a small, avascular scar remains (Augustin and Kuhn 
1999). These degeneration of the tissue is called structural luteolysis.  
The CL with its high rate of angiogenesis and its normally smooth degradation is an 
unique formation in the adult organism. The smooth process of CL development and 
degradation needs a fine balanced interaction between numerous endocrine and locally 
acting factors. At the endocrine level it is thought that luteolysis in the cow occurs as 
follows: Progesterone inhibits the PGF2α synthesis in the endometrium of the uterus. 
Through the decline of its progesterone sensitivity and the stimulation through oxytocin 
occurs an increased release of PGF2α in the endometrium. This leads to secretion of 
luteal oxytocin and PGF2α, which increases in turn  the endometrial production of PGF2α 
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inducing a positive feedback between CL and endometrium. If the concentration of PGF2α 
reaches a certain level, luteolysis occurs (Schams and Berisha 2002; Döcke 1994). The 
role and interaction of the locally acting factors are not totally known today. 
 
The maintenance of the CL function is dependent on the presence of an embryo that 
prevents the signal cascade released from the endometrium to induce luteolysis. To 
ensure the survival of the conceptus not only the secretion of progesterone from the CL is 
necessary, but although provision of an optimal environment and nutrition in the uterus. 
Up to 40% of the embryonic losses are estimated to occur between day 8 and day 17 of 
pregnancy (Thatcher et al. 1994). To improve embryo survival during this critical period 
before implantation (Rüsse and Sinowatz 1994c) a better knowledge of the uterus-
conceptus interaction is required.  
 
Aim of the study 
 
Control of the oestrous cycle in dairy cows plays a central role in herd management of 
dairy farms. A high gravidity rate and short calving intervals assure the profitability of 
these farms. The exact knowledge of the physiological processes during oestrous cycle 
and gravidity is required to understand and treat pathological events correctly. The 
investigation of factors, which are necessary during luteolysis, can furthermore lead to 
more knowledge about fundamental processes during wound healing and tumor 
regression. 
The aim of the first part of this study was to develop a method for the investigation of 
different factors in the uterus milk during preimplantion in cattle. Therefore uterus fluid was 
gained from pregnant heifers using an in vivo uterus flushing technic at specific time 
points. The samples were analysed with enzyme immunoassay (EIA) and 
radioimmunoassay (RIA). 
The aim of the second part was to investigate if extracellular matrix (ECM) degradation 
and apoptosis occurs in the CL during oestrous cycle and induced luteolysis. Therefore 
the mRNA expression of different ECM proteases were evluated in follicles 20 hours after 
GnRH (Gonadotropin realising hormone) injection (shortly before ovulation) for 
comparable reasons and in the CL during oestrous cycle and induced luteolysis. 
Furthermore the mRNA expression of apoptotic and anti-apoptotic factors were evaluated 
in the CL during oestrous cycle and induced luteolysis. 
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2 Literature 
 
2.1 Regulation of the oestrous cycle in cattle 
2.1.1 Folliculogenesis 
In female mammalia the complete number of oocytes is already present at the time of 
birth in the ovaries. ‘Follicle’ describes the structural and functional unit of oocyte and 
follicle-epithel, less than 1% of them will ever reach ovulation. All other follicles go 
through atresia and degeneration at all stages of development. Until its ovulation, the 
oocyte is arrested in the prophase of its first meiotic division. Depending on the size of 
the oocyte and the development of the follicle-ephitel, different stages of the follicle are 
distinguished: In the primordial follicle, the oocyte with a diameter of approximately 30µm 
is embedded in a single layer of flat epithelial cells (Epithelium folliculare). Before 
puberty, the cells of some follicles generate small primary follicles. Here, the oocyte is 
surrounded by a single layer of cubic epithelial cells and the zona pellucida. This 
glycoprotein barrier allows only a single, artspecific sperm to fertilise the oocyte. The 
secondary follicle shows an enlarged volume with a diameter of approximately 50-100µm. 
Within this stage, the follicle ephitel grows and forms several layers, furthermore, stroma 
cells differentiate into the theka follicularis. A tertiary follicle is characterised through the 
development of the antrum folliculare, a liquid filled cavity. In this stage, the oocyte 
reaches its maximum diameter of approximately 150µm. The follicle epithel differentiates 
into the granulosa cell layer and the cumulus oophorus, both have nourishment- and 
control functions. Final stage of the follicular development is reached with the Graafian 
follicle: in this mature, praeovulatory follicle with a diameter up to 2cm, the oocyte loses 
its conection to the follicle layer and moves freely in the liquor folliculi. The oocyte 
finishes the first meiotic division, in which the genetic material is equally distributed 
among two nuclei. However the cytoplasma is not divided equally, after a second meiosis 
only one oocyte is able to get fertilised (Rüsse and Sinowatz 1994a). 
 
2.1.2 Regulation of the oestrous cycle 
Each bovine oestrous cycle (with a duration of about 21 days, fig.1) shows mostly three 
follicular waves (Evans and Fortune 1997). Each wave contains the recruitement of a 
follicle cohort and the selection of one dominant follicle which continues growing whereas 
all others go through atresia (Stock and Fortune 1993). Dominant follicles control the 
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development of other follicles through hormones (like oestradiol, inhibin), which act locally 
as well as systemic (Savio et al. 1993). Follicle growth is promoted by two types of 
gonadotropins, which are secreted from the anterior pituitary as a reaction to pulsatile 
GnRH release from the hypothalamus (Roche 1996). These two types are the follicle 
stimulating hormon (FSH) and the luteinizing hormon (LH), both of them sequestered 
within the whole oestrous cycle. Naturally only the dominant follicle of the last wave 
comes to ovulation (Ginther et al. 1989). Ovulation of the Graafian follicle is the release of 
the oocyte. In this inflammation like process, the follicle liquid rinses the oocyte as well as 
the zona pellucida and the cumulus oophorus into the oviduct. Compulsory for this impact 
is the LH peak, which arises through an increase of frequency and amplitude of the LH 
pulses (Piquette et al. 1991) triggerd by the pulsatile release of oestradiol-17β. 
 
 
 
Figure 1: Hormon profiles, development and regression of the corpus luteum during the oestrous 
cycle of cattle (Intervet modified). 
 
2.1.3 Corpus luteum (CL) formation, function and regression (luteolysis) 
The above mentioned LH peak is also responsible for the formation of a temporary 
endocrine gland, the CL, which is built from the remaining granulosa- and theka interna 
cells after ovulation. This formation starts with the folding of the granulosa cell layer, its 
infiltration by theka cells and its vascularisation. During this process, also a variety of 
Days of oestrous cycle 
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other cell types, such as pericytes, fibroblasts and macrophages enter the granulosa. The 
rapid angiogenesis in the early CL development provides a tense capillary network. 
Parallel occurs the luteinisation of the theka and granulosa cells, which is marked through 
the inclusion of lipochroms and an increase in volume and synthesis rate. Cells of the 
follicle granulosa tissue develop into large luteal cells, while former theca cells become 
small luteal cells. This cubic cells synthesize steroid hormons, mostly progesterone. 
Progesterone is categorised into the group of gestagens, its main formation takes place in 
the CL. The preparation of the uterus mucosa for the implantation of the embryo as well 
as the maintenance of gravidity are the main functions of progesterone (Hesch 1989). 
Progesterone has a gonadotropin inhibiting effect, more precisely it decreases the pulse 
frequency. Thus, its inhibiting function aims at the LH peak (Döcke 1994), which means 
that ovulation only can take place in the absence of a CL and progesterone secretion. 
Small luteal cells produce less progesterone, but are present in greater numbers than 
large luteal cells.  
If no fertilisation takes place, it is essential for the introduction of a new oestrous cycle, 
that the CL regresses. Thus, the uterus releases prostaglandin F2α (PGF2α) around day 
16. PGF2α was discovered as a physiological luteolysin nearly three decades ago, cellular 
events associated with luteolysis however remained poorly characterised. PGF2α interacts 
with its G protein-coupled receptor, present predominantly on large luteal cells, but also 
present on small luteal and endothelial cells of the CL (McCracken et al. 1999) and 
activates Gq/phospholipase C/protein kinase C pathway (McGuire et al. 1994) resulting in 
decreased steroidgenesis. The intracellular signalling events that lead to structural 
regression of luteal tissue are poorly characterised. However, proteases (Curry and 
Osteen 2003; Liu et al. 1997) and programmed cell death seem to play central roles in 
development and regression of the CL in several species (Bacci et al. 1996; Yadav et al. 
2002). 
 
2.2 Early pregnancy in cattle 
After fertilisation of an oozyte the development of an embryo begins. The first three 
divisions of the zygote take place in the oviduct. The conceptus reaches the 8-cell stage 
after 65 to 72 hours and can be found in the apex of the ipsilateral uterus horn after 4-5 
days as a morula. It is transported from the apex to the place of implantation, which is 
mostly found in the middle of the ipsilateral horn. A migration to the contralateral horn is 
seldom (Rüsse and Sinowatz 1994b). On day 8 the early blastocyst stage is reached and 
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the embryo is divided into an “inner cell mass”, also known as embryoblast, and the 
trophoblast. After nine days the blastocyst emerges the zona pellucida and the 
differentiation of the ecto- and endoderm follows. The beginning of the elongation stages 
is reached at day 13. From this time on, the conceptus elongates till it reaches the 
contralateral uterus horn at day 18-19, which is filled out at day 22. The conceptus has no 
contact to the endometrium during the preimplantation period before day 18-19. It floats 
freely in the uterus lumen being nourished only by the so called uterus milk, which is 
secreted by the endometrium (Guillomot 1995). This uterus milk is found abundantly in the 
uterus lumen from the early blastocyst stage till day 24 of gravidity (Chang 1952). Bartol et 
al. (1981) were able to detect 18 different proteins in intrauterine fluid at day 19 of 
gravidity, four of them could not be found in cycling cows during different cycling stages. 
Some of these proteins have been already characterised like retinol-binding-protein 
(MacKenzie et al. 1997), granulocyte-macrophage-colony-stimulating factor (Emond et al. 
2000), bovine granulocyte-chemotactic-protein-2 (Teixeira et al. 1997), bovine Ubiquitin 
cross-reacting protein (Austin et al. 1996), insulin-like growth factor-binding proteins 
(Keller et al. 1998) and PGF (Bartol et al. 1981). It seems possible, that the maternal 
environment given through the uterine secretion plays an essential role in the survival rate 
of blastocysts and early concepti till day 16 of gravidity (Keller et al. 1998).  
 
2.3 Endocrine regulatory factors 
2.3.1 Progesterone  
Progesterone is mainly produced through the CL in cattle and functions as a signal for the 
uterine mucosa to be prepared for the implantation of an embryo. It is also necessary for 
the maintenance of gravidity (Hesch 1989). Progesterone inhibits the action of 
gonadotropins through a down-regulation of the pulse frequence. In this kind of way 
(negative feedback) a blocking of the LH peak occurs. A Graafian follicle can only ovulate, 
when there is no progersterone secreting CL present (Döcke 1994).  
 
2.3.2 Oestradiol-17β 
The most important oestrogen, oestradiol-17β is mainly produced in follicles of the 
ovaries. Its synthesis is stimulated by FSH, which is released from the adenohypophysis. 
Oestradiol-17β itself acts in a negative feedback mechanism on the secretion of FSH. 
Granulosa cells of the follicles receive androgens, which are produced in theca interna 
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cells, and transform them into oestrogens with the help of aromatases. These enzymes 
produce the biological effective forms of oestrogens together with cytochrom P450, 
NADPH (nicotinamid-adenosine-dinucleotid-phosphat-hydrogen) and oxygen. The high 
preovulatory synthesis of oestrogens by the ovulatory follicle triggers the LH peak. 
Oestrogens cause also a proliferation of the uterine mucosa (Döcke 1994). Oestradiol-17β 
is not only produced in follicles, but also in 13 days old bovine embryos (Chenault 1980). 
 
2.3.3 Prostaglandin F2α (PGF2α) 
The regression of the CL, if no fertilisation occured, is essential for the beginning of a new 
oestrous cycle. The luteolytic agent in cattle is PGF2α, which is secreted in a pulsatile 
manner by the endometrium. Progesterone and oestradiol-17β are responsible for the 
initiation of the PGF2α release, whereas progesterone acts as inhibitor and oestradiol as 
promotor (Meyer et al. 1988). PGF2α is inhibited during the luteal phase. At the start of 
luteolysis the secreted oestradiol promotes a rapid distribution of PGF2α (Döcke 1994). 
Also oxytocin stimulates its secretion. The endometrial PGF2α and the luteal oxytocin are 
connected by a positive feedback mechanism. The receptor of oxytocin is in turn affected 
by progesterone and oestradiol (Schams et al. 1985). Endothelin-1 seems also important, 
because it shows a suppression of the oxytocin effect and progesterone production in 
microdialysis experiments (Miyamoto et al. 1997). PGF2α is not only secreted by the 
endometrium at time of luteolysis, but also by bovine blastocyst from day 13 of gravidity 
on. The prostaglandin production rises each day of gravidity, whereas the blastocysts in 
vitro secrete much more PGF2α then PGE2 (Shemesh et al. 1979). Co-incubation with 
tissue from the endometrium changes the secretion pattern to more PGE2 than PGF2α 
(Lewis and Waterman 1983). PGE2 is able to act as a luteotropic agent during early 
pregnancy and can enhance the progesterone production in luteal tissue (Bazer et al. 
1991; Godkin et al. 1977). 
 
2.4 Locally produced factors 
2.4.1 Vascular endothelial growth factors (VEGFs) 
VEGFs are glycoproteins which induce angiogenesis. They are a potent mitogens for 
endothelial cells (Ferrara and Henzel 1989) and enhance the vascular permeability 
(Senger et al. 1986). VEGF-A is a homodimeric heparin binding glycoprotein of 46-48 
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kDa. Several additional members of the VEGF gene familiy have been identified, including 
VEGF-B, VEGF-C, Placenta growth factor and VEGF-D (Garrido et al. 1993, Ferrara 
2001). The human VEGF gene has a length of approximately 12 kb and is composed of 
eight exons, separated by seven introns. Alternative exon splicing of a single VEGF gene 
results in the generation of four different molecular species, having respectively 121, 165, 
189 and 206 amino acids after signal sequence cleavage (VEGF121, VEGF165, VEGF189, 
VEGF206). The bovine VEGF is one amino acid shorter then the human factor. VEGF121 is 
a soluble secreted form, VEGF165 is the most common molecular form produced by a 
variety of normal and transformed cells. In contrast, VEGF206 is a very rare form (Houck et 
al. 1991). The different isoforms of VEGF have different properties in vitro and this may 
apply also to their in vivo functions. VEGF binds on two tyrosinkinase receptors: VEGF-R1 
(= flt-1, fms-like-tyrosine kinase-1) and VEGF-R2 (= flk-1, fetal liver kinase-1), whereas 
the affinity of VEGF-R2 to VEGF is a bit lower than of VEGF-R1. Both receptors are 
localised on endothelial cells (Jakeman et al. 1992). The major regulator of VEGF is the 
oxygen content of the tissue. Hypoxia induces the expression of VEGF and its receptors. 
Further stimulating factors are: LH, IGF-1 (insulin-like growth factor-1), EGF (epidermal 
growth factor), TGF-β (transforming growth factor β), TNF-α (tumor necrosis factor α), IL-1 
(interleukin-1) and IL-6 (interleukin-6) (Ferrara and Davis-Smyth 1997; Schams et al. 
2001). High permeability, uterine oedema and angiogenesis occurs during implantation of 
rabbit embryos. VEGF seems to be critical for a successful implantation in rodents, 
because it was prevented by inhibition of VEGF (Rabbani and Rogers 2001). Although 
VEGF and its receptors have been implicated as key players in vascular remodeling and 
placentation in women (Ahmed et al. 1995), sheep (Bogic et al. 2001), pigs (Winther et al. 
1999) and marmosets (Wulff et al. 2002). 
 
2.4.2 Housekeeping Genes 
Housekeeping genes (HKG) are genes, which are permanently expressed on the same 
level to keep cell functions sustainable and to assure the survival of the cell. It is assumed 
that mRNA from HKG is expressed in excess, so that the cells are able to compensate for 
ineffective posttranscriptional, translational or posttranslational processes (Warrington et 
al. 2000). Quantitative gene expression is typically referenced to an internal control for 
compensation of fluctuations in the used mRNA amount and quality, which can occur 
because of discrepancies in the RNA extraction efficiency or through extraction of RNA 
from different individuals. Interpretation failures should be avoided by elimination of 
unspecific variations. Ideally the experimental conditions have no influence on the 
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expression of HKG (Bustin 2000). There is a general consensus, that one HKG as control 
gene is enough for the normalisation of expression data. GAPDH (Glyceraldehyd-3-
phophat-Dehydrogenase), β-Actin, 18S rRNA and 28S rRNA are most often used as HKG 
(Suzuki et al. 2000). But there are physiological situations existing, where even the 
expression of HKG show strong variations. Therefore not only one HKG, but the mean 
value of serveral carefully selected HKG should be used for normalisation (Vandesompele 
et al. 2002). There are numerous references existing, that also HKG can be regulated 
(Bustin 2000; Suzuki et al. 2000, Thellin et al. 1999). The mRNA expression of GAPDH, 
an enzyme of the glycolysis and gluconeogenesis, is massivley regulated by the following 
effects: different cell cycle stages, gravidity, dexamethason, glucose, insulin, growth 
hormons, oxidativ stress, hypoxia, apoptosis etc. β-Actin is a structural protein of the 
cytoskeleton and its mRNA expression can be influenced by hypoxia, ionising radiation, 
different growth factors, adrenocorticotropin or gonadotropin (Bustin 2000; Suzuki et al. 
2000). Ubiquitin is used for the degradation of proteins and is 2-fold increased during 
DCNP (2,6-dichloro-4-nitrophenol) induced apoptosis in human Chang liver cells (Qi and 
Sit 2000a). An up-regulation of Ubiquitin is also seen in PGF2α induced luteolysis in 
primates, when signs of apoptosis are recognisable (Young et al. 1998). Histones are 
abundant, basic proteins, that bind to the DNA to form nucleosomes (Zong 2004). They 
compromise the protein portion of the nucleosoms, which function to compact the DNA 
into chromatin and to help regulate its activities (Sedelnikova et al. 2003). Several Histone 
variants have been found to regulate gene expression and even acting as apoptotic 
factors (Pusarla and Bhargava 2005).  
 
2.4.3 Extracellular matrix proteases 
2.4.3.1 General aspects 
The life cycle of the CL involves several strictly regulated proteolytic processes that take 
place within the same CL during a relatively short period of time, including angiogenesis, 
tissue remodeling (Smith et al. 1994b) and tissue degradation (Kiya et al. 1999). The CL 
therefore provides a useful model to study the regulation and functional roles of matrix 
remodeling proteases in vivo. In other species like human (Duncan et al. 1998), rat 
(Nothnick et al. 1996), mouse (Liu et al. 2003), porcine (Pitzel et al. 2000), ovine (Ricke et 
al. 2002a; Towle et al. 2002) and in the bovine species (Zhang et al. 2002; Smith et al. 
1996; Goldberg et al. 1996; Juengel et al. 1994) the matrix metalloproteases (MMPs), 
their tissue inhibitors (TIMPs) and the plasminogen activator system seem to play a critical 
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role in development and regression of the CL. Our request was therefore to investigate 
these factors at well defined time points in follicles during 20 hours after GnRH application 
and in the CL during oestrous cycle and induced luteolysis.  
2.4.3.2 Matrix metalloproteases (MMPs) 
Degradation of specific extracellular matrix (ECM) components occurs by the action of 
MMPs, which belong to a large family with at least 25 related proteolytic enzymes 
(Woessner 2002). They are classified on their substrate specificity as collagenases, 
stromelysins, gelatinases, membran-type MMPs (MT-MMPs) and other MMPs (Kuzuya 
and Iguchi 2003). All MMPs share certain common features like being zinc- and calcium-
dependent endopeptidases (Visse and Nagase 2003), which are synthesised as 
preproenzymes and secreted in an inactive form into the extracellular space (Nagase 
1997). Except of MMP-11 and MMP-14 (MT1-MMP), which are activated prior to secretion 
by furin-like proteases (Kuzuya and Iguchi 2003), MMPs are activated in vivo by serine 
proteases like plasminogen activator (Nagase 1997), mast cell proteases (Suzuki et al. 
1995), and other MMPs (Sato et al. 1994). Also non-proteolytic agents as SH – reactive 
agents, reactive oxygen and denaturants are activators of MMPs. For activation  the 
prodomain of the MMPs has to be removed (Kuzuya and Iguchi 2003).  
A different kind of activation occurs to MMP-2. It takes place on the cell surface by 
mediation of the membrane-type MMPs like MMP-14, which functions as receptor for 
MMP-2, and by the interaction with TIMP-2, which belongs to the family of tissue inhibitors 
of metalloproteases (Strongin et al. 1995; Butler et al. 1998; Wang et al. 2000). By binding 
to the hemopexin region of proMMP-2 TIMP-2 forms a tight complex and connects to 
MMP-14 on the cell surface. The now surface - bound - proMMP-2 is then activated by a 
MMP-14, which is free of TIMP-2. An absence or even a high concentration of TIMP-2 can 
decrease MMP-2 activation (Strongin et al. 1995). Degradation of the ECM by MMPs is 
required in endothelial cell migration, organization and, hence, angiogenesis (McCawley 
and Matrisian 2000). All these processes occur during development of the CL, while 
during luteolysis degradation of the different collagen components is necessary to enable 
the rapid regression of the CL.  
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Table 1: Members of the matrix metalloprotease family 
 
2.4.3.3 Tissue inhibitors of metalloproteases (TIMPs) 
Activity of MMPs is strictly regulated in the extracellular environment by the family of 
tissue inhibitors of metalloproteases (TIMPs). These family of small proteins (21-30 kDa) 
contains four members, TIMP-1, TIMP-2, TIMP-3 and TIMP-4. For inhibiting active MMPs 
they form non-covalent complexes by binding to the active site of the catalytic domain of 
the MMPs. These happens in a 1:1 stechiometric ratio. TIMPs act selectively on different 
MMPs. For example, TIMP-2 has a high affinity for MMP-2, whereas TIMP-1 preferentially 
binds to MMP-9. It is reported that TIMPs not only regulate the action of MMPs, but also 
promote embryo growth (Satoh et al. 1994), act as antiangiogenic agents (Murphy et al. 
1993), stimulate cell growth (Hayakawa et al. 1994), influence apoptosis (Talhouk et al. 
1992) and recruit quiescent cells into the cell cycle (Wick et al. 1994).  
 
Subdivision MMP ECM Substrate
Collagenases MMP-1 Type I, II, III, VII, X collagen, gelatin
MMP-8 Fibrillar Collagen
MMP-13 Fibrillar Collagen
MMP-18 Fibrillar Collagen
Gelantinases MMP-2 Type I, IV, V u. fibrillar collagen; gelatin
MMP-9 Type IV, V collagen, gelatin
Stromelysins MMP-3 Laminin, fibronectin, non-fibrillar collagens
MMP-10 Laminin, fibronectin, non-fibrillar collagens
MMP-11 Laminin, fibronectin, non-fibrillar collagens
Membran-type MMPS MMP-14 Gelatinase A, fibrillar collagens, Proteoglycans
MMP-15 Gelatinase A 
MMP-16 Gelatinase A 
MMP-17
MMP-24
MMP-25
Other MMPs MMP-7 Laminin, fibronectin, non-fibrillar collagens
MMP-12 Collagen type I, IV, elastin, fibronectin, gelatin, laminin
MMP-19 Aggrecan, type VI collagen, laminin, fibronectin
MMP-20
MMP-26 Fibronectin, gelatin
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2.4.3.4 Plasminogen activator (PA) system 
Also an important role in degradation of the ovarian ECM plays the plasminogen activator 
(PA) system (Smith et al. 1999). It consists of plasminogen, the inactive form of plasmin, 
tissue and urokinase plasminogen activator (tPA, uPA), the uPA-receptor (uPAR) and two 
plasminogen activator inhibitors (PAI-1, PAI-2). tPA and uPA transform plasminogen into 
its active form plasmin in the extracellular space (Luck 1994). uPA is able to bind on its 
cell surface receptor (uPAR) for building a stable complex. Its purpose is thought to focus 
the plasmin activity at the cell surface. Plasmin is not only able to degenerate specific 
ECM components like types III and IV collagen, fibronectin, laminin and proteoglycans 
(Roldan et al. 1990; Barnathan et al. 1990), but also activates proenzyme forms of MMP-
1, MMP-2 (Monea et al. 2002) MMP-3 and MMP-9 (DeClerck and Laug 1996; Lijnen et al. 
1998; Makowski and Ramsby 1998; Murphy et al. 1999). Working hand in hand together 
the MMPs and the plasminogen activator system are able to degrade all ECM 
components in the ovary (Dow et al. 2002).  
 
2.4.3.5 Monocyte chemoattractant protein-1 (MCP-1) 
MCP-1 is a member of the intecrine β family of cytokines. The cytokines in this group are 
thought to be involved in inflammation and tissue repair (Oppenheim et al. 1991). MCP-1 
has a potent chemoattractant effect on monocytes and CD4+ and CD8+ T lymphocytes. 
MCP-1 is produced by a variety of cells types including endothelial cells, fibroblasts, 
monocytes and T lymphocytes. MCP-1 binds to two receptors, CCR-2 and CCR-4, 
sharing these receptors with other cytokines of its family (Penny 2000). Results of recent 
studies indicate that MCP-1 is produced in the CL during luteal regression and might aid 
in its destruction (Penny et al. 1998; Townson et al. 1996; Townson et al. 2002; Bowen et 
al. 1996; Tsai et al. 1997). MCP-1 is of particular interest because, once expressed within 
blood vessels, this chemokine facilitates the attachment and migration of immune cells, 
especially monocytes, macrophages and T lymphocytes, from the blood stream into sites 
of inflammation (Mukaida et al. 1992). In this regard, macrophages and T lymphocytes 
have been demonstrated to accumulate in regressing CL of many species (Penny et al. 
1999; Townson et al. 2002; Townson et al. 1996; Hehnke et al. 1994) and have been 
implicated in phagocytosis of luteal cells (Paavola 1979), degradation of ECM (Endo et al. 
1993) and secretion of proinflammatory mediators that influence luteal steroidogenesis 
(Benyo and Pate 1992; Rueda et al. 2000b). 
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2.4.4 Apoptosis  
2.4.4.1 General aspects 
Apoptosis or programmed cell death is a evolutionary highly conserved mechanism, that 
allows the organism to tightly control cell numbers, tissue size and protect itself from 
dangerous cells that threaten homeostasis. It is regulated by proteins of the organism 
that form an intrinsic and extrinsic signaling cascade. The intrinsic apoptotic signaling 
cascade is generally thought to be activated by apoptotic stimuli that are caused within a 
cell in response to certain drugs, radiation or growth factor withdrawal and primarily lead 
to changes in mitochondrial permeability through alterations in the ratio of pro-apoptotic to 
anti-apoptotic Bcl-2 family members (Adams and Cory 1998). The extrinsic apoptotic 
signaling cascade on the other hand is activated by extracellular signals like TNFα or 
Fas-Ligand that interact with cell surface receptors to start cell death (Nagata 1997). All 
these signals activate a cascade of intracellular proteases known as caspases (fig. 2). 
Once activated, caspases cleave various cellular substrates including actin, poly(ADP-
ribose) polymerase (PARP), DFF45/inhibitor of caspase-activated DNase (ICAD), fodrin, 
and lamin which contribute to the morphological changes typically for apoptotic cells 
(Martin and Green 1995). The final cellular event during apoptosis is reached with the 
fragmentation of DNA. This is mediated by a huge variety of endonucleases such as 
DFF40/caspase-activated DNase (CAD), Nuc70 etc (Yadav et al. 2005). 
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Figure 2: Apoptotic pathways (Cell Signaling Technologies 2005/2006) 
 
2.4.4.2 Extrinsic pathway 
2.4.4.2.1 Tumor necrosis factor family (TNFα, TNFR1, TNFR2) 
TNFα is a nonglycosylated protein with 17kDa of molecular mass, which belongs to the 
family of cytokines. TNFα has first been described as a tumoricidal factor, which is 
produced by activated macrophages. Nowadays it is known, that besides macrophages 
also granulosa cells (Zolti et al. 1990) and luteal cells (Hehnke-Vagnoni et al. 1995) are 
candidates which express TNFα within the ovary. In rats (Brannstrom et al. 1994a) and 
cows (Skarzynski et al. 2000) it is shown, that macrophages are attracted to and infiltrate 
the CL during luteolysis. This accumulation of macrophages in the regressing CL is 
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believed to be in response to a chemotactic factor. A likely candidate for this is monocyte 
chemoattractant protein-1 (MCP-1), its expression has been demonstrated to be 
regulated by local growth factors and cytokines such as TNFα (Kayisli et al. 2002). 
Various researches verify that TNFα stimulates prostaglandin synthesis by luteal cells, 
and that it furthermore inhibits gonadotropin supported progesterone production in bovine 
luteal cells (Benyo and Pate 1992). This is supported through further studies proving that 
locally expressed cytokines such as TNFα induce follicular atresia and CL apoptosis 
(Friedman et al. 2000). TNFα is able to bind to two different TNF-receptors (TNFR1, 
TNFR2), which are expressed on microvascular endothelial cells in the CL (Okuda et al. 
1999). TNFR1 mRNA is expressed on bovine luteal and endothelial cells and is 
responsible for TNFα induced apoptosis during structural luteolysis via the extrinsic 
pathway mediated by TNFR1 (fig. 2), which mainly effects the endothelial cells (Friedman 
et al. 2000). There is a controverse discussion about the action of TNFR2 in concern to 
trigger or inhibit apoptosis. Some groups report that TNFα is not only able to induce 
apoptotic cell death, but can also induce cell proliferation by binding to TNFR2. This 
receptor can induce gene transcription for cell survival, growth and differentiation, and 
therefore TNFR2 is involved in an anti-apoptotic effect of TNFα (Inoue et al. 2000; Wajant 
and Scheurich 2001; Stanger et al. 1995; Shu et al. 1996). On the other hand TNFR2 is 
able to bind the TNF receptor-associated factor 2 (TRAF2), which is a necessary factor 
for the activation of the anti-apoptotic NFκB pathway by TNFR1. Depending if TNFR1 is 
costimulated with TNFR2 or not, apoptosis occurs or not (Fotin-Mleczek et al. 2002) (fig. 
3).  
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Figure 3: Model of the apoptotic TNFR1 / TNFR2 crosstalk. A) Exclusive stimulation of TNFR1. B) 
Prestimulation of TNFR2. C) Costimulation of both TNF receptors. (Fotin-Mleczek et al. 2002) 
 
2.4.4.2.2  Fas and Fas-Ligand (FasL) 
The Fas antigen (also known as APO-1 or CD95) is a transmembrane glycoprotein of 48 
kDa and encodes a cysteine-rich transmembrane protein of 335 amino acids. It is a 
member of the TNF family of cell surface receptors (Nagata and Golstein 1995), which 
also includes other receptors like TNFR1 and TNFR2, death receptor-3, two receptors for 
the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and many more. Fas 
is expressed on the cell surface in various tissues like heart and kidney, furthermore on 
thymocytes and activated T cells (Nagata, 1999). Fas-Ligand (FasL) is a cytokine that 
belongs to the TNF family (Suda et al. 1993). FasL is predominantly expressed in 
activated T lymphocytes and natural killer cells. It is a type II membrane protein with an 
extracellular region of about 150 amino acids and an cytoplasmic region of 77 amino 
acids. Induced expression of the FasL gene occurs through the binding of NFκB to the 5’ 
flanking region of the FasL gene, stresses as UV radiation or gamma-irradiation also 
show the same effect. Itoh et al. (1991) showed that binding of FasL to Fas induces 
apoptosis in Fas bearing cells. TNF, the prototype of the TNF family has two different 
receptors TNFR1 and TNFR2, especially the interaction of TNFR1 and TNF mediates 
apoptosis. Fas and TNFR1 share a homologous domain in their cytoplasmic domain and 
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mutational analysis indicated that this domain is necessary to transduce the apoptotic 
signal. Thus, this domain has been designated a death domain (Nagata, 1999). Fas and 
TNFR1 must be oligomerized to be activated, and since x-ray diffraction analysis showed 
that TNF induces trimerization of its receptor, the similarity to the structure of FasL 
suggests that FasL also induces trimerization of Fas. The trimerized cytoplasmic region 
then has the ability to transduce the apoptotic signal via the recrutation of FADD (FAS-
associated protein with death domain) and the following binding of caspase8. The 
activation of caspase8 and the further extrinsic pathways is already described above. 
 
2.4.4.3 Intrinsic pathway 
2.4.4.3.1 Tumor suppressor p53 
The tumor suppressor p53 is often described as a “guardian of the genome”, because it is 
a critical component of cellular mechanisms that respond to genotoxic stresses like DNA 
damage, hypoxia etc. to maintain the genomic integrity in part by arresting the cell cycle 
progression or by inducing apoptosis. p53 is a short-lived protein with a half life of about 
20 minutes that is maintained at very low or undetectable levels under normal 
circumstances. Under exposure of stressful stimuli, p53 is activated through post-
translational modifications that increase its stability and activity (Levine 1997). The human 
p53 protein contains 393 amino acids and has been divided structurally and functionally 
into four domains: an acidic amino-terminal domain, which is required for transcriptional 
activation; a central core sequence-specific DNA-binding domain; a tetramerization 
domain and a C-terminal regulatory domain (Somasundaram 2000). p53 can alter the 
transcriptional activity of genes associated with cell death. It was found that p53 increases 
the expression of Bax, an apoptotic factor of the internal pathway, and by the other hand 
decreases the Bcl-2 expression, which is a anti-apoptotic factor that inhibits the action of 
Bax (Miyashita et al. 1994; Miyashita and Reed 1995). It is also reported that p53 is able 
to activate Fas, which belongs to the extrinsic pathway (Kobayashi et al. 1998). p53 
expression occurs in apoptotic granulosa cells of atretic rat follicles (Tilly et al. 1995) and 
is also induced by reactive oxygen species (ROS) in bovine luteal cells (Nakamura and 
Sakamoto 2001). 
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2.4.4.3.2 Bax and Bcl-XL 
The intrinsic pathway is used extensively in response to internal insults such as DNA 
damage (Rich et al. 2000). The diverse response pathways affect the mitochondria 
through the activation of a set of apoptotic regulators, the Bcl-2 family. This family is 
divided into three groups, based on structural similarities and functional criteria. Some 
molecules like Bcl-2 and Bcl-XL are attached to the mitochondria-membrane, others can 
shuttle between the cytosol and organelles (Gross et al. 1999). Members of group I (like 
Bcl-2, Bcl-XL) posses anti-apoptotic activity, whereas group II (Bax, Bak) and group III 
(Bid, Bik) members promote cell death. The Bax protein was originally identified via its 
ability to interact with Bcl-2 in cells. Bcl-X is a unique gene among the other members of 
this family as it produces both positive (“short” isoform, death inducer) and negative 
(“long” isoform, death suppressor) regulators of the cell death pathway (Goodman et al. 
1998). Bcl-2 members control cell death through their ability to form heterodimers from 
pro- and anti-apoptotic molecules. Thus, heterodimerization can be thought as resulting 
in neutralization of these proteins. This leads to the point, that overall levels of pro-and 
anti-apoptotic factors have to be compared in order to estimate whether cells are 
sensitive to death or resistant (Hengartner 2000). How the increase in the expression 
levels of Bcl-2 members is achieved has not been fully investigated yet, but it is obvious, 
that p53 plays a significant role (Miyashita and Reed 1995). The key function of Bcl-2 
family however is to regulate the release of pro-apoptotic factors from the mitochondrial 
intermembrane compartment into the cytosol (Adams and Cory 1998). The most 
prominent factor among these is cytochrome c, an electron carrier. This protein is one of 
the components required for the activation of caspase9 in the cytosol. Unlike other 
caspases, proteolytic processing of procaspase9 has only a minor effect on its activity. 
The urgent requirement for the activation of caspase9 is its association with the adaptor 
protein Apaf-1 (Li et al. 1997). Apaf-1 thus is nowadays believed as an essential 
regulatory subunit of a caspase9 holoenzyme, the so called apoptosome. Heat shock 
proteins act as multiple steps in the pathway to regulate apoptosis (Xanthoudakis and 
Nicholson 2000). The extrinsic and intrinsic pathway then converge at the level of 
caspase3 activation (fig. 2).  
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2.4.4.3.3 Second mitochondria derived activator of caspases (Smac ) 
In the intrinsic pathway, the key event leading to the activation of caspases is the release 
of several pro-apoptotic proteins from the intermembrane space of mitochondria into the 
cytosol (Wang 2001). One such protein is the second mitochondria derived activator 
(Smac), which is also called Diablo (Verhagen et al. 2000). The newly synthesised Smac 
protein contains of 239 amino acids. Its N-terminal 55 residues encode the mitochondrial 
targeting sequence and are proteolytically removed in the mature Smac protein (Du et al. 
2000). This cleavage results in the exposure of four hydrophobic amino acids at the N-
terminus of the mature Smac. This tetrapeptide represents the founding member of a 
family of inhibitors of apoptosis proteins (IAPs) binding motifs in mammals (Shi 2002a). 
The binding of Smac to IAPs prevent their interactions with caspase9 and the inhibition of 
the intrinsic pathway (Srinivasula et al. 2001). 
 
2.4.4.3.4 Survivin 
Survivin belongs to the family of inhibitors of apoptosis proteins (IAPs). These proteins 
prefent aberrant activation of caspases, which can be detrimental to cells. To protect 
against inadvertent damages and death, cells have evolved a system of checks and 
balances. At the heart of the system is the evolutionarily conserved IAP family. 
Membership of this family requires a 80 amino acid zink-binding module, which is referred 
to as a baculoviral IAP repeat (BIR) domain. At least eight distinct IAPs have been 
identified in the mammalian genome, each of which contains 1-3 copies of the BIR 
domain. Except of survivin, all other IAPs contain other functional domains such as RING 
(really interesting new gene) (Deveraux and Reed 1999; Salvesen and Duckett 2002). 
Survivin contains only one BIR domain and does not inhibit caspase activity in vitro (Shi 
2002b). In contrast to the relatively stable expression levels of other IAPs, expression of 
survivin oscillates with cell cycle and peaks at the G2/M phase (Li et al. 1998). Survivin is 
able to inhibit Smac and prevent cells from apoptosis (Song et al. 2003). Survivin is 
expressed in human endothelial cells of newly formed blood vessels (Tran et al. 1999). 
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2.4.4.4 Caspase3, -6, -7 
Caspases share homology with the Caenorhabditis elegans gene, Ced-3, its product is 
required for mediating apoptosis during development. Caspase3 is the vertebrate-
caspase most similar to Ced-3 concerning amino acid sequence homology as well as 
substrate specificity. The active mammalian form, consisting of p17 and p12 subunits, is 
processed from an inactive 32-kDa proenzyme after auto- or heterocatalysis, 
preferentially cleaving substrates containing a DEVD motif (Nicholson and Thornberry 
1997). The active form of mammalian caspase6 consists of p18 and p11 subunits 
(processed from a 34-kDa proenzyme). caspase7 shares its signature cleaving site with 
caspase3 and thus has a great similarity in subtrat specifity. Studies have demonstrated 
the existence of at least 11 additional homologous mammalian proteases, caspase1 
through -14, that together compose the caspase family of cysteine proteases. All 
identified mammalian caspases are synthesised as inactive proenzymes and activated 
after cleavage at a specific N-terminal domain aspartate cleavage sites. Within this family 
of enzymes, caspase7  and caspase9  are considered to be most homologous in 
sequence to caspase3 and -6, while the amino acid sequences of caspase8 and 
caspase10 are the next most related (Miller 1997; Nicholson and Thornberry 1997). 
Although the mechanism of caspase action is highly conserved, differences among 
primary sequences account for different substrate specificity. As a group, caspase 
members generally form a cascade of enzymatic activity that results in the initiation and 
amplification of early apoptotic events (e.g. caspase8, -9, so called initiator-caspases) as 
well as mediating the later executioner steps of apoptosis (e.g. caspase3, -6, -7, the 
effector-caspases) (Nicholson and Thornberry 1997). Both apoptotic pathways result in 
the activation of this cascades, independend wether it is done directly or via activation of 
the mitochondrial death program. On one hand, the extrinsic pathway starts with ligand-
binding to death-receptors such as CD95 (Apo-1/Fas). As an effect, those receptors form 
membrane-bound signalling complexes, which recruit through adapter proteins several 
molecules of caspase8. The induced proximity model (Muzio et al. 1998) posits that 
under these conditions the molecules cleave and thus activate each other. As described 
above, this activated caspase now activates further caspases of the cascade like -3, -6, -
7, which leads to cleavage of specifc death substrates. The intrinsic pathway on the other 
hand also activates caspase3 and following caspases, however it starts out in quite a 
different way. 
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3 Material  
3.1 Development of a method to gain uterus milk in vivo 
3.1.1 Equipment 
 
blood withdrawal system Vacuette 20G, 450.077, Vacuette K3E EDTA K3, 
455.036, Greiner Labortechnik, (Kremsmünster, 
Austria) 
buckler Stopfen Sarstedt 65.806 (Nürnbrecht) 
catheter disposable embryo flushing catheter steril incl. 
steel mandrin, CH 12, Minitüb (Tiefenbach)  
cellulose tissue Ärztekrepp, Heiland (Hamburg) 
centrifuge Sigma 3-16K (Osterode) 
clipping machine Typ GT 104, Aesculap AG & Co.KG (Tuttlingen) 
microscope Zeiss Axiovert 25, Carl Zeiss AG, 
(Hallbergmoos) 
microtiter plates Nunc-Immuno-Platte Maxisorb F 96, Nunc 
Gmbh (Wiesbaden) 
microtiter plate dispensor Manifold-8-Changonel, SLT Labinstruments 
(Crailsheim) 
microtiter plate washer SLT 96.PW, SLT Labinstruments (Crailsheim) 
needles sterile Microlane 3 18G x 1½, BD (Drogheda, Ireland) 
pipettes 
 
Abimed, Gilson (Frankreich) 
Eppendorf (Hamburg) 
Pipetus akku, Hirschmann Laborgeräte 
(Eberstadt) 
pipettetips 
 
Diamond D10 tips, Gilson (Hamburg) 
Standardtips Eppendorf (Hamburg) 
Sarstedt (Hamburg) 
reaction tubes 2ml, Eppendorf (Hamburg) 
5ml Sarsted-Röhrchen 55.525 (Nürnbrecht) 
15ml Cell Star 188.271, Greiner 
(Frickenhausen) 
syringes disposable Terumo 5ml, Heiland (Hamburg) 
Basik 20ml, Heiland (Hamburg) 
tissue culture dish Corning, Sigma-Aldirch (München) 
vaginal flushing system Irrigator 2L, Heiland Vet (Hamburg) 
flexible hose, Heiland Vet (Hamburg) 
 
3.1.2 Medicaments 
 
Buserelinacetat Receptal, Intervet Deutschland GmbH 
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(Unterschleißheim) 
Cloprostenol Estrumate, Essex Tierarznei (München) 
Gentamicinsulfat Genta-Sleecol 5, A. Albrecht GmbH + Co. KG 
(Aulendorf) 
0,9% NaCl Fresenius Kabi Deutschland Gmbh (Bad 
Homburg) 
Procainhydrochlorid Procasel 2%, Selectavet Dr. Otto Fischer GmbH 
(Weyarn-Holzolling) 
 
3.1.3 Biochemicals 
 
99% acetylsalicylic acid Merck (Darmstadt) 
BSA Fraktion V, pH 5,2; Standard Grade, Serva, 
11930 (Heidelberg) 
citric acid x 1 H2O Merck, 244 (Darmstadt) 
ethanol (100%) Merck (Darmstadt) 
H2O2-urea Merck, 818356 (Darmstadt) 
H2SO4 Merck, 100731 (Darmstadt) 
Kathon pH 5.0, Rohm & Haas Ltd., 62368 (U.K.) 
NaCl Merck (Darmstadt) 
Na2CO3 x 10 H2O Merck, 6391(Darmstadt) 
NaHCO3 Merck, 6329 (Darmstadt) 
Na2HPO4 x 2 H2O Merck, 6580 (Darmstadt) 
sperm deep frozen FV Weber IN 184593 27.07.01, D-KBR015 EWG 
(München - Grub) 
TMB Boehringer, 784974 (Mannheim) 
0,05% Tween-80 Sigma, P 1754  (Taufkirchen) 
 
3.1.4 Reagents 
 
assay-buffer 7.12 g/l Na2HPO4 x 2 H2O 
8.5 g/l NaCl  pH 7.2 
1.0 g/l BSA (0.1%) 
coating buffer 4.29 g/l Na2CO3 x 10 H2O 
2.93 g/l NaHCO3    pH 9.6 
substrate solution A 1 g/l H2O2-urea 
18 g/l Na2HPO4 x 2 H2O 
10.3 g citric acid x 1 H2O 
0.1 ml Kathon 
pH 5.0       photosensitiv 
substrate solution B 300 mg TMB (Tetramethylbenzidin) 
  Material 
 34
40 ml DMSO (Dimethylsulfoxid) 
960 ml H2O 
10.3 g citric acid x 1 H2O 
pH 2.4       photosensitiv 
peroxidase-labeled oestradiol-17β self-production 17β/2pool1 26.07.95 
unlabeled oestradiol-17β Serva 31100 (Heidelberg) 
oestradiol-17β antibody (rabbit) self-production E2/2pool1 23.11.77 
peroxidase-labeled PGF2α self-production 29.10.97 
unlabeled PGF2α Sigma, P0424 (Taufkirchen) 
PGF2α antibody (rabbit) R. Claus, AS S5, Ka III, E. 20.09.87, 
(Hohenheim) 
peroxidase-labeled progesterone Sigma, P3659 (Taufkirchen) 
unlabeled progesterone Sigma, P 0130 (Taufkirchen) 
progesterone anti-body (rabbit)  K. Okuda, OK-1 03.12.97, (Japan) 
prostaglandin stabilisator 111.7g 0.3 m EDTA 
10g 1% acetylsalicylic acid 
pH 7.4  photosensitiv 
VEGF-165 antiserum self-production H21 30.9.93 
VEGF-165 protein, bovine,  recombinant D. Gospodarowicz, 28.10.97 (Chiron, Oakland, 
USA) 
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3.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic 
factors in the CL during oestrous cycle and induced luteolysis  
3.2.1 Tissue collection 
3.2.1.1 Follicles 20 hours after GnRH application  
For comperable reasons follicles (n=5) were taken 20h after GnRH application from the 
experiment published by Berisha et al. (2006). German Fleckvieh cows were 
superovulated using FSH (Ovagen; Immunochemical Products Ltd, Auckland, New 
Zealand) injections (in total seven), which were given i.m. at 12h intervals in gradually 
decreasing doses for 3.5 days, starting between days 8 and 11 of the oestrous cycle after 
previous oestrus observation. After the sixth FSH injection, a luteolytic dose of 500 µg 
PGF2 analogue (cloprostenol, Estrumate; BERNA Veterinärprodukte AG, Bern, 
Switzerland) was injected i.m., and then 40h after PGF2α injection, 100 µg gonadotrophin-
releasing hormone (GnRH) (Receptal; BERNA Veterinärprodukte AG, Bern, Switzerland) 
were injected to induce the LH surge. For confirmation of LH surge, blood samples were 
collected from the jugular vein at –24, –12, –1 and 0h before and 3 and 12h after GnRH 
application. Lack of an endogenous LH surge prior to GnRH was confirmed by LH 
determination in blood plasma (range 0.8–1.0 ng/ml); 4h after GnRH the mean LH level 
(induced LH surge) was 11.50 ng/ml (range 8.5–14.1 ng/ml) and at 12h 0.73 ng/ml (range 
0.2–1.0 ng/ml). The ovaries were collected by transvaginal ovaryectomy (n=5 cows/group) 
20h after GnRH application. 
 
3.2.1.2 CL during oestrous cycle 
The CLs (4 per group) were collected 10-20 minutes after slaughter, frozen in liquid 
nitrogen and kept at –80°. According to a modified method by Ireland et al. (Ireland et al. 
1980) the CLs were divided into four groups: 
 Group I + II (day 1-4): 
 Time before ovulation until development of one epithelial cell layer over the 
rupture site with further differenciations like: 
 Day 1-2: only a blood-clot is present, 2-6mm in diameter (group I) 
 Day 3-4: development of a small umbilicus, growing diameter (group II) 
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 Group III (day 5-7): 
 Day 5-7: developing stage; blood vessel formation in the periphery is seen; 
cutting of the CL displays a red apex; 5-12mm in diameter 
 
 Group IV (day 8-12): 
 Day 8-12: mature stage; the apex is red, the rest of the CL yellow; the CL is 
clearly bigger than in group III (over 12mm of diameter) and is softly demarced 
3.2.1.3 CL during induced luteolysis  
CL tissue was taken from the experiment described by Neuvians et al. (2003). In this 
experiment 5 CLs per group were taken from cycle synchronised cows after defined time 
points during induced luteolysis at day 8-12 of the oestrous cycle. The time intervals were 
as follows:  
 0, 2, 4, 12, 24, 48 and 64 hours after PGF2α injection 
Additionally we decided to complement the experiment with an earlier time point at 0.5 
hours after luteolysis (Az: 209.1/211-2531.3-29/04). Therefore we synchonised five non 
lactating Brown Swiss cows with two injections of 500μg Cloprostenol (Estrumate) i.m. 
within eleven days. 10-12 days after the second injection luteolysis was induced by further 
administration of 500μg Cloprostenol. After 0.5h the ovaries were taken by transvaginal 
ovaryectomy. The CLs were dissected, cut in slices and either fixated in Bouin´s solution 
or in methanol-glacial acetic acid for immunohistochemistry, or frozen in liquid nitrogen 
and stored at –80°. Blood samples were taken at each PGF2α injection and daily from the 
second day after the second PGF2α injection on for measuring the progesterone level. 
 
3.2.2 Equipment 
 
blood withdrawal system Vacuette 20G, 450.077, Vacuette K3E EDTA K3, 
455.036, Greiner Labortechnik, (Kremsmünster, 
Austria) 
buckler Stopfen Sarstedt 65.806 (Nürnbrecht) 
centrifuge Sigma 3-16K (Osterode) 
clipping machine Typ GT 104, Aesculap AG & Co.KG (Tuttlingen) 
syringes disposable Terumo 5ml, Heiland (Hamburg) 
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3.2.3 Surgical instruments 
 
cervix clamp Hauptner (Dietlikon-Zürich, Schweiz) 
effeminator Hauptner (Dietlikon-Zürich, Schweiz) 
knife by Höhne Hauptner (Dietlikon-Zürich, Schweiz) 
ligature carrier by Deschamps 45cm Eickemeyer (Tuttlingen) 
suture material PBS 2USP, 5EP absorbable, WDT (Garbsen)  
swabs sterile Fuhrmann (Much) 
 
3.2.4 Medicaments 
 
Benzylpenicillin-Procain Procillin, Alvetra (Neumünster) 
Cefquinomsulfat Cobactan 2.5%, Intervet (Unterschleißheim)  
Cloprostenol Estrumate, Essex Tierarznei (München) 
Metamizol-Natrium  Vetalgin, Intervet (Unterschleißheim) 
Poly(1-vinyl-2-pyrrolidon)-Jod-Komplex Vet-Sept-Lsg., Albrecht (Aulendorf) 
Procainhydrochlorid Procasel 2%, Selectavet Dr. Otto Fischer GmbH 
(Weyarn-Holzolling) 
Xylazinhydrochlorid Rompun 2%, Bayer Vital (Leverkusen) 
 
3.2.5 Laboratory equipment 
 
beads Matrix Green, Bio 101 Systems, MP 
Biomedicals (Heidelberg) 
Bioanalyzer 2100 Agilent Technologies (Waldbronn) 
centrifuge Biofuge 13, Heraeus Instruments, 75003635/01 
(Osterode) 
 Biofuge fresco, Heraeus Instruments, 75005510, 
(Osterode) 
 Biofuge pico, Heraeus Instruments, 75003280,  
(Osterode) 
 Zentrifuge 5415 D, Eppendorf (Hamburg) 
 Zentrifuge 5415 R, Eppendorf (Hamburg) 
 Zentrifuge 5804, Eppendorf (Hamburg) 
 Sigma 3K30 (Osterode) 
cuvettes Uvette, Eppendorf (Hamburg) 
electrophoresis module Standard Power Pack P25, Biometra 
(Göttingen) 
embedding form 10mm x 20mm, Plano (Wetzlar) 
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embedding slide Histosette II tissue, Simport (Beloeil, Canada) 
heating plate hotplate magnetic stirrer, Cenco (Breda, 
Netherlands)) 
homogenisator FastPrep FP 120 Bio 101 Systems, MP 
Biomedicals (Heidelberg) 
homogenisator tubes with cap Lysing Matrix D, Bio 101 Systems, MP 
Biomedicals (Heidelberg) 
gel-chamber Agagel Mini/Midi-Wide, Biometra (Göttingen) 
microtiter plates Nunc-Immuno-Platte Maxisorb F 96, Nunc 
Gmbh (Wiesbaden) 
microtiter plate dispensor Manifold-8-Changonel, SLT Labinstruments 
(Crailsheim) 
microtiter plate washer SLT 96.PW, SLT Labinstruments (Crailsheim) 
microwave-oven Panasonic NN 6275B (UK) 
photometers Biophotometer Eppendorf (Hamburg) 
Titrek-Multiscan, Typ 310 C, Flow Laboratories 
with SLT-Easy-Fit, SLT Labinstruments 
(Crailsheim) 
pipettes 
 
Abimed, Gilson (Frankreich) 
Eppendorf (Hamburg) 
pipettetips 
 
Diamond D10 tips, Gilson (Hamburg) 
Standardtips Eppendorf (Hamburg) 
Sarstedt (Hamburg) 
reaction tubes 0.2ml micro-tube, Abgene (Epson, UK) 
0.5ml Biozym 710912 (Oldendorf) 
1.5ml; 2.0ml, Eppendorf (Hamburg) 
5ml Sarsted-Röhrchen 55.525 (Nürnbrecht) 
10ml Sarstedt-Röhrchen 26.323 (Nürnbrecht) 
15ml Cell Star 188.271, Greiner 
(Frickenhausen) 
50ml Cell Star 227.261, Greiner 
(Frickenhausen) 
RNA nano chips Agilent Technologies (Waldbronn) 
rotor-gene 3000 Corbett Research (Australia) 
scales Sartorius MC 210 P (Göttingen) 
Sartorius 2001 MP2 (Göttingen) 
shaker Vortex-Genie 2 Bender & Hobein (München) 
thermoblock Thermomixer 5436, Eppendorf (Hamburg) 
thermocycler Mastercycler gradient, Eppendorf (Hamburg) 
video-documentationsystem Image Master JVDS, Pharmacia 
80-6247-01 (Freiburg) 
warming cupboard Shinko MCS, Bachofer (Reutlingen) 
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3.2.6 Biochemicals 
 
agarose Amresco 710-50G (Ohio, USA) 
bromphenolblue Merck 8122 (Darmstadt) 
BSA Fraktion V, pH 5.2; Standard Grade, Serva, 
11930 (Heidelberg) 
butanol tert.  Roth (Karlsruhe) 
buthyl methyl ether Roth (Karlsruhe) 
chloroform Merck, 2445 (Darmstadt) 
DEPC (diethylpyrocarbonat) Aldrich 15.922-0 (Steinheim) 
DMSO  Serva, 20385 (Heidelberg) 
dNTP (each 25 µmol) deoxynucleoside triphosphate set, R0182, 
Fermentas (St. Leon-Rot) 
EDTA Merck 8418 (Darmstadt) 
ethanol (100%) Merck (Darmstadt) 
ethidiumbromid 1% solution 3.8-Diamino-5-Ethyl-6-Phenylphenanthridinium- 
Bromid (10mg/ml), Carl Roth GmbH + Co. KG 
(Karlsruhe) 
formaldehyd (35%) Merck, 1.04001 (Darmstadt) 
formaldehyd (37%) Merck, 1.04094 (Darmstadt) 
glacial acetic acid (100%) Merck, 1.00063 (Darmstadt) 
HCL (5M) Combi Titrisol, Merck (Darmstadt) 
H2O2-urea Merck, 818356 (Darmstadt) 
H2SO4 Merck, 100731 (Darmstadt) 
hexamere Pharmacia 27-2166-01 (Freiburg) 
iso-2-propanol Merck, 9634 (Darmstadt) 
Kathon pH 5.0, Rohm & Haas Ltd., 62368 (U.K.) 
methanol Merck, 1.06009 (Darmstadt) 
MgCl2 Merck (Darmstadt) 
MOPS Roth, 6979.2 (Karlsruhe) 
NaCl Merck (Darmstadt) 
Na2CO3 x 10 H2O Merck, 6391(Darmstadt) 
NaHCO3 Merck, 6329 (Darmstadt) 
Na2HPO4 x 2 H2O Merck, 6580 (Darmstadt) 
NaOH Merck (Darmstadt) 
paraffin Vogel-Histo-Comp, Vogel (Gießen) 
PCR- H2O Sterile, deionized DEPC-H2O 
PeqGold TriFast Peq Lab (Erlangen) 
petroleum ether Scharlau (Barcelona, Spain) 
picric acid Merck, 1.00621 (Darmstadt) 
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RNA-H2O Sterile, deionized DEPC-H2O 
TMB Boehringer, 784974 (Mannheim) 
Tris(hydroxymethyl)-amiomethan Riedel-deHaën, 33742 (Seelze) 
0,05% Tween-80 Sigma, P 1754  (Taufkirchen) 
citric acid x 1 H2O Merck, 244 (Darmstadt) 
 
3.2.7 Reagents 
 
coating buffer 4.29 g/l Na2CO3 x 10 H2O 
2.93 g/l NaHCO3    pH 9.6 
assay-buffer 7.12 g/l Na2HPO4 x 2 H2O 
8.5 g/l NaCl  pH 7.2 
1.0 g/l BSA (0.1%) 
substrate solution A 1 g/l H2O2-urea 
18 g/l Na2HPO4 x 2 H2O 
10.3 g citric acid x 1 H2O 
0.1 ml Kathon 
pH 5.0  photosensitiv 
substrate solution B 300 mg TMB (Tetramethylbenzidin) 
40 ml DMSO (Dimethylsulfoxid) 
960 ml H2O 
10.3 g citric acid x 1 H2O 
pH 2.4       photosensitiv 
progesterone antibody (rat)  Sigma, P1922 (Taufkirchen) 
peroxidase-labeled progesterone Sigma, P3659 (Taufkirchen) 
unlabeled progesterone Sigma, P 0130 (Taufkirchen) 
 
3.2.8 Kits 
 
DNA-digestion DNA-freeTM, Ambion (USA) 
Light Cycler FastStart DNA Master SYBR 
Green I  
Roche Diagnostic Gmbh (Mannheim) 
RNA 6000 Nano reagents & supplies Agilent Technologies (Waldbronn) 
Wizard SV Gel and PCR Clean-Up System Promega (Mannheim) 
 
3.2.9 Enzymes 
 
reverse transcriptase 
M-MLV RT Rnase H(-) Point Mutant 
Promega (Mannheim) 
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taq-polymerase 
 
Roche (Mannheim) 
 
3.2.10 Markers 
 
100bp-sizemarker 
 
New England Biolabs 100bp DNA 
Ladder N3231S (Frankfurt) 
 
3.2.11 Buffers and solutions 
 
agarose-gel 1,5% 
 
0.45g agarose 
30ml 1x TAE-buffer 
3µl Ethiduimbromid-solution 
Bouin´s solution 375ml picric acid (saturated) 
125ml formaldehyd (37%) 
25ml glacial acetic acid 
bromphenolblue/glycerin 
 
15ml bromphenolblue solution 
85ml RNA-H2O 
100ml glycerin (pure) 
DEPC-H2O 
 
1ml DEPC in 1l H2O bidest, incubate 24h at 
4°, autoclave 20min at 121°C 
dNTP-working solution 
 
100µl dATP  (100mM) 
100µl dCTP  (100mM) 
100µl dGTP  (100mM) 
100µl dTTP  (100mM) 
600µl DEPC H2O 
Formaldehyde-Loading Dye Ambion (USA) 
Methanol - glacial acetic acid methanol : glacial acetic acid (2:1) 
 
10x MOPS 0.2M MOPS 
50mM Natriumacetat 
10mM EDTA 
autoclave 20min at 121° 
RNA-Gel 
 
0.4g Agarose MP 
33.8ml Rnase free H2O 
4ml MOPS 10x conz. 
2.2ml formaldehyde 37% 
2µl ethidiumbromid-solution 
50x TAE-buffer 2M Tris(hydroxymethyl)-amiomethan 
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 1M acetic acid 
90mM EDTA 
Tris-buffer 50mM Tris, pH 8.0 adjust with HCL 
 
3.2.12 Primersequences and polymerase chain reaction (PCR) products 
 
Forward (for) and reverse (rev) primers were designed either by colleges of the institut or by myself 
or taken out of literature and produced by MWG-Biotech AG (Ebersberg).  
 
primer 
5’-----------3’ 
reference/ 
Acc. No 
length of  
PCR-product [bp] 
Housekeeping Genes   
ß-Actin 
for  AACTCCATCATGAAGTGTGACG  
rev GATCCACATCTGCTGGAAGG 
NM_001033618 233 
GAPDH 
for  GTCTTCACTACCATGGAGAAGG 
rev TCATGGATGACCTTGGCCAG 
U85042 
U94889 
197 
Histone 
for  ACTGCTACAAAAGCCGCTC 
rev ACTTGCCTCCTGCAAAGCAC 
AF469469 233 
Ubiquitin 
for  AGATCCAGGATAAGGAAGGCAT 
rev GCTCCACCTCCAGGGTGAT 
Z18245 198 
Matrixmetalloproteases   
MMP-1 
for  GAGGAGACGCTCATTTTGATG 
rev ACTGGCTGAGTGGGATTTTG 
AF134714 235 
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MMP-2 
for  CCCAGACAGTGGATGATGC 
rev TTGTCCTTCTCCCAGGGTC 
NM_174745 248 
MMP-9 
for  GACCAGGACAAGCTCTACGG  
rev CAGAAGCCCCACTTCTTGTC 
NM_174744 203 
MMP-14 
for  ACTTGGAAGGGGGACACC  
rev AGGGGGCATCTTAGTGGG 
AF144758 236 
MMP-19 
for  TTTCAAGGGGGACTATGTGTG 
rev CAATAGAGAGCTGCATCCAGG           
X92521 240 
TIMP-1 
for  CATCTACACCCCTGCCATG 
rev  CAGGGGATGGATGAGCAG          
AF144763 231 
TIMP-2 
for  GGGTCTCGCTGGACATTG 
rev TTGATGTTCTTCTCCGTGACC        
 
AF144764 
 
256 
Plasminogen activator system   
tPA 
for  GGGGAAGCACAACCACTG  
rev AGCTGATCAGGATCCCCC        
X85800 263 
uPA 
for  TGCAGCCATCTACAGGAGG 
rev TGGTGAGCAAGGCTCTCC 
X85801 240 
uPAR 
for  TGTTTCCAGAAACCGCTACC 
rev AAGTGGAAGGTGTGGTTGTTG 
S70635 234 
PAI-1 
for  CAGCGACTTACTTGGTGAAGG 
rev TCCAGGATGTCGTAGTAACGG 
BC103451 231 
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PAI-2 
for  TACGGGCTTGGAGATGCTAG 
rev GGTCATTCTTTCCCGACATG 
AF416234 218 
Monocytes chemoattractant proteins   
MCP-1 
for  CTCACAGTAGCTGCCTTCAGC 
rev GCTTGGGGTCTGCACATAAC 
L32659 205 
Apoptotic- and anti-apopotic factors   
Bax 
for  TCTGACGGCAACTTCAACTG  
rev AAGTAGGAGAGGAGGCCGTC 
L22473 
U92569 
194 
BCL-XL 
for  GGCATTCAGCGACCTGAC 
revCCATCCAAGTTGCGATCC 
AF245487 203 
Caspase3 
for  AACCTCCGTGGATTCAAAATC 
rev TTCAGGRTAATCCATTTTGTAAC 
NM-214131 
NM-012922 
114 
Caspase6 
for  TGTTCAAAGGAGACAAGTGTCAG 
rev CAGAGTAGCACATGAGGAAGTC 
(Sakumoto et al. 
2000) 
206 
Caspase7 
for  CTCTTCAAGTGCTTCRAARC 
rev TTCTCTARCAGGGTTTTGCATC 
NM-033338 
AF072124 
241 
Fas 
for  AGAAGGGAAGGAGTACAYMGA 
rev TGCACTTGTATTCTGGGTCC 
NM-000043 
NM-007987 
124 
FasL 
for  CATCTTTGGAGAAGCAAATAG 
rev GGAATACACAAAATACAGCCC 
X89102 205 
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p53 
for  CATGACGGAGGTTGTGAGG 
rev TGGTGCACTCAGAGTCGATC            
NM_174201 191 
Smac  
for  AGGAAGATGAGGTGTGGCAG   
rev AACTGGATGTGATTCCTGGC 
AF203914 184 
Survivin 
for  AGCTCTACCTCAAGGACCACC   
rev CTTCTATGGGGTCGTCATCTG 
AY606044 195 
TNFα 
for  TAACAAGCCGGTAGCCCACG 
rev GCAAGGGCTCTTGATGGCAGA 
AF011926 277 
TNFR1 
for  CACCACCACCATCTGCTT 
rev TCTGAACTGGGGTGCAGA 
(Sakumoto et al. 
2000) 257 
TNFR2 
for  AGCAGCACGGACAAGAGG  
rev CTGTGTCCCTCGTGGAGC 
AF031589 220 
 
Since there were no sequence information about cow in this specific gene regions, the 
author designed multispecies primers fitting for either human, rat or mouse. 
Abbreviations in the primer sequences: 
r = a or g 
y   = c or t 
m  = a or c
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4 Methods 
4.1 Development of a method to gain uterus milk in vivo 
Investigations during the preimplantation periode of pregnancy is a difficult undertaking in 
the bovine species. To gain specific samples like uterus tissue, concepti or uterus milk, 
pregnant cows are slaughtered at certain time points after artificial insemination. 
Nowadays exists a national attempt to reduce the number of animals being dispachted in 
animal experiments. Therefore I attempted to develop an in vivo method, which enables 
me to take uterus milk samples and embroys at specific time points after artificial 
insemination without slaugthering the cows. Also this would give the possibility to reduce 
the number of animals being used for experiments. I also wanted to investigate if it was 
possible able to detect progesterone, oestradiol-17β, PGF2α and VEGF in the gained 
uterus milk. 
 
Experimental setup  
Nine about two years old Brown Swiss heifers were taken as experimental animals (Az: 
209.1/211-2531.3-13/04). They were cycle synchronised using the OvSynch method 
followed by a double artificial insemination. Blood plasma samples were taken from the 
first day of the synchronisation till day 33 of gravidity for the measurement of 
progesterone. Within the first 24 days of gravidity the ipsilateral and contralateral uterus 
horn were flushed each five times with 13ml sterile 0.9% NaCl using a disposable sterile 
baloon embryo transfer catheter. The catheter was placed 1cm cranial of the bifurcatio 
uteri in both horns. The flushing fluid of the ipsilateral horn was inspected for an embryo 
under the microscope. Viable embryos would have been separated from the fluid and 
frozen in a specific RNA-Later at –80°. After that a prostaglandin stabilisator (200μl /10ml) 
was given to the regained flushing fluid of both horns, which was aliquoted and frozen at –
20°.  
 
 OvSynch synchronisation of nine Brown Swiss heifers 
day 0: each 3.5ml Receptal i.m. 
day 7: each 2.5ml Estrumat i.m. 
day 9: each 3.5ml Receptal i.m. plus first artificial insemination 
day 10: second artificial insemination 
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 Blood withdrawal from the vena jugularis via EDTA-Vacuette: 
During the first 24 days, blood samples were taken every second day. From day 26 
till day 33 blood samples were taken daily to see if the heifers were still ipsilateral. 
The blood was centrifugated for 15min at 2000g and 4°. The gained blood plasma 
was aliquoted and frozen at –20°. 
 
 Uterus flushing of the ipsilateral and contralateral horn via disposable balloon 
embryo catheter: 
 Time points: 
day 5 of gravidity 
day 7 
day 12 
day 17 
day 24 
 
 Epiduralanaesthesia: 
An about 10cm x 15cm large area was shaved at the sacrococcygeal region 
and disinfected with ethanol 70%. 5ml Procasel 2% was injected into the 
epidural space between the last sacral and the first tail vertebra. 
 
 Ipsi- and contralateral uterus horn: 
Both ovaries were transrectally palpated. The uterus horn belonging to the CL 
bearing ovary was refered to as ipsilateral horn. The other uterus horn was 
designated as contralateral horn. Dry cleaning of the vulva area and disinfection 
with ethanol 70% followed. 
 
 Flushing: 
A sterile embryo catheter was rinsed thoroughly with 3ml of sterile 0.9% NaCl 
and strengthened with a steel mandrin. After spreading of the labiae vulvae the 
catheter was brought in to the vagina under rectal control. Passing the cervix it 
was first placed in the contralateral horn 1cm cranial the bifurcatio uteri. The 
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balloon was inflated with 10ml air to seal the uterus horn from caudal. The 
mandrin was removed from the catheter. 13ml of sterile 0.9% NaCl was injected 
into the catheter using a sterile 20ml syringe. The uterus horn was massaged 
gently and an aspiration of the injected fluid followed. For flushing the ipsilateral 
horn in the same way, the balloon was deflated, the catheter removed from the 
vagina, reinforeced with the mandrin and placed into the ipsilateral horn. The 
flushing was done as discribed above. 200μl of stabilisator per 10ml was given 
to the gained fluid. The samples of the contralateral horn were kept in falcon 
tubes on ice, the samples of the ipsilateral horn were collected in cultur plates 
on ice. This procedure was kept for all nine heifers. A new catheter was used 
for each heifer, the mandrin was disinfected with ethanol 70% before each use. 
 
 Microscopical inspection of the ipsilateral horn flushing fluid: 
From day 7 on all gained flushing fluids from the ipsilateral horns were 
inspected under the microscope for embryos. A migration of the embryo during 
the preimplantation periode into the contralateral horn is very seldom (Rüsse 
and Sinowatz 1991b), so that the flushing fluids from these horns were not 
inspected. Located embryos were charactarised according to the developing 
stage and viability. Afterwards they were removed from the flushing fluid and 
viable ones were kept in RNA-Later and frozen at –80°. The flushing fluid was 
pipetted into a falcon tube and kept on ice. 
 
 Aliquotation: 
All samples were aliquoted and frozen at –20°. 
 
4.1.1 Enzyme immuno assay (EIA) of progesterone, oestradiol-17β and PGF2α 
 
The frozen flushing fluid samples of both horns were defrosted at 37° in a water bath.  
Progesterone, oestradiol-17β and PGF2α concentration were measured using an EIA with 
second antibody technique (Prakash et al. 1987; Meyer et al. 1990; Meyer et al. 1989).  
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Coating of the microtiter plates: 
Firstly the microtiter plates were coated with sheep anti-rabbit IgG (100µl/well), which was 
diluted in coating buffer (1μg IgG /100µll) followed by an overnight incubation at 1°C. After 
the incubation the coating buffer was tipped over and 250µl of a BSA containing assay 
buffer was given on the wells. BSA is supposed to block unspecific bindings sites on the 
surface of the wells. The plates were put on a shaker and incubated for 15-30 minutes at 
room temperature. After tilting the buffer the plates were washed twice in Tween-80 
0.05% and beaten well. 
Test procedure: 
For each measurement a standard curve was established using unmarked progesterone, 
oestradiol-17β or PGF2α. The concentration ranged for progesterone from 0.05 to 
25ng/ml, for oestradiol-17β from 0.1 to 50pg/50μl and for PGF2α from 60 to 70000pg/ml. 
A dilution of 1:20000 was produced with horseradish peroxidase (HRP) conjugated 
progesterone, 1:12000 for oestradiol-17β and 1:50000 for PGF2α (progesteron-6β-
hydroxyhemisuccinat-HRP, oestradiol-6-carboxy-methyl-oxim-HRP and PGF2a-Tris-HRP). 
Rabbit anti-progesterone, anti-oestradiol-17β and anti-PGF2α (antibody against 
progesterone-7α-carboxyethylthioether-BSA, 6-Keto-17β-oestradiol-6-carboxymethyloxim-
BSA and PGF 2α) were diluted like following: 1:150000, 1:400000 and 1:40000. 
20μl of undiluted sample or standard were pipetted in each well. Afterwards 100μl with 
horseradish peroxidase marked progesterone, oestradiol-17β or PGF2α and 100μl of the 
second antibody are given to each well. The unmarked protein of the sample and 
standard respectively competes against the enzyme marked protein for free binding sites 
on the first antibody. To estimate unspecific bindings assay buffer without anit-
progesterone, anti-oestradiol-17β or anti-PGF2α was taken instead of the sample. The 
microtiter plates are incubated over night in the dark at 4°, slightly shaking. In the morning 
they were tilted and washed four times with 400μl Tween-80 0.05% for each well. For 
starting the colouring 11ml of substrate A and B were mixed together and 150μl  per each 
well was given on the plates. After a incubation at 37° for 40min in the dark the colouring 
was stopped with 50μl of 4N H2SO4 per each well.  
Analysis: 
The extinction of the colouring was measured at 450nm by a photometer and analysed by 
a specific computer programm (SLT-Easy-Fit, SLT, Crailsheim). The more the samples 
contain of progesterone, oestradiol-17β or PGF2α the lower is the extinction. The ED50 for 
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progesterone was 6 ng/ml, for oestradiol-17β 3.5 pg/ml and for PGF2α 245pg/ml. The 
intra-assay variance was 4-5% for progesterone, 6-7% for oestradiol-17β and 7% for 
PGF2α. The inter-assay variance rest with 8-9% for progesterone, 9-10% for oestradiol-
17β and 13% for PGF2α. 
 
4.1.2 Radio immuno assay (RIA) of VEGF 
VEGF protein was measured using a RIA according to the method described by Berisha 
et al. (2000). 
 
4.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic 
factors in the CL during oestrous cycle and induced luteolysis  
 
4.2.1 Transvaginal ovariectomy 
The perianal regions of the cows were shaved, cleaned and desinfected. The cows were 
sedated each with 0.8ml Rompun i.v. An epidural anaesthesia was given with 6ml 
Procasel 2%. The vagina was flushed and desinfected with 1L of Vet-Sept solution. 
Pulling the cervix caudal with a cervix clamp a crest of the vaginal mucosa was created on 
the dorsal part of  the vagina. An about 3cm large hole was cut into this crest with a 
Höhne knife. Either the ovary bearing the CL was pulled through this hole and clipped with 
the effeminator or it was cut off in the abdominal cavity. The stumps of the ovary vessels 
were compressed for further four minutes with the effeminator to minimise the bleeding 
risk. The hole in the vagina was closed with 2-3 stitches using an absorbable suture 
material and the ligature carrier by Deschamps. Several swamps were saturated with 
Procillin and left in the vagina for two days to prefent an infection of the wound. 
Furthermore a systemic antibioticum (30ml Cobactan 2.5%) and 40ml Vetalgin were 
given.  
 
4.2.2 Immunohistochemistry 
4.2.2.1 Fixation and Paraffin embedding 
The CLs were cut in slices and labeled. One part was fixated in Bouin´s solution, the other 
part in methanol-glacial acetic acid according to the following time table: 
 12h in Bouin´s solution or methanol-glacial acetic acid, slightly swivelling 
  Methods 
 51
 Dehydration, 2h for each step: 
 ethanol 70%, 90%, 96% and 100% 
 ethanol 100%: tertiary butanol (1:1) 
 tertiary butanol at 40° 
After dehydration the CL slices were kept for 12h in liquid paraffin at 60° in the warming 
cuboard. Afterwards the slices were embedded in paraffin. Therefore the slices were 
placed in specific embedding forms and covered with hot liquid paraffin. The cooling 
process was slowed down by touching the wax surface with a hot metal loop, so that wax 
block cooled down constantly. At the end an embedding slide was placed on the still hot 
surface and the block was given into crashed ice to cool down totally. The completed 
paraffin blocks are stored at 4°. 
 
4.2.3 Molecular techniques 
4.2.3.1 Enzyme immuno assay (EIA) 
To be sure that all five cows were synchronised properly and that all of them had 
developed a mature CL, an analysis of the progesterone level was made by an enzyme-
immunoassay (EIA) (Prakash et al. 1987). The EIA was performed as described in 
chapter 4.1.1. As it was necessary to have a shorter incubation time, a goat anti-rat IgG 
and a rat anti-progesterone was used. The incubation time for the competition of the 
enzyme labeled progesterone and the samples changed to 2h in the dark at 20° and for 
the substrate reaction to 20min at 20° in the dark. 
 
4.2.3.2 RNA extraction 
RNA with its short half-life is quickly degraded by ubiquitous ribonucleases (RNases). This 
enzymes are found on all surfaces, especially on hands. Thus, in order to prevent 
degradation, RNA has to be stored at -80°C where RNase activity is reduced to a 
minimum. 
Handling RNA samples induces the use of one-way gloves, autoclaved materials and 
RNase-free DEPC-water. RNA of CL tissues was extracted with Peq Gold RNAPure. For 
100mg tissue 1ml Peq Gold was given into a FastPrep tube filled with 1g inert beads. The 
small tissue-samples itself were extracted through cutting pieces of the big tissue under -
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25°C and inserting them as fast as possible into the provided tubes. Subsequently, 
samples are homogenised in the FastPrep FP120 with 6.5m/s and 45sec for two times 
and afterwards incubated at room temperature for five minutes. After addition of 200µl 
chloroform the mixture was vortexed for 10 seconds and incubated yet another 10 
minutes. Through the following centrifugation (15min) with 12000rpm at 4°C the upper 
phase containing water and RNA is seperated from the phenolphase. The upper phase is 
then collected and the same volume of isopropanol is added in order to precipiate RNA. 
The tube was inverted several times and incubated at room temperature for 10 minutes. 
After a 10min centirfugation (4°C, 12000rpm) the solution is discarded and the pellet 
washed two times with 500µl 75% ethanol. Following, the pellet is dried for 10min at 37°C 
to completely evaporate remaining alcohol. The dry pellet is then resuspended in 50µl 
RNA-H2O and incubated at 55°C for 5min in order to ensure complete and homogenic 
solvation. The extracted RNA-solutions are finally stored at -80°C until further usage. 
4.2.3.3 DNA digestion 
Because of the lack of DNA digestion during the RNA extraction, DNA attendance is quite 
possible. The disposed DNA-free kit is designed to remove contaminating DNA from RNA 
preparations and to subsequently remove the DNase and divalent cations from samples. 
The protocol of this method allows a removal of trace to moderate amounts of 
contaminating DNA (up to 50µg DNA/ml RNA) from pirufied RNA to a level that is 
mathematically insignificant by RT-PCR. At first, 0.1 volume 10x DNase buffer and 1µl 
rDNase are added to the RNA, the sample is mixed gently and incubated at 37°C for half 
an hour. Afterwards, 0.1 volume DNase inactivation reagent is added and again mixed 
well. During adjactant incubation at room temperature for about 2 minutes, it is important 
to mix the contents well in order to redisperse the DNase inactivation reagent. Finally, the 
sample is centrifuged at 10000g for 1,5min. The supernatant, which contains the RNA, is 
then added into a fresh tube, the pelleted inactivation reagent is discarded for it would 
disturbe further enzymatic reactions. 
 
4.2.3.4 Control of the RNA quantity and quality 
4.2.3.4.1 Quantity 
Quantification of the total RNA concentration is done photometric at a wavelenght of 
260nm, which is the absorption maximum of nuclein acids. In order to fit the measurement 
range, all samples have to be diluted to absorption levels of 0.05<A260<0.8. 
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Simultaneously, the absorption of aromatic amino acids in proteins at a wavelenght of 
280nm is measured in order to achive the quality of the samples. Ratio of A260/A280 should 
be at least 1.6 (measurement against water). A third measurement at 230nm furthermore 
identifies possible sample contaminations with salts or phenol residues. All samples are 
measured three times and middled in order to retain precise values and minimise 
calculation errors. Additionally, the photometer is leveled to the blank value (water) before 
each measurement in order to ensure unique circumstances and thus allows a 
comparison of all samples. 
 
4.2.3.4.2 Quality 
RNA-gel 
Denaturing RNA-agarose-gelelectrophoresis is used in order to determine RNA quality. 
The 1% agarose gel contains ethiduimbromid, 10x MOPS buffer and formaldehyde and is 
left to polymerise in a gel chamber that had previously been incubated for 20min with 
0.1M NaOH to inactivate RNases. One volume RNA sample (containing 1µg RNA) is 
mixed with two volumes of 1x Formaldehyde Loading dye, denaturated for 5min at 95°C 
and then placed on ice immediately. Afterwards, the gel is applied into the running 
chamber (filled with 1x MOPS as running buffer) and loaded with the samples. 
Electrophoresis is conducted for 1.5 hours at 30 volts. After the run, the quality fo the RNA 
is evaluated under UV-light: The 28S rRNA und 18S rRNA have to be visible as defined, 
clearly marked bands (fig. 4). Smear of the same intensity throughout the covered 
distance in the gel represents degraded RNA pieces of all lengths, remaining nuclein 
acids in the gel bags are contaminating DNA. 
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Figure 4: RNA agarose gel 1% with 1μg RNA per pocket (CL induced luteolysis samples) 
 
Bioanalyzer 
The bioanalyzer provides a framework for the standardisation of ribonucleic acid (RNA) 
quality control. Therefore RNA samples are electrophoretical separated on a 
microfabricated chip and subsequently detected with laser induced fluorescence 
detection. Each chip contains an interconnected set of microchannels that is used for 
separation of nucleic acid fragments based on their size as they are driven through it 
electrophoretically. An electropherogram and a gel like image are generated by the 
bioanalyzer software and results such as sample concentration and the so-called 
ribosomal ratio are displayed. The RNA 6000 ladder standard is used as a reference for 
data analysis. It contains six RNA fragments with following sizes: 0.2 kb, 0.5 kb, 1.0 kb, 
2.0 kb, 4.0 kb and 6.0 kb. The software compares the unknown samples to the ladder 
fragments to determine the concentration and to identify the ribosomal RNA peaks of the 
unknown sample (Bioanalyzer Service). Major features of a successful ladder run are: six 
RNA peaks and one marker peak. The Bioanalyzer electropherogram of total RNA shows 
two distinct ribosomal peaks corresponding to either 18S and 28S for eucaryotic RNA and 
a relatively flat baseline between the 5S and 18S ribosomal peaks. Major features for a 
successful total RNA run are: two ribosomal peaks and one marker peak, the baseline 
between 27 seconds and the 18S rRNA is relatively flat as well as free of small rounded 
peaks corresponding to smaller molecules. 
The electropherogram provides a detailed visual assessment of the quality of a RNA 
sample. The RNA Integrity Number (RIN) software algorithm allows for the classification of 
eucaryotic total RNA, based on a numbering system from 1 to 10, with 1 being the most 
degraded profile and 10 being the most intact (Mueller O et al. 2004). Figure 5 shows an 
example for two different RNA qualities. A further quality-indicator is the ratio of 28S rRNA 
28S rRNA 
18S rRNA 
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amount to 18S rRNA (this is provided through the area under the correlating peaks), 
which should be 2 at its best. 
The measurement preparation starts out with the application of 9µl dye-gel into the lading-
well, which is then pressed into the chip channels using the loading-station. As a pool, two 
more wells are filled with dye-gel furthermore. Following, 1µl RNA-sample and 5µl marker 
are pipetted into one sample-well respectively and 1µl ladder with 5µl marker into the 
ladder-well. The loaded chip afterwards is vortexed for one minute and then applied into 
the bioanalyzer. 
 
 
         
 
 
 
 
Figure 5: Two electropherograms; FU = fluorescence, S = second, first peak = marker, peak at 25s 
= 5S rRNA, peak at 40s = 18S rRNA, peak at 47s = 28S rRNA, RIN value of sample 11 = 10,0, RIN 
value of sample 2 = 7,5 
 
4.2.3.5 Reverse transcription 
To be able to use extracted mRNA for PCR based expression studies a reverse 
transcription (RT) reaction is performed with the total RNA of each sample. In this reaction 
the enzyme reverse transcriptase generates double stranded complementary DNA 
(cDNA) from single stranded RNA. In an optimal reaction one molecule cDNA  is 
produced for each molecule mRNA, rRNA and tRNA. To enable the RT reaction the 
enzyme has to be in a correctly buffered solution and supplied with random primers and 
dNTPs. As preparation for the RT, 1µg total RNA are diluted in 41µl Rnase-free water 
then heated for 5min with 65°C and immediatly put on ice. This provides the linearisation 
of the RNA (i.e. no secondary structures) needed for the further transcription process. 
Following, 19ml mastermix (tab. 2) were added to each reaction. 
sample 2sample 11 
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 1x volume [µl] for RT 1x volume [µl] for neg. RT 
5x first strand buffer 12 12 
10mM dNTPs 3 3 
50µM hexamere 3 3 
M-MLV RT Rnase H(-) Point 
Mutant 1 - 
Table 2: RT-mastermixes 
 
To acquire a control for following PCR-steps, which should grant the absence of genomic 
DNA in the samples, one so called negative RT sample completes the procedure: A pool 
of all samples is generated and 1µg total RNA of this pool then diluted (the same way than 
all other samples). This neg. RT is added with a mastermix of 19µl (tab.2) in which the 
enzyme is displaced by an equal amount of RNase-free H2O. 
The RT programm starts out with the incubation of all samples 10min at 21°C in order to 
have an optimised primer annealing,  and continues with 48min at 48°C for the RT 
reaction. At the end of the process, the enzyme is inactivated and RNA templates are 
disrupted through a heating step of 2min at 90°C. The resulting cDNA is stored at -20°C. 
 
4.2.3.6 Polymerase chain reaction (PCR) methods 
4.2.3.6.1 Block PCR 
Conventional block PCR is a method used to specifically amplify target genes or gene 
fragments. Short sequences flanking the sequence of interest on both sides are known to 
be able to design gene specific primers. These should be complementary to sequences 
located at the 5’ and 3’ end of the target and about 20 base pairs in lenght. Both primers 
take advantage of similar melting points (determined by the GC-content), which should be 
around 60°C, because of the PCR-reaction being temperature controlled. 
Amplification of a target is conducted by a thermo stable DNA polymerase and includes 
the following three steps. Successive completion of these three steps is called a cycle. 
Denaturation: At the beginning of each cycle the DNA is denatured at a high temperature 
to separate the double stranded (ds) DNA. The first cycle of the PCR starts with a long 
denaturation step to ensure that both strands of the template DNA are completely 
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separated. 
Annealing: After denaturation the reaction is cooled down in order to enable primers to 
anneal to the complementary sequences of the template DNA. The annealing temperature 
is primer specific and has to be optimized for each PCR product. 
Elongation: At the optimal temperature for the polymerase (usually at around 72°C), the 
enzyme can bind to the single stranded DNA and synthesise a new strand that is 
complementary to the template strand. Thus, a dsDNA is generated from each original 
strand and functions throughout the next cycle as an additional template. 
This semi-conservative replication method leads to an exponential amplification of the 
target sequence. An optimal reaction results after n cycles in 2n dsDNA strands. 
Mastermix components of conventional PCR and general parameters are shown in table 3 
and table 4. 
 
substance 1x volume [µl] 
PCR-H2O 18.9 
10x buffer 2.5 
dNTP’s 0.5 
forward primer 0.5 
reverse primer 0.5 
taq-polymerase 0.1 
template DNA 1.5 
Table 3: Master mix for conventional PCR 
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step temperature [°C] time [s] cycles 
denaturation 94 120 1 
denaturation 94 45 
annealing depending on primer 45 
elongation 72 45 
depending on primer 
elongation 72 120 1 
hold 5 not limited  
Table 4: PCR-parameters 
 
4.2.3.6.2 Gradient PCR: 
Gradient PCR includes the same steps as conventional block PCR, but is conducted in 
special cyclers that allow different temperature profiles to be programmed for each cavity 
in the cycler. This method can be used to optimize PCR conditions with respect to the 
primer annealing temperature. A PCR is done with several replicates of the same sample. 
All samples are treated equally, only the annealing temperature is changed. In an agarose 
gel (see below) the PCR efficiency can then be analysed investigating intensity and 
integrity of the product bands. 
 
4.2.3.6.3 Quantitativ real time PCR (qPCR) 
New PCR-platforms, such as Rotor-Gene or Light-Cycler, and modern dyeing and 
detection systems allow visualisation of PCR reaction in real time and quantification of the 
DNA amount originally in a sample tube. The fluorescence dye used with the Rotor-Gene 
is SYBR-GREEN I, it intercalates with the minor groove of dsDNA and emits light at 
530nm when excited at 497nm. Due to DNA amplification by polymerase, the amount of 
dsDNA doubles with each cycle, resulting in more and more intense signals (measured at 
the end of the elongation step). This event can be monitored for each sample with 
analysing software even while the PCR is still in progress. This advantage gives the 
possibility to continue PCR reaction over the exponential phase (in contrast to 
conventional PCR). Figure 6 displays a characteristic amplification curve calculated by the 
Rotor-Gene software V5.0, which can be divided into four phases. Phase 1 is described 
by an exponential amplification and the fluorescence signal below background correction, 
phase 2 is the exponential amplification phase, phase 3 the linear amplification phase 
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where the PCR loses efficiency and phase 4 the plateau phase which is limited by 
inhibition or lack of chemicals (Pfaffl M.W. 2005). 
       Figure 6: Fluorescence data of a real time RT-PCR  
The Rotor-Gene offers as another feature, the determination of the melting point. After 
amplification the samples are heated from 60°C to 99°C to separate the two DNA strand 
of the PCR-product, which results in a loss of fluorescence. During this heating process 
the fluorescence signal is measured continuously to generate a melt curve. This results in 
a curve that shows a sudden drop in signal intensity at the melting temperature for each 
amplicon, which can also be displayed as a peak (fig. 7). This melting point is depending 
on the guanin- and cytosin bases in the PCR-product (GC content) and on the product 
length. After an initial product size verification in an agarose gel, this graph can be used to 
check if the right product was amplified or if unspecific product information occurred. 
4th phase 
3rd phase 
1st phase 2nd phase 
Background level 
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Figure 7: Melt curve analysis calculated by the Rotor-Gene Analysis Software V5.0 
 
Table 5 shows the parameters used for qPCR experiments. Annealing temperatures are 
primer specific. The optimal annealing temperatures have been determinded preliminary 
using the gradient PCR and were further optimised for the qPCR (fig. 7). 
 
 temperature [°C] time [s] cycles 
denaturation 95 600 1 
denaturation 95 10 
annealing primer specific 10 
elongation 72 15 
40-45, 
product specific 
melt 60-99 0.5°/sec 1 
hold 40 not limited 1 
Table 5: qPCR parameters 
 
Duration of the single steps is decreased comparing to conventional PCR. This is effected 
through the minimized reaction volume of 10µl and the effective heating and cooling 
system which allows quick acquiring of target temperatures. Since the method being 
extremely sensitive, 9µl master mix are added to only 1µl template cDNA. Contents of 
qPCR master-mix are listed in table 6. 
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 1x volume [µl] 
cDNA 1 
PCR-H2O 6.4 
MgCl2 3mM 1.2 
forward primer 0.2 
reverse primer 0.2 
LCM (including SYBR-GREEN) 1 
Table 6: qPCR master mix 
 
Primer annealing temperature [°C] melting temperature [°C] 
β-Actin 63 91.3-91.5 
Histone 60 88.7-89.4 
GAPDH 60 89.9-90.3 
Ubiquitin 60 90.2-91.6 
MMP-1 60 87.8-88.5 
MMP-2 60 90.4-90.8 
MMP-9 60 93.6-94.0 
MMP-14 60 91.3-91.4 
MMP-19 60 88.8-89.0 
TIMP-1 60 89.9-90.2 
TIMP-2 60 90.1-90.3 
tPA 60 93.5-93.7 
uPA 60 89.5-89.9 
uPAR 60 90.4-90.8 
PAI-1 60 90.3-90.5 
PAI-2 60 86.0-86.1 
MCP-1 60 88.4-88.9 
Fas 60 83.4-84.0 
FasL 60 86.5-87.0 
TNFα 66 92.2-92.6 
TNFR1 68 95.59-95.8 
TNFR2 60 94.5-94.7 
p53 62 89.8-90.1 
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Bax 62 91.8-92.0 
BCL-XL 60 89.4-90.0 
Smac/Diablo 60 88.5-88.7 
Survivin 60 92.5-92.8 
Caspase3 60 80.4-80.9 
Caspase6 60 91.3-91.8 
Caspase7 60 85.4-86.1 
Table 7: Product-specific annealing and melting temperatures of the examined factors for qPCR 
 
The tubes for Rotor-Gene qPCR are closed after Mastermix and DNA sample have been 
added and put into the rotor-chamber, the program given above is started. After the run 
has ended, crossing point (CP) values were acquired by using the “comparative 
quantitation” method of the Rotor-Gene Analysis Software V5.0. The CP is a value for the 
target cDNA/mRNA content of the sample. Since the increase in fluorescence is due to 
increase in DNA, a sample initially containing more DNA subsequently reaches 
fluorescence above background earlier (and thus has a lower CP value) than a sample 
containing less DNA. Theoretically the amplification rate for the PCR product in each cycle 
is 2. But, with the reaction conditions being dependend on the investigated tissue and 
primers, the amplification is seldom optimal. Therefore the efficiency of each run is 
acquired using a standard curve. It is calculated via the inclination of the standard curve 
according to the following formula (Rasmussen R 2001): 
E = 10[-1/Steigung] 
For the standard curve the cDNA was diluted to the following concentration: 33, 6, 1, 0.2 
and 0.05ng/μl. A standard curve was established for each primerpair. An example is given 
in figure 8 and 9. 
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Figure 8: An example of a sigmoid amplification curve using a dilution series of TIMP-1; dilution 
concentrations from left to right: 33, 6, 1, 0.2 and 0.05 ng/μl cDNA; the CP value of each 
amplification curve is caluculated where the threshold crosses the curves.  
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Figure 9: Determination of the slope of a dilution series for calculation of the PCR-efficiency of 
TIMP-1. 
 
4.2.3.7  Primer design and optimation      
New primers were designed using the HUSAR software (DKFZ, Heidelberg). For the 
optimal primer pair design the following parameters were considered: length of the PCR-
product about 180-250 bp, primer length 18-24 bp, GC content 40-55%, similar melting 
temperature of the forward and reverse primer, no annealing between both primers, no 
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primer self-annealing. For the design of multi species primer a homolog region of the 
coding sequenze (CDS) of different species was taken. The primers were first optimised 
by block PCR using a gradient cycler. Afterwards the primers were tested by real time 
PCR and adjusted further if necessary. 
 
4.2.3.8 Analysis of the PCR-product 
For established primer pairs the PCR-product was identified by the charactaristic melting 
point and by the specific product length in an agarose gel. The melting curve should show 
only one melting point and the agarose gel only one band. For new primers the PCR-
product was furthermore extracted by a DNA extraction kit using a filter columm and 
several washing steps ( Manual of the Wizard SV Gel and PCR Clean-Up System, 
Promega (Mannheim)) and sent for sequencing (Medigenomix Gmbh (Martinsried)). The 
received cDNA sequence was compared with the bovine sequence in the EMBL database 
using BLAST software (www.ncbi.nlm.nih.gov/BLAST/). If the primers were not made of a 
bovine sequence the gained sequence was compared with the sequence the primers 
were made of. The resulting new bovine sequence was published in the EMBL database. 
 
4.2.4 Data processing 
To make sure that different CP values are only caused by different amounts of total RNA 
and that not other factors are able to distinguish samples from each other, four HKGs 
were used as a reference. HKGs are genes supposed to be not regulated in tissue, this 
might be genes of nuclein acid synthesis like GAPDH as an example of glycolysis or 
structure proteins like Histone. In this experiment Ubiquitin, Histone, GAPDH and β-Actin 
were chosen as reference HKGs. An index was calculated using the CPs of all four 
housekeeping genes using the Bestkeeper software (Pfaffl et al. 2004). With these index a 
normalisation of the retained qPCR CP-values was done by the ΔΔCP methode (Livak 
and Schmittgen 2001) using the following formula:  
 
    ΔΔCP = (CPt - CPí) Control – (CPt – CPi)Time x 
(t: target gene; i: bestkeeper index ) 
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The Cl luteolysis group 0.5h after PGF2α injection was only investigated when the group 
2h showed a significant difference to the control. The statistical analysis of the data was 
done with the software “SIGMA STAT 3.0” after normalisation. For calculation of 
significances, the “one-way ANOVA” was disposed. If data reveal normal distribution, 
significances have been acquired through multiple comparison with the “Holm-Sidak”-test 
method. Differences are estimated significant, if the significance level P is ≤ 0.05. All 
datas are shown as mean values ± standard error of means (SEM). The expression x-fold 
is equal to 2ΔΔCP.  
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5 Results 
5.1 Development of a method to gain uterus milk in vivo 
 
5.1.1 Flushing of the uterus horns 
The amount of regained flushing fluid ranged between 3ml and 13ml. As can be seen in 
the follwing table 8, the flushing was sometimes not possible in two heifers, because the 
cervix was to narrow. On day 7 of gravidity we were able to gain one embryo, which was 
already dead since three days. Several flushing fluids were contaminated with sanies at 
different time points. All heifers having an endometritis, except one, which showed signs 
of oestrus and slight inflammation. Heifers were treated with 40ml Genta-Sleecol 5 i.v. 
From day 17 to day 24 all nine heifers were in oestrus. 
 
Heifer day 5 day 7 day 12 day 17 day24 
1 NAD NAD NAD S, G NAD 
2 NAD embryo  NAD S, O NAD 
3 NAD NAD NAD S, G NAD 
4 NAD NAD NAD S, G NAD 
5 NAD NAD NAD O NAD 
6 NAD missing S missing, G NAD 
7 NAD missing S S, G NAD 
8 NAD NAD NAD S S, G 
9 NAD NAD S S, G NAD 
Table 8: Schedule of flushings and special features; NAD= no abnormality detected; missing= 
flushing was not possible; S= sanies; G= Genta-Sleecol 5; O= oestrous 
 
5.1.2 Progesterone analysis 
5.1.2.1 Blood plasma: 
The progesterone levels in the blood plasma were not measured, because all nine heifers 
were in oestrus between day 17 and day 24 after artificial insemination. Non of the heifers 
were gravid after day 21. 
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5.1.2.2 Uterus milk  
It was possible to detect progesterone in the uterus milk of the contralateral (A) and 
ipsilateral (B) horn. The progesterone value ranged from <0.1 to 0.4 ng/ml in both horns. 
 
5.1.3 Oestradiol-17β analysis in the uterus milk 
We were able to detected oestradiol-17ß values between 2pg/ml and 333pg/ml. The 
values between the different animals and between the ipsi- and contralateral horn showed 
great differences, so that no correlation could be seen. A further test revealed that 0.9% 
NaCl with EDTA-stabilisator contains 138 pg/ml oestradiol-17β, whereas 0.9% NaCl 
without stabilisator only contains <2 pg/ml. 
 
5.1.4 VEGF analysis in the uterus milk 
The detected VEGF values ranged between 0.06ng/ml and 2.58ng/ml, whereas the values 
of both horns were partly similar during the different time points.  
 
5.1.5 PGF2α analysis in the uterus milk 
It was possible to detect PGF2α values between 0.23ng/ml and >70.00ng/ml. A level 
increase can be seen at the beginning and during endometritis, which is reduced after 
medical treatment and oestrus (tab. 9). 
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PGF2α (ng/ml) 
Cow day 5 day 7 day 12 day 17 day 24 
1A 6.81 2.52 30.00 73.00 * 16.20 ** 
1B 3.75 2.70 28.00 54.00 * 12.90 ** 
2A 6.70 1.30 67.70 3.40 * ° 1.18 
2B 19.60 3.50 ~ 21.30 4.40 * ° 0.23 
3A 2.60 19.00 29.50 25.60 * 6.64 ** 
3B 5.00 22.00 28.90 21.70 * 6.86 ** 
4A 5.10 5.94 26.70 20.50 0.78 ** 
4B 6.80 6.88 38.60 59.70 0.82 ** 
5A 14.40 21.00 42.70 14.20 ° 0.69 
5B 10.80 34.50 30.60 32.70 ° 0.93 
6A 7.60 missing 15.40 * missing 9.60 ** 
6B 16.20 missing >70.00 * missing 9.50 ** 
7A 18.00 missing 44.60 * 2.97 * 3.27 ** 
7B 23.30 missing 36.60 * 15.60 * 9.70 ** 
8A 11.50 10.80 26.40 20.60 * 51.00 * 
8B 13.30 24.50 19.60 12.60 * 25.00 * 
9A 11.80 18.50 32.00 * 10.50 * 4.60 ** 
9B 7.60 26.70 38.00 * >70.00 * 4.80 ** 
Table 9: PGF2α concentration in the uterus milk of the contralateral (A) and ipsilateral (B) 
uterus horn. *= sanies; **= after gentamicin treatment; °= in oestrus; ~ =  embryo rinsed 
 
5.1.6 Recapitulating comment to 5.1. 
We were able to gain uterus milk in a sufficient concentration and amount to dectect 
progesterone, VEGF and PGF2α within the sensitivity of EIA and RIA. Oestradiol-17β 
levels were also detected via EIA, but these seem to be erratic due to the used EDTA-
stabilisator. The ballooned embryo catheter turned out to be a good instrument for gaining 
uterus milk in a not too invasive kind of way.  
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5.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic 
factors in the CL during oestrous cycle and induced luteolysis  
5.2.1 Enzyme immuno assay (EIA) of progesterone 
The progesterone level was analysed in blood plasma of five Brown swiss cows to see if 
their oestrous cycle was correctly synchronised. The progesterone level of all five cows 
was below 0.2ng/ml three days after the second PGF2α injection. 13 days after these 
injection the level of all five cows ranged between 2.79ng/ml to 4.08ng/ml indicating a 
functional CL. 
 
5.2.2 RNA quality control by the Bioanalyzer 
The RNA qualitiy of the CL samples during oestrous cylce on day 1-12 and the CL 
samples during induced luteolysis 0h, 0.5h, 2h, 4h, 12h, 24h, 48h and 64h were verified. 
The Cl oestrous cycle and CL luteolysis samples showed a good to very good RNA 
integrity and qualtity with RIN values between 10.0 to 7.5 and 9.4 to 6. respectively (tab. 
10). 
 
Group 
CL cycle 
RIN       
value 
SEM Group 
CL luteolysis 
RIN        
value 
SEM 
1-2 8.88 0.52 0h 8.46 0.47 
3-4 9.53 0.23 0.5h 7.74 0.40 
5-7 9.77 0.12 2h 8.38 0.13 
8-12 9.65 0.17 4h 8.72 0.15 
   12h 8.42 0.24 
   24h 7.98 0.06 
   48h 8.58 0.12 
   64h 8.38 0.21 
Table 10: RIN values of the CL oetrous cycle samples day 1-12 and CL induced luteolysis samples 
0h, 0.5h, 2h, 4h, 12h, 24h, 48h and 64h 
 
5.2.3 Sequencing of PCR-products 
No bovine sequences were available for MMP-19 and Smac, so that the primers were 
designed using human or mouse sequences, respectively. The bovine MMP-19 sequence 
showed 93% homology to the human sequence. The bovine Smac sequence was 87% 
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homologous to the mouse sequence and was published in the EMBL database under the 
no. AJ867847. 
 
5.2.4 Quantitative real time PCR (qPCR) 
5.2.4.1 Housekeeping genes 
5.2.4.1.1 Follicle phase and CL during oestrous cycle 
The housekeeping genes Histone, β-Actin, GAPDH and Ubiquitin were investigated in the 
follicle 20h after GnRH  for comparable reasons and during oestrous cycle in the CL. The 
relative quantitation is shown in reference to the follicle group 20h after GnRH application 
and as logarithm to the basis 2. The mRNA expression datas of Histone showed no 
significant differences between the groups. β-Actin was significantly up-regulated at days 
1-7. GAPDH reveals nearly the same expression pattern like β-Actin, except that day 1-2 
is not only significantly increased to the follicle group and day 8-12 but also to day 5-7. 
Ubiquitin was not regulated during follicle phase and CL oestrous cycle (fig. 10).  
 
Figure 10: mRNA expression data of four housekeeping genes Histone, β-Actin, GAPDH and 
Ubiquitin in follicle (20h after GnRH) and in the CL during different days of the oestrous cycle in the 
CL; data are shown as ΔCP ± SEM to the follicle group. Different superscript letters indicate 
significant differences (P < 0.05). 
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5.2.4.1.2 CL during induced luteolysis 
The housekeeping genes Histone, β-Actin, GAPDH and Ubiquitin were also investigated 
during luteolysis in the CL. The relative quantitation is shown in reference to the control 
group (day 8-12 = 0h) and as logarithm to the basis 2. The mRNA expression data of 
Histone showed slight, but significant differences from 12h after PGF2α till 64h. The β-
Actin expression increased significantly to control after 0.5h and reached the control level 
again after 12h. At 24h a siginificant up-regulation to all groups was seen, which 
decreased again to the level seen at 2h. GAPDH was not significantly regulated during 
induced luteolysis. Ubiquitin showed a significant down-regulation at 48h and 64h as 
compared to all other groups (fig. 11). 
Figure 11: mRNA expression data of four housekeeping genes Histone, β-Actin, GAPDH and 
Ubiquitin in the CL during specific hours after PGF2α injection; data are shown ΔCP ± SEM to 0h 
(control). Different superscript letters indicate significant differences (P < 0.05).
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5.2.4.2 Extracellular matrix proteases 
 
5.2.4.2.1 MMPs and TIMPs during follicle phase and CL during oestrous cycle  
The mRNA expression of MMP-1 (fig. 12), MMP-2 and MMP-14 showed no significant 
regulation during follicle phase and CL oestrous cycle. The mRNA expression of TIMP-2 
was constantly increased from 20h after GnRH till day 8-12 of the oestrous cycle in the 
CL. The follicle phase showed the lowest expression and was significant to the groups 
day 3-4, day 5-7 and day 8-12 of the oestrous cycle, while all other time points of the 
oestrous cycle were also significantly lower to day 8-12 (fig. 13). MMP-9 was significantly 
up-regulated from day 1-12 compared to 20h after. Day 8-12 was also significant higher 
than all other groups. MMP-19 also revealed significant increase from day 1-12 compared 
to 20h after GnRH with the highest expression from day 3-12. TIMP-1 showed a 
significant up-regulation from day 1-12 compared to the follicle group. (fig. 14). 
 
 
 
 
 
 
 
 
 
 
Figure 12: mRNA expression of MMP-1 in follicle group and Cl during oestrous cycle; the changes 
in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to the follicle group, where ΔCP=CPtarget - CPindex and ΔΔCP = ΔCP(goup I=follicle) - 
ΔCP(goup II-V). The statistic analysis were determined from ΔCP values (n=4-5). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). CP value of the follicle group was 28.09. 
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Figure 13: mRNA expression of MMP-2, MMP-14 and TIMP-2 in follicle group and Cl during 
oestrous cycle; the changes in mRNA expression for the different groups were calculated by 
normalisation with the Bestkeeper index and relative to the follicle group, where ΔCP=CPtarget - 
CPindex and ΔΔCP = ΔCP(goup I=follicle) - ΔCP(goup II-V). The statistic analysis were determined from ΔCP 
values (n=4-5). Results are presented as expression changes ΔΔCP ± SEM. Different superscript 
letters indicate significant differences (P < 0.05). CP values of the follicle group were 19.80, 23.45, 
17.91. 
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Figure 14: mRNA expression of MMP-9, MMP-19 and TIMP-1 in follicle group and Cl during 
oestrous cycle; the changes in mRNA expression for the different groups were calculated by 
normalisation with the Bestkeeper index and relative to the follicle group, where ΔCP=CPtarget - 
CPindex and ΔΔCP = ΔCP(goup I=follicle) - ΔCP(goup II-V). The statistic analysis were determined from ΔCP 
values (n=4-5). Results are presented as expression changes ΔΔCP ± SEM. Different superscript 
letters indicate significant differences (P < 0.05). CP values of the follicle group were 30.20, 26.00, 
16.88.  
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5.2.4.2.2 PA system during follicle phase and CL during oestrous cycle  
tPA showed no significant regulation during follicle phase and CL oestrous cycle (fig. 15). 
The mRNA expression of uPA was constantly increased from the follicle phase to day 8-
12 of the oestrous cycle. The follicle phase showed the lowest expression with significant 
differences to all days of the oestrous cycle. Day 1-2 was also significantly lower 
expressed than day 8-12. uPAR expression showed nearly the same expression pattern 
like uPA, but day 8-12 was significant lower expressed than day 5-7 (fig. 16). The mRNA 
expression of PAI-1 was significantly increased during the first seven days of the oestrous 
cycle compared to the follicle phase and day 8-12 of the oestrous cycle. PAI-2 revealed 
the same expression pattern as PAI-1, but the increase from day 1-2 to day 5-7 was much 
higher than for PAI-1 (fig. 17). 
 
 
Figure 15: mRNA expression of tPA in follicle group and Cl during oestrous cycle; the changes in 
mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to the follicle group, where ΔCP=CPtarget - CPindex and ΔΔCP =ΔCP(goup I=follicle) - 
ΔCP(goup II-V). The statistic analysis were determined from ΔCP values (n=4-5). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). CP value of the follicle group was 22.68.  
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Figure 16: mRNA expression of uPA and uPAR in follicle group and Cl during oestrous cycle; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to the follicle group, where ΔCP=CPtarget - CPindex and ΔΔCP = 
ΔCP(goup I=follicle) - ΔCP(goup II-V). The statistic analysis were determined from ΔCP values (n=4-5). 
Results are presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate 
significant differences (P < 0.05). CP values of the follicle group were 28.18 and 27.37.  
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Figure 17: mRNA expression of PAI-1 and PAI-2 in follicle group and Cl during oestrous cycle; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to the follicle group, where ΔCP=CPtarget - CPindex and ΔΔCP = 
ΔCP(goup I=follicle) - ΔCP(goup II-V). The statistic analysis were determined from ΔCP values (n=4-5). 
Results are presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate 
significant differences (P < 0.05). CP values of the follicle group were 23.90 and 29.17. 
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5.2.4.2.3 MMPs and TIMPs during induced luteolysis 
The mRNA expression during luteolysis of MMP-1 showed a highly significant 256- to 
1024-fold up-regulation beginning 2h after induction of luteolysis till 64h with the highest 
increase at 48h. (fig 18). MMP-2 showed a significant increase 48h to 64h after PGF2α. A 
significantly higher expression level to control group was seen for MMP-14 from 12h on to 
64h, with the highest expression rate between 24h to 64h. TIMP-2 showed the opposite 
expression pattern than MMP-14 with a significant down-regulation of maximal 8-fold at 
48h to 64h (fig. 19). MMP-9 was steadily significantly up-regulated from 12h till 64h with 
the highest expression at 48h. The expression of TIMP-1 was significantly increased from 
4h to 24h with a peak at 12h. MMP-19 showed an increased expression from 24h to 64h 
with a maximal up-regulation of 32-fold at 48h (fig. 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: mRNA expression of MMP-1 in the Cl during induced luteolysis; the changes in mRNA 
expression for the different groups were calculated by normalisation with the Bestkeeper index and 
relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group I=control (0h)) - ΔCP(goup II-VIII). 
The statistic analysis were determined from ΔCP values (n=5). Results are presented as 
expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P < 
0.05).  
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Figure 19: mRNA expression of MMP-2, MMP-14 and TIMP-2 in the Cl during induced 
luteolysis; the changes in mRNA expression for the different groups were calculated by 
normalisation with the Bestkeeper index and relative to control (0h), where ΔCP=CPtarget - CPindex 
and ΔΔCP=ΔCP(group I=control (0h)) - ΔCP(goup II-VII). The statistic analysis were determined from ΔCP 
values (n=5). Results are presented as expression changes ΔΔCP ± SEM. Different superscript 
letters indicate significant differences (P < 0.05). 
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Figure 20: mRNA expression of MMP-9, MMP-19 and TIMP-1 in the Cl during induced luteolysis; 
the changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
I=control (0h)) - ΔCP(goup II-VII).  The statistic analysis were determined from ΔCP values (n=5). Results 
are presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). 
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5.2.4.2.4 PA system during induced luteolysis  
During induced luteolysis tPA mRNA expression showed a significant increase of all time 
points to control group with the highest up-regulation at 2h and 24h. uPA expression was 
significantly increased from 2h to 12h followed by a further increase from 24h to 64h. 
uPAR showed a significant up-regulation from 2h till 64h, which stayed on the same 
expression level (fig. 22). PAI-1 revealed a significant rising increase from 2h to 24h, 
which decreased to a lower expression level from 48h to 64h, which was still significantly 
up-regulated to control. The expression of PAI-2 was quite similar to PAI-1 with a 
significant increase on the same level from 2h to 12h, but increase decreased already at 
24h to a lower expression level till 64h. This level was still significantly up-regulated to 
control (fig. 23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: mRNA expression of tPA in the Cl during induced luteolysis; the changes in mRNA 
expression for the different groups were calculated by normalisation with the Bestkeeper index and 
relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group I=control (0h)) - ΔCP(goup II-VIII). 
The statistic analysis were determined from ΔCP values (n=5). Results are presented as 
expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P < 
0.05). 
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Figure 22: mRNA expression of uPA and uPAR in the Cl during induced luteolysis; the changes in 
mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group I=control (0h)) - 
ΔCP(goup II-VIII). The statistic analysis were determined from ΔCP values (n=5). Results are presented 
as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P 
< 0.05). 
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Figure 23: mRNA expression of PAI-1 and PAI-2 in the Cl during induced luteolysis; the changes in 
mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to control (0h), where ΔCP=CPtarget - CPindex and =ΔCP(group I=control (0h)) - ΔCP(goup II-
VIII). The statistic analysis were determined from ΔCP values (n=5). Results are presented as 
expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P < 
0.05). 
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5.2.4.3 Monocyte chemoattractant protein-1 (MCP-1)  
5.2.4.3.1  CL during oestrous cycle 
MCP-1 mRNA expression was not regulated during oestrous cycle (fig 24). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: mRNA expression of MCP-1 in Cl during oestrous cycle; the changes in mRNA 
expression for the different groups were calculated by normalisation with the Bestkeeper index and 
relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group IV=day 8-12) - 
ΔCP(group I-III). The statistic analysis were determined from ΔCP values (n=4). Results are presented 
as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P 
< 0.05).  
ΔΔ
C
P 
1-2 3-4 5-7 8-12
0
1
2
3
4
5
6
CL days of oestrous cycle 
MCP-1 
  Results 
 85  
0h 0,5h 2h 4h 12h 24h 48h 64h
0
1
2
3
4
5
6 a
a
bb
b b
c
d
time in hours after PGF2α 
MCP-1
5.2.4.3.2 CL during induced luteolysis 
All time points after PGF2α treatment showed a significant increase of mRNA for MCP-1 
compared to control group. The first increase is seen 0.5h, which is significantly lower 
then the next increase from 2h to 12h. From 24h to 48h the expression rices again 
significantly higher than from 2h to 12h with a decline at 64h to the leve seen at 4h. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: mRNA expression of MCP-1 in the Cl during induced luteolysis; the changes in mRNA 
expression for the different groups were calculated by normalisation with the Bestkeeper index and 
relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group I=control (0h)) - ΔCP(group II-VIII). 
The statistic analysis were determined from ΔCP values (n=5). Results are presented as 
expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P < 
0.05). 
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5.2.4.4 Apoptosis 
5.2.4.4.1 Extrinsic pathway during oestrous cycle in the CL 
The mRNA expression of Fas showed no significant regulation in the CL during oestrous 
cycle (fig. 26). Fas-Ligand, TNFα and TNFR1 revealed the same expression pattern with 
a significant down-regulation from day 1 to 7 compared to day 8-12. TNFR2 on the other 
hand was significantly decreased from day 1 to 4 during oestrous cycle (fig. 26, fig. 27).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: mRNA expression of Fas and Fas-Ligand in Cl during oestrous cycle; the changes in 
mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
IV=day 8-12) - ΔCP(group I-III). The statistic analysis were determined from ΔCP values (n=4). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05).  
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Figure 27: mRNA expression of TNF-α, TNFR1 and TNFR2 in Cl during oestrous cycle; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and 
ΔΔCP=ΔCP(group IV=day 8-12) - ΔCP(group I-III). The statistic analysis were determined from ΔCP values 
(n=4). Results are presented as expression changes ΔΔCP ± SEM. Different superscript letters 
indicate significant differences (P < 0.05).  
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5.2.4.4.2 Intrinsic pathway during oestrous cycle in the CL 
The mRNA expression of p53, Bax and Smac revealed no significant regulation during 
oestrous cycle. Bcl-XL was significantly downregulated from day 1 to day 7 compared to 
the midluteal phase. The expression of Survivin was significantly increased during the first 
seven days of oestrous cycle (fig. 28, fig. 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: mRNA expression of p53 and Bax in Cl during oestrous cycle; the changes in mRNA 
expression for the different groups were calculated by normalisation with the Bestkeeper index and 
relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group IV=day 8-12) - 
ΔCP(group I-III). The statistic analysis were determined from ΔCP values (n=4). Results are presented 
as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P 
< 0.05). 
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Figure 29: mRNA expression of Bcl-XL, Smac and Survivin in Cl during oestrous cycle; the changes 
in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
IV=day 8-12) - ΔCP(group I-III). The statistic analysis were determined from ΔCP values (n=4). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05).  
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5.2.4.4.3 Caspase3, -6, -7 during oestrous cycle in the CL 
Caspase3 and caspase7 showed no regulation during oestrous cycle (fig 30). The mRNA 
expression of caspase6 was significantly down-regulated from day 1 to day 7 compared to 
the mid luteal group. The expression during the first two days was also significant lower 
than at day 5-7 (fig 31.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: mRNA expression of caspase3 and caspase6 in Cl during oestrous cycle; the changes 
in mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
IV=day 8-12) - ΔCP(group I-III).  The statistic analysis were determined from ΔCP values (n=4). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). 
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Figure 31: mRNA expression of caspase7 in Cl during oestrous cycle; the changes in mRNA 
expression for the different groups were calculated by normalisation with the Bestkeeper index and 
relative to the day 8-12 (group IV), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group IV=day 8-12) - 
ΔCP(group I-III). The statistic analysis were determined from ΔCP values (n=4). Results are presented 
as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P 
< 0.05). 
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5.2.4.4.4 Extrinsic pathway during induced luteolysis in the CL 
The expression of Fas in the CL during induced luteolysis was constantly increased from 
2h onwards till 64h. All time points were significantly up-regulated to control group. Fas-
Ligand was significantly up-regulated after 0.5h with a further significant increase to 12h 
and 24h. These increase was reduced at 48h nearly to the level of 0.5h again with a slight 
increase at 64h (fig. 32). For TNFα a significant increase of 16-fold was seen after 0.5h, 
which increased to a significant expression level of 32-fold at 2h. All other time points 
were significantly less expressed compared to 2h, but still significantly increased 
compared to control group. TNFR1 was not regulated during induced luteolysis. The 
expression of TNFR2 was significantly increased from 2h to 64h on a constant level (fig. 
33). 
 
 
 
 
 
 
 
Figure 32: mRNA expression of Fas and Fas-Ligand in the Cl during induced luteolysis; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
I=control (0h)) - ΔCP(group I-VIII), The statistic analysis were determined from ΔCP values (n=5). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05).  
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Figure 33: mRNA expression of TNFα, TNFR1 and TNFR2 in the Cl during induced luteolysis; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
I=control (0h)) - ΔCP(group I-VIII).  The statistic analysis were determined from ΔCP values (n=5). Results 
are presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). 
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5.2.4.4.5 Intrinsic pathway during induced luteolysis in the CL 
During induced luteolysis only Smac showed no significant regulation in the CL at all. The 
mRNA expression of p53 increased significantly from 24h to 64h compared to control 
group. Bax showed the same expression pattern than p53 with a significant up-regulation 
from 24h to 64h (fig. 34). In contrast to Bax, Bcl-XL revealed a significantly increased 
expression only from 48h to 64h. Survivin was significantly downregulated from 2h to 12h 
after PGF2α, with an increase to control level from 24h to 64h (fig. 35). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: mRNA expression of p53 and Bax in the Cl during induced luteolysis; the changes in 
mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group I=control (0h)) - 
ΔCP(group I-VII). The statistic analysis were determined from ΔCP values (n=5). Results are presented 
as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P 
< 0.05). 
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Figure 35: mRNA expression of Bcl-XL, Smac and Survivin in the Cl during induced luteolysis; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
I=control (0h)) - ΔCP(group I-VII). The statistic analysis were determined from ΔCP values (n=5). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). 
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5.2.4.4.6 Caspase3, -6, -7 during induced luteolysis in the CL 
Caspase3 mRNA expression during induced luteolysis showed a significant increase from 
12h to 64h with the highest expression at 64h. Caspase6 showed a rising up-regulation 
from 2h to 64h, which was significant to control group at all time points (fig. 36). The 
expression of caspase7 was significantly increased from 24h on with the highest up-
regulation of 45-fold at 64h (fig. 37). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: mRNA expression of caspase3 and caspase6 in the Cl during induced luteolysis; the 
changes in mRNA expression for the different groups were calculated by normalisation with the 
Bestkeeper index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group 
I=control (0h)) - ΔCP(group I-VIII). The statistic analysis were determined from ΔCP values (n=5). Results are 
presented as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant 
differences (P < 0.05). 
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Figure 37: mRNA expression of caspase7 in the Cl during induced luteolysis; the changes in 
mRNA expression for the different groups were calculated by normalisation with the Bestkeeper 
index and relative to control (0h), where ΔCP=CPtarget - CPindex and ΔΔCP=ΔCP(group I=control (0h)) - 
ΔCP(group I-VIII). The statistic analysis were determined from ΔCP values (n=5). Results are presented 
as expression changes ΔΔCP ± SEM. Different superscript letters indicate significant differences (P 
< 0.05). 
 
 
 
 
 
 
 
time in hours after PGF2α 
0h 2h 4h 12h 24h 48h 64h
0
1
2
3
4
5
6 a
b
cd
bc
bcdbcd
d
Caspase7
ΔΔ
C
P 
  Discussion 
 98  
6 Discussion 
6.1 Development of a method to gain uterus milk in vivo 
6.1.1 Method 
The aim of the first part of these study was to develop a method to gain uterus milk in vivo 
at specific time points during the preimplantation periode in cattle. Therefore a technique 
used for flushing embroys during embryo transfer with a specific baloon catheter for 
heifers was modified. The first concern was to evaluate the correct volume of the used 
flushing fluid. As less as possible should be used for not disturbing the development of the 
embryo till day 24 of pregnancy, but the regained volume had to be enough for the 
investigations via different biomolecular methods. Normaly flushing of embryos is made 
with 5 x 50ml flushing fluid for each uterus horn (H. Thenhumberg personal notice). As no 
flushing of the embryo should occur till day 24, the volume of the catheter was evaluated, 
which was 3ml, and it was decided to try the flushing with a total volume of 13ml per horn. 
It was possible to gain between 3ml to 13ml back, which was enough for the measurment 
of different factors, placing the catheter 1cm cranial to the bifurcatio uteri and massaging 
gently. But despite using sterile instruments and fluid, and working as clean as possible 
an infection of the uterus occurred in three heifers after the second and in five heifers after 
the third flushing. In one heifer no infection was found. The flushing fluids of all these 
heifers were contaminated with sanies. After treatment with Genta-Sleecol 5 the flushing 
fluid was clear again. One embryo was gained by chance at day 7 of gravidity, which 
showed no viability and the developing stage of day 4 of gravidity. All heifers showed 
signs of oestrus between day 17 and 24 of gravidity. Therefore the value of progesterone 
in the blood plasma for confirming the gravidity was not evaluated. For the evaluation of 
prostaglandins an EDTA-stabilisator was given to the gained flushing fluid, which was 
found by further tests to desturbe the oestradiol-17β evaluation via EIA. The first attempt 
of developing an in vivo method for gaining uterus fluid showed positive and negative 
aspects, so that further changes are necessary. The biggest problem was the infection of 
the uterus using these flushing method five times in a row at different time points during 
preimplantation, which led to a resorbtion of the embryo. To prevent these infection, just 
one flushing should be done per gravidity time point with gaining of the embryo afterwards 
for confirmation of pregnancy, so that the heifer can be inseminated again after two 
oestrous cycles. Again both horns should be flushed, whereas one sterile disposable 
catheter should be used for each horn and the flushing should be devided into two parts: 
first flushing with 13ml of sterile 0.9% NaCL for biomolecular methodes, then flushing of 
the embryo using 5 x 50ml sterile PBS buffer. With this procedure the embryo and the 
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uterus milk can be gained at the same time, which might be necessary for the 
investigation of the source of proteins found in the uterus milk. The embryo can be 
classified by the developing stage and stored in RNA-Later at –80° for further 
biomolecular investigations. The received flushing fluid should be separated in two 
aliquotes, whereas one is used for the oestradiol-17β measurement and must not contain 
EDTA-stabilisator. These two aliquotes should be centrifugated and the fluid should be 
stored seperatly at –20° from the received cell pellet. Part of the cell pellet can be used for 
the identification of the cells found in the uterus lumen and the rest stored in RNA-Later at 
–80° for further biomolecular investigations. For the evaluation of prostaglandins in the 
uterus milk it should be considered to treat the heifers with a prostaglandin synthetase 
inhibitor shortly before flushing. It was reported in pony mares that cervical stimulation 
elevates the intrauterin PGF level. This increase was inhibited by treatment with flunixin- 
meglumine before flushing (Berglund et al. 1982). 
 
6.1.2 Results 
We were able to measure progesterone, oestradiol-17β, PGF2α and VEGF in the uterus 
milk. It was seen that the concentration of the measured factors were in the detectable 
range of the used EIA and RIA. It should be kept in mind that the uterus milk was diluted 
in 13ml of flushing fluid, so that all values are higher in the undiluted uterus milk. As the 
uterus infection occurred after the second and third flushing respectively, no statistic 
evaluation was made. It was seen that progesterone ranged between <0.1 and 0.4ng/ml, 
whereas no correlation to the inflammation was found. The pattern of oestradiol-17β was 
erratic, because the oestradiol-17β levels of the flushing fluid from heifers with no infection 
till day 12 of gravidity could not be related to each other. This could be due to the fact, that 
a EDTA-stabilisator was given to the samples, which seems to influences the EIA 
measurement of oestradiol-17β (erratic higher level), which we evaluated in further tests. 
VEGF was evaluated by RIA and revealed levels between 0.08 and 2.58ng/ml, whereas 
the higher levels were seen during inflammation. The level of PGF2α showed a clear 
correlation to the infection. The differences seen between the different heifers or even 
between the two uterus horns of one animal during the first flushing might be also due to 
the different massage intensity or sensitivity of the uterus horns while flushing, which can 
induce prostaglandin secretion (Berglund et al. 1982). In general we can assume that the 
hormone levels in undiluted uterine milk are about 10-fold higher according to the diluting 
effect.  
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6.2 Expression of housekeeping genes, proteases, apoptotic and anti-apoptotic 
factors in the CL during oestrous cycle and induced luteolysis  
6.2.1 Housekeeping Genes (HKGs) 
RT-PCR specific errors in the quantification of mRNA transcript are easily generated by 
any variation in the amount of starting material between samples. These can happen 
through pipetting failures or by uncorrect photometric measurement of the total RNA 
amount per μl. The quantification errors are especially relevant when the samples have 
been obtained from different individuals like in this experiment, and can result in 
misinterpretation of the expression profiles of the target genes. Consequently, the 
question of what constitutes an appropriate standard arises (Thellin et al. 1999). The 
accepted method for minimising these errors and correcting for sample to sample 
variation is to amplify a cellular RNA that serves as an internal reference against which 
other RNA values can be normalised (Karge et al. 1998). The ideal standard should be 
expressed at a constant level among different tissues of an organism or in the same 
tissue of different individuals, at all stages of development, and should be unaffected by 
the experimental treatment. It was not possible to find such a housekeeping gene, which 
is stable expressed during oestrous cycle and induced luteolysis. Therefore we decided to 
calculate an index out of the four different housekeeping genes Histone, β-Actin, GAPDH 
and Ubiquitin using the Bestkeeper software (Pfaffl et al. 2004) and to normalise all target 
gene data with these index following the ΔΔCP method (Livak and Schmittgen 2001). 
There is evidence that the gene expression of all these four housekeeping genes changes 
during different physiological stages of the cells and that they have specific cell functions 
(Bustin 2000; Gillespie and Vousden 2003; Thellin et al. 1999; Warrington et al. 2000). 
Histones are abundant, basic, structural proteins that bind to the DNA and enable a tight 
packing of the DNA into nucleosomes. 147bp of DNA is folded over a Histone octamer 
(two molecules each of the four core Histones H2A, H2B, H3 and H4) to form a 
nucleosome. In between two nucleosomes another Histone (H1) bindes to 20bp of DNA to 
enable the spiralisation of the DNA into solenoides (Koolmann and Röhm 1998). Different 
variants were found for the four core Histones H2A, H2B, H3, H4 and for the linker 
Histone H1 (Gillespie and Vousden 2003; Pusarla and Bhargava 2005). These linker 
variant (H1.2) was found to be a pro-apoptotic factor in cells undergoing X-ray irridation 
(Konishi et al. 2003). These group showed that H1.2 has the ability to release cytochrom c 
from the mitochondria, which leads to apoptosis via the intrinsic pathway. How these 
release actually functions is not known definitively, but it seems to be a p53 dependent 
mechanism (Zong 2004). The pro-apoptotic action of H1.2 could be the reason for the 
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increase of mRNA expression of Histone from 12h to 64h shortly before the structural 
luteolysis begins. p53 shows nearly the same expression pattern like Histone, which could 
be due to its posssible regulatory action on Histone. β-Actin, a structur protein of the 
cytosceleton, is up-regulated during the first 7 days of the oestrous cycle and after 0.5h as 
well as from 24h to 64h after luteolysis. The luteal tissue of the developing CL consists of 
highly mitotic cells, mainly endothelial cells, which could explain the increase of 
expression at the early luteal stages. How β-Actin expression is regulated in apoptotic 
cells is presently not known. The work of Naora et al. (1995) indicates that β-Actin is 
differently expressed in different cells and that these expression is also dependend on the 
apoptotic stimulus. It is possible that PGF2α is responsible for the increased expression 
after 0.5h. At the time of structural luteolysis, 24h after PGF2α, apoptotic cells are found in 
the CL of marmoset monkeys (Young et al. 1998) showing the formation of apoptotic 
bodies. These formation effects the cytosceleton of the cells and is associated with the 
depolymerisation of Actin, which also plays a particular role in the formation and 
maintenance of these apoptotic bodies (Suarez-Huerta et al. 2000). These results might 
indicate the reason for the up-regulation of the β-Actin expression during structural 
luteolysis. GAPDH is an enzyme necessary for the glycolysis and gluconeogenesis. It 
shows an increased expression during the first seven days of the oestrous cycle, which 
could be due to the higher mitotic cell rate and the higher metabolic rate of these cells 
compared to the midluteal stage. It is reported that GAPDH expression is different during 
the cell cycle (Mansur et al. 1993) and that growth hormons can activate its transcription 
(Freyschuss et al. 1994). Two groups (Qi and Sit 2000b) also reported that GAPDH is up-
regulated during apoptosis and that it is regulated by p53 (Chen et al. 1999). Our data 
show that GAPDH is not regulated during luteolysis, although an increase of expression 
can be seen from 24h onwards just like the expression of p53. It might be due to the 
greater variances in the groups that no significancies were found. Ubiquitin is necessary 
for the degradation of proteins and acts as regulator of all aspects of cell biology, including 
cell division, growth, communication, movement and apoptosis (Johnson 2002; Pickart 
2001). It is reported that Ubiquitin is up-regulated during PGF2α induced luteolysis in 
marmoset monkeys (Young et al. 1998) and in sheep (Murdoch et al. 1996). This is in 
contrast to our data, which revealed a slight but significant decreased expression of 
Ubiquitin from 48h to 64h during induced luteolysis. The reason for these down-regulation 
is not know and has to be futher investigated. For the evaluation of factors in tissues 
undergoing apoptosis it seems to be necessary to normalise these datas with more than 
one HKG, because of their specific roles during apoptosis. 
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6.2.2 Extracellular matrix proteases in the CL during oestrous cycle and induced 
luteolysis 
6.2.2.1 CL during oestrous cycle 
6.2.2.1.1 Matrix metalloproteases (MMPs) 
After ovulation, the follicular tissue is reorganised as granulosa cells hypertrophy, theca 
and granulosa-cells differentiate into luteal cells, and vasculature forms in the granulosa 
luteal compartiment (Young et al. 2002). The CL is a most highly vascularised organ and 
receives the greatest rate of blood flow per unit of tissue of any organ in the body 
(Wiltbank et al. 1988). Degradation of the ECM by MMPs is required in endothelial cell 
migration, organisation and, hence, angiogenesis (McCawley and Matrisian 2000). For the 
formation of new vessels, the basement membrane of capillaries must be degraded (fig. 
38) to allow migration of endothelial cells from the theca interna compartment into the 
surrounding avascular granulosa luteal tissue. Even if the expression of MMP-1 during 
20h after GnRH and during the first seven days of oestrous cycle is not significantly 
regulated, which might be caused by a higher variance within the groups, there is 
evidence that MMP-1 is able to facilitate the in vitro migration of microvascular endothelial 
cells, and is therefore associated with advancing angiogenesis (Partridge et al. 2000). 
Although a number of studies on the regulation of in vitro endothelial MMP expression by 
angiogenic growth factors have shown an induction of MMPs. bFGF and VEGF have been 
reported to induce MMP-1 expression, whereas VEGF also increases MMP-2 expression 
(Lamoreaux et al. 1998; Sato et al. 2000; Unemori et al. 1992). As shown for the bovine 
CL (Berisha et al. 2000) VEGF is up-regulated in the first seven days of the oestrous 
cycle, while bFGF (FGF-2) increases at day 1-2 in the bovine CL (Schams et al. 1994), so 
that a regulatory effect of these growth factors on MMPs could be assumed. Not only 
MMP-1, but also MMP-2, its receptor MMP-14 and inhibitor TIMP-2 may play a critical role 
in angiogenesis. Even though no statistically significant regulation for MMP-2 and MMP-
14 could be evaluated during oestrous cycle, TIMP-2 mRNA expression was significantly 
increased during the first seven days. Our hypothesis is, that at the beginning of CL 
formation not all bindings site of MMP-14 are blocked by TIMP-2, because of its reduced 
expression compared to the mid luteal phase. This could suggest, that MMP-2 might not 
be inhibited at the beginning of vessel sprouting in the CL, but during mid luteal phase, 
when angiogenesis is completed. Our findings are in agreement with recent data 
(Goldberg et al. 1996; Smith et al. 1996; Zhang et al. 2002; Zhang et al. 2005). MMP-2, 
MMP-14 and TIMP-2 are localized in bovine luteal endothelial cells during early and mid 
cycle (Zhang et al. 2002, Zhang et al. 2003), which enables these cells to digest collagen 
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type IV, a major component of the basement membrane (Moses 1997), which has to be 
penetrated to ensure their migration. A lack of MMP-14 leads to insufficient angiogenesis 
in mice (Zhou et al. 2000) and a neutralising MMP-2 antibody could inhibit capillary tube 
formation by bovine endothelial cells, an indispendable step in angiogenesis (Zhang et al. 
2005). In ewes, administration of a MMP-2 antibody results in incomplete CL formation, 
whereby the build up of normal vasculature is blocked (Gottsch 2001). All these findings 
suggest, MMP-2 play an essential role in neovascularisation events in the developing CL. 
MMP-2, MMP-14 and TIMP-2 were also found to be expressed in large luteal cells and the 
activation of MMP-2 during CL development enables these cells to degrade the 
pericellular ECM, which is necessary to accommodate the enlargement of these cells 
during this time (Zhang et al. 2003). The same action as activated MMP-2 on basal 
membrans is thought of MMP-19, which was detected in endothelial and vascular smooth 
muscle cells (Djonov et al. 2001; Kolb et al. 1999). In the rat CL the lowest expression of 
MMP-19 mRNA was seen during day 2 to 8 of the oestrous cycle (Jo and Curry, Jr. 2004). 
TIMP-1 is able to counteract with MMP-19 (Kolb et al. 1999), which could be possible in 
the developing bovine CL to hold the action of MMP-19 in bay. MMP-9 shows an steadily 
increased expression 20h after GnRH till the mid luteal phase. This expression pattern 
could be caused by invading macrophages, which are known to produce MMP-9 (Welgus 
et al. 1990). 
 
6.2.2.1.2 Tissue inhibitors of matrix metalloproteases (TIMPs) 
The massive capability of proteases to degrade the ECM must be hold in bay by inhibitors 
like TIMPs. These inhibitory action of TIMP-1 and TIMP-2 can be assumed in the 
developing CL, where TIMP-1 is, among others, expressed in vascular smooth muscle 
cells. These cells play a critical role in vascular maturation and survival. TIMP-1 might be 
a protectiv factor for newly formed capillaries by curbing MMP-19 acitvity (Nehls et al. 
1992; Zhang et al. 2003). TIMP-1 deficient mice display reduced serum progesterone 
levels during CL development, which can be linked to its ability to regulate MMP action 
(Nothnick 2003). Additionaly to their inhibitory activities TIMP-1 and TIMP-2 stimulate the 
growth of endothelial cells and fibroblasts as well as other cell types unrelated to their 
MMP inhibitory activity (Hayakawa et al. 1992; Hayakawa et al. 1994). In the bovine, ovine 
and porcine CL TIMP-1 is expressed in large luteal cells during the oestrous cycle (Pitzel 
et al. 2000; Smith et al. 1994a; Zhang et al. 2003). These presence of TIMP-1 in 
steroidogenic cells may be associated with its ability to enhance steroid production during 
maturation of the CL, which could explain the higher mRNA expression in the first seven 
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days of CL development additionaly to its ability to inhibit MMP-19. 
 
6.2.2.1.3 Plasminogen activator system (PAs) 
Another important proteolytic system, which influences the rapid angiogenesis in the CL 
are the plasminogen activators tPA and uPA with its receptor uPAR and their inhibitors 
PAI-1 and PAI-2. Our data revealed a constant expression of tPA, which was not 
regulated during oestrous cycle, while uPA, uPAR, PAI-1 and PAI-2 levels were increased 
from 20h after GnRH onwards till the mid luteal phase, respetively till day 5-7 for PAI-1. 
Previous studies in the rat (Bacharach et al. 1992), mouse (Liu et al. 2003) and monkey 
(Liu et al. 1997) showed a distinct expression of uPA and PAI-1 in the developing CL. uPA 
was found to be expressed by endothelial cells along the route of capillary extensions, 
while PAI-1 was expressed in fibroblasts in the environments of uPA expressing capillary 
like structures. These results suggest, that PAI-1 may protect neovascularised tissues 
from excessive proteolysis (Bacharach et al. 1992; Bacharach et al. 1998). Interaction 
between uPA and its receptor appear to be mandatory for the angiogenic effect of uPA as 
was shown with monoclonal antibodies anti-uPA and anti-uPAR that blocked the 
proangiogenic effects of uPA at the endothelial cell level (Fibbi et al. 1998). In addition to 
their proteolytic impact uPA, uPAR and PAI-1 seem to play an essential role in cell 
migration. Both uPAR and PAI-1 are able to bind to vitronectin (Okumura et al. 2002), an 
adhesive glycoprotein in the ECM, which attachs cells to the ECM. uPA increases the 
affinity of uPAR to vitronectin and at the same time enables PAI-1 to compete with uPAR 
for the binding site on vitronectin. This process leads to endocytosis of the 
uPA/uPAR/PAI-1 complex and detachment of the cells from their environment, which is 
necessary for migration. It is thought that PAI-1 is only able to detach cells, if cell surface 
uPAR is increased over the engaged integrins. This hypothesis is supported by the 
observation that overexpression of uPAR in CHO cells (i.e. increased ratio of uPAR to 
integrins) led to a pronounced increase in the efficiency of PAI-1 to detach the cells from 
fibronectin (Czekay et al. 2003). A recent study (Isogai et al. 2001) revealed that 
endothelial cells escape the vitronectin rich environment of their perivascular space and 
penetrate the unvascularised and fibronectin rich stroma. In terms of these data it seems 
possible that endothelial cells in the CL expressing uPA/uPAR interact with PAI-1 
secreted from fibroblast, become detached from the ECM and are now able to migrate 
into the unvasculated stroma to form new capillaries, which is the fundamental step to 
enable the supply of luteal cells. One could assume an angiogenic effect during oestrous 
cycle due to the high expression of uPA, its receptor uPAR and PAI-1 during the time of 
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angiogenesis, which is normally completed at days 5-7 of the oestrous cycle (Berisha et 
al. 2000). Like some MMPs the PAs are induced in endothelial cells upon stimulation with 
angiogenic factors like VEGF and bFGF (Mandriota and Pepper 1997). PAI-2 shows an 
equal expression pattern like PAI-1. PAI-2 is known to be expressed by monocytes (von 
Heijne et al. 1991) and eosinophils (Swartz et al. 2004). Eosinophils seem to play an 
essential role in neovascularisation of the newly formed CL (Murdoch and Steadman 
1991). Immediately before ovulation a recruitment of eosinophils into the junction between 
the theca and granulosa cell layer of the dominant follicle takes place. Our data suggest, 
that this happens between 20h after GnRH and ovulation. After follicle ruptur high 
numbers of eosinophils gather in the former follicle antrum and are accumulating within 
and around dilated vessels in the developing bovine CL (Reibiger and Spanel-Borowski 
2000). In sheep, eosinophils are assumed to influence angiogenesis, because cortisol 
induced eosinopenia causes small-sized corpora lutea with an underdeveloped vascular 
bed and thus insufficient endocrine function (Murdoch and Steadman 1991). Having these 
circumstances in mind it seems possible that the increased mRNA expression of PAI-2 is 
due to the invasion of eosinophils into the developing CL. The role of PAI-2 in eosinophils 
is not clear thus a protective function against degradation of their cell membran through 
uPA being released from endothelial cells seems possible. 
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Figure 38: Schematic presentation of cells, which express matrix metalloproteases, their inhibitors 
and the plasminogen activator system during angiogenesis in the bovine CL. 
 
6.2.2.2 CL during induced luteolysis 
6.2.2.2.1 Matrix metalloproteases (MMPs) and tissue inhibitors of matrix 
metalloproteases (TIMPs): 
A complete different mRNA expression pattern then during the oestrous cycle was seen 
for all investigated factors during PGF2α induced luteolysis. To our astonishment MMP-1 
mRNA expression was 256-fold up-regulated within two hours after PGF2α application 
and remained constant at this high level till 64h with a peak of 1024-fold increase at 48h 
compared to control group. MMP-1 and the plasminogen activator system were the only 
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ones of the investigated factors showing an increased expression already at the beginning 
of luteolysis 0.5h and 2h after PGF2α injection, respectively. These synergistic expression 
might be linked to the infiltration of T lymphocytes and macrophages into the regression 
CL as was demonstrated in cattle (Penny et al. 1999), rat (Townson et al. 1996), pig 
(Standaert et al. 1991) and human (Brannstrom et al. 1994b). Recently, the expression of 
the monocyte chemoattractant protein-1 (MCP-1) by cells of the CL has been postulated 
as mechanism for the recruitment of monocytes/macrophages within the CL during 
luteolysis (Townson et al. 2002), which have been implicated in phagocytosis of luteal 
cells (Paavola 1979), degradation of ECM (Endo et al. 1993) and secretion of 
proinflammatory mediators (Benyo and Pate 1992; Rueda et al. 2000). Our own study of 
MCP-1 as well as results from other groups (Bowen et al. 1996; Penny et al. 1998; Tsai et 
al. 1997) shows a significant increase of mRNA expression from 0.5h until 64h after 
induction of luteolysis with a 16- to 32-fold up-regulation at 2h and 24h. MCP-1 is 
expressed in bovine endothelial cells in the CL as well as in fibroblasts, monocytes and T 
lymphocytes (Penny 2000). We hypothesise that the early increase of MCP-1 after 0.5h 
might be due to expression by endothelial cells, which recruit monocyctes from the 
circulation into the cellular compartment of the CL. Monocytes themselves express MCP-
1, which could lead to a higher expression level seen from 2h onwards after induction of 
luteolysis. They are also thought to contribute to the loss of connective tissue component 
of the ECM through production of MMP-1, MMP-9, MMP-2 (Welgus et al. 1990) and the 
plasminogen activator system (Sitrin et al. 1994) while migrating from blood vessels into 
the surrounding tissue. There is evidence that collagen I, which is a major component of 
the ECM in the CL (Luck and Zhao 1993) induces the expression of MMP-1 in 
macrophages already after 2h in culture (Shapiro S.D. et al. 1993) and that laminin up-
regulates uPA as well as MMP-9 expression after 1h and 4h, respectively (Khan and 
Falcone 1997). Collagen I is degraded primarily by MMP-1 whereas MMP-9 is involved in 
degrading collagen I that has been denatured by the initial cleavage by MMP-1 (Zhou et 
al. 2003). In context of these data the chronology of MMP-1 and MMP-9 expression during 
luteolysis could be explained.  
Considering all these data monocytes/macrophages seem likely to play an important role 
in degradating the ECM in the regressing CL through their ability to secrete different 
proteases. There is evidence that TNFα, INFγ, IL-β and GM-CSF enhance the protein 
secretion of MMP-1, MMP-9, uPA and uPAR in monocytes when they are differently 
combined among each other (Kirchheimer et al. 1988; Sitrin et al. 1994; Zhang et al. 
1998; Zhou et al. 2003). The same regulatory mechanism through inflammatory cytokines 
like TNFα, INFγ and IL-β can be hypothesised in the regressing CL. All of these cytokines 
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show an increased expression during luteolysis in cattle and are known to be produced by 
macrophages, lymphocytes, fibroblasts and endothelial cells all of them being abundant in 
the CL (Neuvians et al. 2004). Another MMP regulated by TNFα is MMP-2. Different 
groups showed in cell culture experiments that TNFα up-regulates the MMP-2 expression 
in luteal cells in porcine (Pitzel et al. 2000) and bovine (Zhang et al. 2005) species in a 
time and concentration depending manner. In bovine luteal cells mRNA expression of 
MMP-2 is significantily increased after 12h to 48h, which is in contrast to our in vivo data 
showing a significant up-regulation only at 48h and 64h after induced luteolysis. This 
could be due to lower TNFα concentration acting in the in vivo system than used in cell 
cultur. The connecting link between TNFα and MMP-2 is p53, a tumor suppressor gene, 
which expression is increased by TNFα (Bian and Sun 1997b; Gotlieb et al. 1994; Yeung 
and Lau 1998). p53 acts as a transcription factor on the promotor of MMP-2 and thereby 
increasing the MMP-2 mRNA expression (Bian and Sun 1997). We could show during 
induced luteolysis that the p53 mRNA expression pattern is identic to the MMP-2 
expression. This congruence in mRNA expression might give evidence of a connection 
between ECM degradation and apoptosis of cells, which is also necessary for the 
regression of the CL. Detachment of cells from the ECM results in apoptosis (Alexander et 
al. 1996), whereas endothelial cells expressing MMP-2 in the regressing CL (Duncan et 
al. 1998; Ricke et al. 2002b; Young et al. 2002; Zhang et al. 2005) seems to be the first 
cells to undergo separation from the ECM and apoptosis (Modlich et al. 1996). At the 
beginning of structural regression of the CL an alteration on the vascular elements, which 
includes detachment of endothelial cells from the basal membrane and occlusion of small 
blood vessels, occurs (Davis et al. 2003). MMP-2 is known to degrade basement 
membrans and is therefore necessary for detaching endothelial cells (Moses 1997). The 
activation of MMP-2 is regulated through the expression of its receptor MMP-14 and 
TIMP-2, which either enhances or suppresses the MMP-2 activation depending on the 
concentration of TIMP-2 (Curry, Jr. and Osteen 2003). At the time of structural regression 
after 12h of induced luteolysis an up-regulation of MMP-14 and simultaneous decrease of 
TIMP-2 till 64h can be seen. It might be that TIMP-2 being high expressed at the midluteal 
phase suppresses MMP-2 activation and as recently as its expression decreases an 
activation of MMP-2 can occur while structural regression. Our data concerning TIMP-2 
are in contrast to older findings (Juengel et al. 1994), who showed an up-regulation of 
TIMP-2 mRNA expression at 8h and a decrease at 48h after induced luteolysis. This could 
be due to different detection methodes. The same action as activated MMP-2 on basal 
membrans is thought for MMP-19, which was detected in endothelial and vascular smooth 
muscle cells (Djonov et al. 2001; Kolb et al. 1999). In the rat ovary the highest expression 
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of MMP-19 mRNA was localised in the regressing CL (Jo and Curry, Jr. 2004), which is in 
agreement with our mRNA expression data. TIMP-1 is able to counteract with MMP-19 
(Kolb et al. 1999), which can be assumed till 12h after induced luteolysis when TIMP-1 is 
high and MMP-19 still low expressed. MMP-19 expression starts to increase after the 
beginning of structural luteolysis, which could potentiate the degradation of laminin and 
therefore the detachment and apoptosis of endothelial cells.  
 
6.2.2.2.2 Plasminogen (PA) activator system  
The plasminogen activator system, especially uPA, uPAR and PAIs, is supposed to play a 
important role in enabling monocytes, neutrophils and activated T cells to migrate through 
basal membrans by degrading laminin (Khan and Falcone 1997). Migrating monocytes 
polarise uPAR at the leading edge focusing the chemotactic gradient and thereby binding 
uPA on their specific site of the plasma membran (Plesner et al. 1997). It has been shown 
that monocytes synthesise PAI-2, which function extracellulary to limit uPA activity and 
thus regulate the invasive capabilities of monocytes (Estreicher et al. 1990). The vast 
majority of PAI-2 synthesized by monocytes, however, remains intracellular (von Heijne et 
al. 1991). Activation of monocytes by inflammatory agents such as TNFα induces a rapid 
accumulation of high levels of PAI-2 in the cytoplasma that does not appear to be 
correlated with uPA synthesis (Vassalli et al. 1992) and may play a functional role in 
regulating apoptotic cell death in these cells (Chapman et al. 1990; Dickinson et al. 1995). 
Chapman et al. (1990) revealed that macrophages also produce PAI-1, which is mainly 
found in the extracellular space. This indicates that PAI-1 is the major extracellular PA 
inhibitor which is able to retard tPA and uPA. An increased expression of tPA was recently 
shown in monkey and rat CL during luteolysis (Liu et al. 1996; Liu et al. 2003). The source 
of tPA seem to be luteal cells (Liu et al. 2003) and macrophages (Hart et al. 1989). The 
functional role of tPA while luteolysis is not clear, but addition of exogenous tPA to 
cultured rat or monkey luteal cells significantly decreased their progesterone production 
(Feng et al. 1993; Liu et al. 1995). This suggests that tPA might be not only a molecule 
that participates in the extracellular matrix degradation during luteal tissue regression, but 
also a molecule that may have other activities to inhibit progesterone synthesis via 
possible autocrine and paracrine pathways.  
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6.2.3 Apoptosis in the CL during oestrous cycle and induced luteolysis 
6.2.3.1 CL during oestrous cycle 
6.2.3.1.1 Fas antigen (Fas) and Fas-Ligand (FasL) 
The Fas antigen is a member of the tumor necrosis factor family of cell surface receptors 
(Nagata and Golstein 1995) and engagement of Fas with its ligand induces apoptosis. 
FasL is expressed at high levels on activated T lymphocytes (Suda et al. 1993) and 
mediates apoptosis of target cells (Nagata and Golstein 1995). Expression of Fas and 
FasL mRNA has been demonstrated in CL of mice, rats and humans (Sakamaki et al. 
1997; Roughton et al. 1999; Kondo et al. 1996). Moreover, FasL has been shown to 
enhance mouse structural luteolysis in vivo (Sakamaki et al. 1997). The present study 
demonstrates that Fas mRNA expression is not regulated during the first twelve days of 
oestrous cycle as is in agreement with the data of Taniguchi et al. (2002), who found an 
up-regulation only during regression of the bovine CL. Fas is expressed on human 
granulosa cells (Quirk et al. 1995) as well as on bovine (Taniguchi et al. 2002) and mouse 
luteal cells (Quirk et al. 2000b), which became only sensible to Fas mediated apoptosis 
when treated with INFγ alone or with INFγ in combination with TNFα. These cytokines are 
expressed by activated T cells and macrophages (Pate 1995), which are located in the 
bovine CL during the whole oestrous cycle. But an activation of these cells with a greater 
increase in numbers occurs not before day 14  (Penny et al. 1999). Also progesterone and 
growth factors like insulin-like-growth-factor (IGF) suppress the up-regulation of Fas 
expression, proving an anti-apoptotic function of growth factors and progesterone 
(Kuranaga et al. 2000; Quirk et al. 2000). Our data reveal that FasL is significantly up-
regulated on day 8-12, which could be interpreted as a slight increased numbers of 
invading T cells.  
 
6.2.3.1.2 Tumor necrosis factor alpha (TNFα), TNF receptor 1 and 2 (TNFR1, TNFR2)  
The expressions of TNFα and its receptors, TNFR1 and TNFR2, show a equaly higher 
level during the midluteal phase compared to the early luteal phase in the bovine CL. 
TNFα is known to have luteotropic as well as luteolytic functions in the CL, depending on 
its concentration. A high dose of TNFα leads to a prolongation of the luteal lifespan, 
whereas a low dose induces luteolysis and shortens the oestrous cycle (Skarzynski et al. 
2003). TNFα, TNFR1 and TNFR2 are evident in the early stage CL in cows (Sakumoto et 
al. 2000; Skarzynski et al. 2003), pigs (Wuttke et al. 1997; Miyamoto et al. 2002) and 
  Discussion 
 111  
human (Vaskivuo et al. 2002). TNFα is a potent stimulator of luteal prostaglandins (PGs) 
including PGF2α and PGE2 (Benyo and Pate 1992; Sakumoto et al. 2000). Luteal PGs 
are known to stimulate progesterone secretion from bovine CL in vitro, suggesting that 
they have luteotropic abilities (Miyamoto et al. 1993). Macrophages (Zhao et al. 1998, 
Hehnke-Vagnoni et al. 1995) and endothelial cells are sources of TNFα, and these cells 
infiltrate into newly formed CL concomitant with vascular angiogenesis (Reynolds et al. 
1994). These findings could be the reason, why the mRNA expression of TNFα elevates 
during the development of the CL. Thus it could be assumed that TNFα contributes to the 
production of PGs in the early CL and may partly promote the formation of the CL. 
Additional studies in human luteinised granulosa cells support a luteotropic role of TNFα 
(Yan et al. 1993). This effect is not limited to steroidogenic cells since TNFα is capable of 
stimulating PGE2 secretion in bovine luteal endothelial cells (Okuda et al. 1999). Since 
both TNFα (Leibovich et al. 1987) and PGE2 (Schror 1985) are known to affect the 
proliferation of endothelial cells, both of these factors may have a regulatory influence on 
the proliferation of endothelial cells during the luteal development. The action of TNFα is 
mediated through its two receptors TNFR1 and TNFR2 (Okuda et al. 1999). In the bovine 
CL TNFR1 is expressed by small and large luteal cells as well as by endothelial cell. In 
these cells the expression was significantly higher as in the steroidogenic cells (Friedman 
et al. 2000). TNFR1 is increasing in the same pattern as TNFα during oestrous cycle, 
which might be due to the proliferative stage of the endothelial cells during angiogensis in 
the early CL. Our datas are in contrast to earlier findings of Sakumoto et al. (2000), who 
could show an increased expression during days 3-7 followed by a decrease at day 8-12 
to the level seen at days 1-2. A higher sensitivity of the real time PCR compared to the 
block PCR could be the reason for these differences. TNFR2 is also expressed in bovine 
endothelial cells in the CL (Okuda et al. 1999) as well as in T cells and macrophages 
(Carpentier et al. 2004; Mukhopadhyay et al. 2001). In macrophages both receptors seem 
to be required for TNFα induced proliferation (Mukhopadhyay et al. 2001). If TNFR2 is 
also needed for endothelial cell proliferation is not known. The increased expression 
during oestrous cycle could be a sign of infiltration of macrophages into the developing 
CL.  
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6.2.3.1.3 p53, Bax and Bcl-XL 
The mRNA expression of p53 and Bax showed no significant regulation during oestrous 
cycle in the bovine CL. There are no data available how p53 is regulated in other species 
during oestrous cycle. But different groups reported a regulated expression of p53 in 
bovine luteal cells, human and rat granulosa cells during apoptosis (Nakamura and 
Sakamoto 2001; Herr et al. 2004; Amsterdam et al. 2003). It seem unlikely that apoptosis 
occurs during the the first seven days of oestrous cycle being the time were massive 
formation of new capillaries occurs (Berisha et al. 2000) as well as during days 8-12, 
when the CL reaches its highest secretory abilities. bFGF seems to have a suppressive 
action on the expression of p53 in human granulosa cells. It enhances MDM2 expression, 
which blocks p53 activity (Amsterdam et al. 2003). VEGF as angiogenic factor is also 
linked with p53. Wild type p53 is able to decrease VEGF expression in human 
leiomyosarcoma cells and to inhibit angiogenesis, which is very improtant for the 
development of the CL (Zhang et al. 2000). These data could explain, why p53 is not 
regulated during oestrous cycle. p53 is associated with the mitochondrial pathway during 
apoptosis and increases the expression of Bax, an apoptotic factor of the intrinsic 
pathway, and by the other hand decreases the Bcl-2 expression, which is an anti-apoptotic 
factor that inhibits the action of Bax (Miyashita et al. 1994; Miyashita and Reed 1995). Bax 
was found to be expressed in human granulosa and theca cells, bovine luteal cells and rat 
granulosa cells (Rodger et al. 1998; Liszewska et al. 2005; Tilly et al. 1995). We showed 
that Bax is not regulated during oestrous cycle as well as its enhancer p53 in the bovine 
CL, which was also found in the human CL during early and midluteal phase (Sugino et al. 
2000). There is evidence that progesterone not only regulates Fas expression, but also 
prevents an up-regulation of Bax in bovine luteal cells during early to mid luteal phase. 
The same result is seen for PGE2, which stimulates the progesterone secretion in bovine 
CLs and so might prevent apoptosis (Liszewska et al. 2005). How progesterone regulates 
the expression of Bax is not clear, but there seems to be a possible correlation with the 
progesterone receptor (Marone et al. 1998). The opponents of Bax are either Bcl-2 or Bcl-
XL, which are forming heterodimers with Bax and preventing the activation of capsase3 
through the mitochondrial pathway (Hengartner 2000). Bcl-XL was found in rat granulosa 
cells and in the bovine corpus luteum during structural luteolysis (Tilly et al. 1995; Rueda 
et al. 1997). As for Bax, progesterone plays a regulatory role in Bcl-2 expression in bovine 
luteal cells. It increases the Bcl-2 expression and prevents apoptosis of these cells 
(Liszewska et al. 2005). We were not able to detect Bcl-2 cDNA in the bovine CL despite 
the use of serveral primer pairs, which were designed using the bovine Bcl-2 sequence 
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(acc. no. XM_612457), which was also used by Liszewska et al. (2005). The same 
experience was made by Rueda et al. (1997), who decided to use Bcl-XL instead. These 
Bcl-2 familiy member has the same anti-apoptotic functions like Bcl-2, so that a 
comparable regulation could be assumed. If progesterone up-regulates Bcl-XL in the same 
manner like Bcl-2, the increase of the Bcl-XL expression during the midluteal phase could 
be explained by a higher progesterone level compared to the early luteal phase. Other 
regulatory factors of Bcl-2 and Bcl-XL are bFGF and VEGF, which were found to increase 
the expression of these factors in endothelial cells (Pardo et al. 2002; Del Bufalo et al. 
2003). Inhibition of Bcl-XL with antisense oligonucleotides lead to an antiangiogenic effect 
with a decrease in endothelial cell proliferation (Del Bufalo et al. 2003). 
 
6.2.3.1.4 Smac and Survivin 
Pro-angiogenic factors seem to play a critical role in the regulation of not only p53, Bax 
and Bcl-XL, but also of Smac and Survivin. Angiopoietin-1 (Ang-1) promotes endothelial 
cell survival during vascular development and maintains the vascular integrity (Suri et al. 
1996; Thurston et al. 2000). Recent findings show that Ang-1 plays an important role in 
the modulaton of angiogenesis in the human and bovine CL during oestrous cycle (Wulff 
et al. 2000; Tanaka et al. 2004). It was found that Ang-1 is able to suppress the 
expression of Smac and to enhance the expression of Survivin in serum deprivated 
endothelial cells, whereas cell survival is mediated. These effects were only seen, when 
Ang-1 interacted with Tie-2 and not with integrins (Harfouche et al. 2002). Minimal 
detectable levels of Survivin are found in quiescent endothelial cells, whereas an 
abundantly expression is seen in endothelial cells of three-dimensional vascular tubes in 
vitro and in newly formed capillaries during angiogenesis in vivo. Survivin expression can 
be stimulated by VEGF (O'Connor et al. 2000) and bFGF (Tran et al. 1999), which is 
consistent with the cell cycle dependent expression of the survivin gene in G2/M phase (Li 
et al. 1998) and suggests that this pathway maintain a critical anti-apoptotic threshold at 
cell division. bFGF is not only able to increase Survivin, but also to decrease the release 
of Smac from the mitochondria of lung cancer cells (Pardo et al. 2003). Survivin regulates 
cell survival during angiogenesis either by binding to Smac, which is then not able to 
inhibit XIAP (Song et al. 2003), or by inhibiting caspase3 in a direct or indirect way 
(Johnson et al. 2002). Having this in mind it seems possible that the up-regulation of 
Survivin during the first seven days of the oestrous cycle is related to the massive 
angiogensis occuring during this time.  
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6.2.3.1.5 Caspase3, -6 and -7 
The caspases 3, -6 and -7 belong to the so called effector caspases, which are able to 
cleave specific substrates during apoptosis including poly (ADP-ribose) polymerase, DNA-
dependent protein kinase and structural proteins like actin and lamins (Rosen and 
Casciola-Rosen 1997). These caspases play an essential role in the regression of the CL 
as was seen in caspase3 deficient mice (Carambula et al. 2002). Not many data can be 
found about their expression, especially of caspase6 and -7, during oestrous cycle in 
different species. It is reported, that caspase3 protein is constantly expressed through out 
the oestrous cycle in the human CL (Vaskivuo et al. 2002). In the macacque CL 
immunohistochemistry revealed a constant expression of caspase3 during early and mid 
lutal phase with a higher expression at the onset of regression. The mRNA expression 
was not regulated during the whole menstrual cycle (Peluffo et al. 2005). This confirmes 
our data, which showed a not regulated expression of caspase3 during the first twelve 
days of the oestrous cycle. D'haeseleer et al. (2006) also found an expression of 
caspase3 in small and large luteal cells during diffurent stages of the bovine oestrous 
cycle- which were not significantly regulated. In the human CL only few cells are found to 
undergo apoptosis during early and mid luteal phase (Vaskivuo et al. 2002), which could 
be also possible for the bovine CL, so that no regulation of caspase3 and -7 can be found. 
Caspase6 is significantly up-regulated from the early to the mid luteal stage, which one 
could see as gradual progress of accumulation of mRNA for the following regression of 
the CL. Studies with non-pregnant and pregnant ewes showed, that such a accumulation 
of mRNA is not needed for caspase3 (Rueda et al. 1999b). Progesterone is thought to be 
one of the suppressors of caspase3 activation, because a specific progesterone 
antagonist increased the caspase3 mRNA level in bovine luteal cells of the mid luteal 
phase (Okuda et al. 2004). The same action on caspase3 activation has VEGF. It was 
shown that a VEGF antagonist induces apoptosis and caspase3 activation in endothelial 
cells of the CL in marmoset monkies (Fraser et al. 2005). The highest levels of VEGF 
mRNA and protein is seen during the first seven days with a decline in expression in the 
mid and late luteal stage of the bovine CL (Berisha et al. 2000). 
6.2.3.2 CL during induced luteolysis 
Structural luteolysis is a complex process that eliminates the CL from the ovary. There is 
evidence that structural luteal regression in the cattle occurs via apoptosis (Juengel et al. 
1993; Zheng et al. 1994). This has also been demonstrated in the regression CL of rabbits 
(Dharmarajan et al. 2004), sheep (Rueda et al. 1995), rats (Orlicky et al. 1992) and 
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humans (Shikone et al. 1996). Two major intracellular apoptosis signaling cascades have 
been charactarised, the extrinsic pathway via the death receptors and the intrinsic 
pathway via factors released from the mitochondria.  
 
6.2.3.2.1 Extrinsic pathway 
Apoptosis can be initiated via several cytokine receptors including the TNF superfamily 
receptors (TNFRs). TNFα is acting via TNFR1, which is expressed on steroidogenic 
(Petroff et al. 2001) and endothelial cells (Friedman et al. 2000) of the bovine CL, and 
TNFR2, which was demonstrated to be expressed on the granulosa cells of porcine 
ovaries (Nakayama et al. 2003) and bovine endothelial cells (Okuda et al. 1999). 
Cytokines, especially TNFα and INFγ, produced by immune cells, which infiltrate the CL 
during luteolysis, seem to participate in the regression of the bovine CL (Pate and Landis 
2001). The number of leukocytes (cytotoxic T cells and macrophages) increases at the 
time of luteolysis (Penny et al. 1999; Townson et al. 2002). Subluteolytic release of 
PGF2α from the uterus acts on T cells (Penny et al. 1999) and endothelial cells (Townson 
et al. 2002) to promote the monocyte chemoattractant protein-1 (MCP-1) production 
during the late luteal phase. MCP-1 is a member of the chemokine family of cytokines that 
is involved in leukocyte physiology and chemotaxis (Penny 2000). Provement that PGF2α 
is involved in the regulation of MCP-1 is given by a study in which PGF2α production was 
inhibited between day 16 and 18 (around natural time of luteolysis) of the oestrous cycle 
in cattle. No increase in MCP-1 expression or macrophage infiltration was observed in the 
animals in which luteolysis was inhibited (Penny 2000). These findings could explain the 
rapid up-regulation of MCP-1 expression seen after 0.5h of PGF2α injection. This is in 
agreement with data from Tsai et al. (1997), where MCP-1 expression was increased 1h, 
4h and 24h after PGF2α treatment in the CL of ewes. Luteal endothelial cells may express 
MCP-1 in response to a product from steroidogenic luteal cells or eosinophils (Murdoch 
1987). Reactive oxygen species are produced as an early response to PGF2α (Sawada 
and Carlson 1991) and these products have been found to stimulate MCP-1 expression in 
endothelial cells (Kilgore et al. 1997; Xu et al. 1996). In response to the MCP-1 action 
there is an influx of macrophages and cytotoxic T cells into the CL, which may also 
express MCP-1 and explain the further increase seen at 24h after PGF2α treatment. 
Macrophages and T cells secrete TNFα and INFγ (Pate and Landis 2001), which is in 
agreement with our data, where a rapid increase of TNFα can be seen from 0.5h after the 
beginning of induced luteolysis with the highest expression at 2h, which declines to a still 
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significantly increased expression level at 64h compared to control group. TNFα acts by 
binding to its two receptors TNFR1 and TNFR2, which are both expressed in bovine 
endothelial cells in the CL (Friedman et al. 2000; Okuda et al. 1999). Friedman et al. 
(2000) found that TNFR1 is higher expressed in endothelial cells than in steroidogenic 
cells and that apoptosis was seen in these cells after 6h incubation with TNFα. There is 
evidence that capillary regression and endothelial cell death is a hallmark of PGF2α 
induced luteal regression, these include studies in the pig (Bacci et al. 1996), guinea pig 
(Azmi and O'Shea 1984), sheep (Rueda et al. 1995) and human CL (Gaytan et al. 1999). 
Steroidogenic luteal cells were found to undergo apoptosis at a later stage, when a 
massive degeneration of capillaries had already occurred (Juengel et al. 1993; Bacci et al. 
1996). We found a constant, but not regulated expression of TNFR1 during induced 
luteolysis as well as a significantly increased expression of TNFR2 from 2h till 64h. It 
could be that apoptosis of endothelial cell in the CL is triggerd through the interaction of 
TNF with both receptors as it was described by Fotin-Mleczek et al. (2002). The 
prestimulation of TNFR2, compared to the expression of TNFR1, can lead to its binding of 
tumor necrosis factor receptor-associated factor-2 (TRAF2), which is a necessary factor 
for the activation of the anti-apoptotic NFκB pathway by TNFR1, and lead to apoptosis of 
endothelial cells. Pru et al. (2003) reported that TNFα mainly acts on microvascular 
endothelial cells of the bovine CL, which induces apoptosis potentiated by INFγ. It was 
shown that progesterone is able to inhibit apoptosis in endothelial and luteal cells 
(Friedman et al. 2000; Rueda et al. 2000a), suggesting that progesterone may serve as a 
regulator of luteal cell survival. The decrease of progesterone during luteolysis is initiated 
by PGF2α, which also increases the production of endothelin-1 (ET-1) (Meidan et al. 
1999) and angiotensin (Schams et al. 2003) in endothelial cells. ET-1 augments PGF2α 
induced inhibition of progesterone synthesis and then may act by stimulation of TNFα 
secretion from macrophages (Meidan et al. 1999), thereby promoting the apoptotic 
cascade in cells of the CL. TNFα may also induce a further increase of ET-1 (Woods et al. 
1999) at the time of luteolysis. If progesterone is able to regulate the TNFRs is not known 
up to date, but there is evidence that the mRNA expression of Fas, another death receptor 
belonging to the TNFR familiy, can be increased by a progesterone antagonist 
onapristone (OP) in cultured bovine luteal cells (Okuda et al. 2004). This was also found 
in rat luteal cells, where progesterone suppresses prolactin induced steroidogenic cell 
apoptosis via a reduction of the Fas expression levels (Kuranaga et al. 2000). This could 
be in agreement with our findings that the expression of Fas is steadily up-regulated from 
2h onwards till 64h. Fas induces apoptosis in luteal cells (Taniguchi et al. 2002; Kuranaga 
et al. 2000) by binding of Fas-Ligand (FasL), which is expressed on cytotoxic (CD8+) T 
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cells (Suda et al. 1993). Expression of Fas and FasL has been demonstrated in the CL of 
mice, rats and humans (Sakamaki et al. 1997; Roughton et al. 1999; Kondo et al. 1996). 
The highest protein expression of Fas was found during regression of the CL in rats 
(Roughton et al. 1999). Moreover, FasL has been shown to enhance mouse structural 
luteolysis in vivo (Sakamaki et al. 1997), while Kuranaga et al. (2000) found that FasL 
expression on immune cells are necessary to induce apoptosis in rat luteal cells. But it 
was also found that FasL alone has no cytotoxic effect on luteal cells. However, treating 
luteal cells with FasL in combination with OP resulted in killing of 55% of the cells, while 
with OP alone only 30% were killed (Okuda et al. 2004). Other cytokines may also initiate 
and escalate Fas apoptotic action in the CL. The expression of Fas mRNA was increased 
by INFγ, and TNFα augmented the stimulatory action of INFγ on Fas expression. 
Moreover, apoptotic bodies were observed in luteal cells treated by FasL in the presence 
of INFγ and/or TNFα, showing that leukocyte-derived TNFα and INFγ play important roles 
in FasL/Fas mediated luteal cell death in the bovine CL (Taniguchi et al. 2002). The 
increase of Fas seen during induced luteolysis can therefore be enabled by the decrease 
in progesterone and further elevated through the secretion of TNFα and INFγ by invading 
macrophages, whereas the increased expression of FasL might be due to the infiltration of 
the CL by cytotoxic T cells.  
 
6.2.3.2.2 Intrinsic pathway 
The intrinsic apoptotic signaling cascade is generally thought to be activated by apoptotic 
stimuli that originate within a cell in response to certain drugs, radiation or growth factors 
withdrawal and primarily cause changes in mitochondrial permeability through alterations 
in the ratio of pro- and anti-apoptotic Bcl-2 family members (Adams and Cory 1998). 
There is evidence that the activation of luteal cell death during luteolysis can be triggered 
by oxidative stress (Rueda et al. 1995a). PGF2α increases the free intracellular calcium 
concentration, activates protein kinase C and affects progesterone production by inhibiting 
cholesterol transport or 3β-hydroxysteroid dehydrogenase (3β-HSD) expression 
(Niswender et al. 1994). PGF2α also increases the production of reactive oxygen species 
(ROS) (Riley and Behrman 1991; Sawada and Carlson 1991; Aten et al. 1992; 
Shimamura et al. 1995), while progesterone inhibits ROS production (Sugino et al. 1996). 
Decreased blood flow in the CL during regression also activates a xanthine-xanthine 
oxidase system and produces ROS in the presence of oxygen (Sugino et al. 1993). The 
mononuclear phagocytes produce ROS in the CL throughout the luteal phase, but this 
production is inhibited during the mid luteal phase by high concentrations of progesterone 
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(Sugino et al. 1996). When ROS overcomes the anti-apoptotic system, nuclear 
translocation of p53 is known to be induced by H2O2 (Uberti et al. 1999) and p53 induced 
apoptosis requires the generation of ROS (Li et al. 1999). It was shown that bovine luteal 
cells treated with H2O2 underwent apoptosis with an increased mRNA expression of p53 
and Bax (Nakamura and Sakamoto 2001). This indicates that p53 and Bax are increased 
by ROS, which production is induced by PGF2α and inhibited by progesterone. It was also 
found that progesterone decreases Bax expression (Liszewska et al. 2005), which might 
not be possible during the beginning of structural luteolysis, when the progesterone level 
has declined. Our data show an increased mRNA expression of p53 and Bax from the 
beginning of the structural luteolysis at 24h to 64h after PGF2α treatment, while the anti-
apoptotic factor Bcl-XL only shows a slight increase from 48h to 64h. This up-regulation of 
p53 might be due to an increase in oxidative stress and the beginning of p53 
accumulation in the nucleus of the compromised cells (Kastan et al. 1991). The 
expression of Bax shows a higher and earlier increase then Bcl-XL, which might indicate a 
insufficient inhibition of Bax and therefore an activation of the intrinsic pathway leading to 
apoptosis of luteal cells. An up-regulation of Bax and a constant expression of Bcl-2 
mRNA and protein was found in buffalo CL 4h after PGF2α treatment (Yadav et al. 2002). 
In this study a different PGF2α analogon in a higher dose was used, which might explain 
the more rapid increase in expression. Nevertheless it was also reported that p53 and Bax 
are higher expressed in the regressing than in the bovine CL during pregnancy and that 
the level of Bcl-XL was unchanged (Rueda et al. 1997). The same was seen in the human 
CL (Sugino et al. 2000). The both opponents Smac and Survivin are expressed in the 
bovine CL during induced luteolysis, but Smac is not regulated, while Survivin shows a 
down-regulation during the first twelve hours of luteolysis. It seems that Smac as pro-
apoptotic factor might be posttranscriptionally regulated, which needs to be further 
evaluated. Survivin is only up-regulated during cell cycle, otherwise it is constantly 
expressed. The down-regulation during functional luteolysis is not explainable to date. 
 
6.2.3.2.3 Caspase3, -6 and -7: 
Both apoptotic pathways lead to the activation of certain effector caspases. The intrinsic 
pathway leads to the activation of caspase3, -6 and -7, whereas the initiator caspase9 
activates caspase3 and -7. In the extrinsic pathway the activation of caspase3 is made by 
caspase8, if it also activates caspase7 is not known. Caspase6 is activated in both 
pathways through caspase3, which is able to cleave caspase8 in positiv feedback loop. 
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These feedback is also seen for caspase3 by cleaving caspase9 (Slee et al. 1999). 
Among the 11 caspases presently known, the vast majority of data support a fundamental 
role for caspase3 in proteolytic disruption of cellular homeostasis and the ultimate 
dismantling of the cells destined for apoptosis (Nicholson et al. 1995; Casciola-Rosen et 
al. 1996; Wang et al. 1994). Caspase3 was found to be expressed in various cells in the 
ovary of different species (Carambula et al. 2002; Vaskivuo et al. 2002; Boone and Tsang 
1998; Rueda et al. 1999; Yadav et al. 2005; Peluffo et al. 2005; Johnson and Bridgham 
2000). It was found, that caspase3 mRNA expression was increased during PGF2α 
induced luteolysis in the ovine CL after 12h and that these increase was followed by a 
significant elevation of activity of caspase3. Also no changes in the mRNA expression was 
seen on day 12 or day 14 of the oestrous cycle or pregnancy. Thus, if induction of 
caspase3 is an important factor in luteolysis, changes in caspase3 mRNA level appear to 
thightly coincide with the actual initiation of luteolysis as opposed to being the result of a 
gradual process of accumulation throughout the luteal phase (Rueda et al. 1999). These 
findings are in agreement with our data, where the caspase3 mRNA expression also 
increases from 12h till 64h after PGF2α and was not regulated during oestrous cycle. This 
might indicate, that the activity of caspase3 could be equally in the cow as in the sheep 
CL during luteolysis. Yadav et al. (2005) report that caspase3 activation was highly 
increased 18h after induction of luteolysis. In the monkey CL capsase3 protein expression 
was highest during the regression phase (Peluffo et al. 2005) and caspase3 deficient mice 
show a resistant to PGF2α induced apoptosis (Carambula et al. 2003) that further 
confirms the involvement of these caspase in luteal cell apoptosis. Matikainen et al. 
(2001) showed that apoptosis in granulosa cells from caspase3 knock out mice occur later 
than in wild typ mice, which might be due to the stimulatory activation of caspase7 in the 
mitochondrial pathway. Caspase7 is later up-regulated in granulosa cells of wild type mice 
than caspase3, which could explain the later onset of apoptosis in the knock out mice. 
This might also explain the late up-regulation of caspase7 seen in the bovine CL starting 
at 24h with an immense increase of 23-fold at 64h. Not many data are available about 
caspase6 expression in ovarian cells. Only Johnson and Bridgham (2000) reported 
capsase6 mRNA and protein expression as well as enzyme activity in granulosa and 
theka cells of hen follicles. Caspase6 is activated by caspase3, both showing similar 
mRNA expression patterns during induced luteolysis in the bovine CL.  
The infiltration of macrophages and T cells seems to be a necessary step in the induced 
luteolysis of the bovine CL, because of their ability to degradate components of the ECM 
by expressing matrix metalloproteinases and the plasmingen activator system, and 
through their induction of apoptosis in endothelial and luteal cells. 
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6.2.4 Conclusion 
 
It can be ascertained by reviewing our findings and the data published by other groups 
that ECM degrading proteases play a critical role in the successful angiogenesis during 
development of the CL after ovulation. VEGF and bFGF seem to be important regulatory 
factors in these process. They are able to stimulate the expression of MMP-1, MMP-2 in 
luteal endothelial cells, which enable these cells to degrade the vascular basement 
membranes for sprouting new capillaries. MMP-19 is also expressed by these cells and 
has the same action like MMP-2 on basement membranes. The action of MMP-2 is not 
only regulated by VEGF and bFGF, but also by TIMP-2, which is lower expressed during 
angiogenesis in the CL and therefore might not block the action of MMP-2. TIMP-1 and 
TIMP-2 seem to be not only necessary for the inhibition of MMPs, but they are also able to 
enhance the proliferation of endothelial cell during angiogenesis. VEGF and bFGF also 
stimulate the expression of uPA in endothelial cells during angiogenesis. By forming a 
complex with uPAR and PAI-1 on the outer cell membrane these cells might be now able 
to detach from the vitronectin rich perivascular region and migrate towards the 
fibronection rich stroma of the CL in order to form new capillaries.  
Not only angiogenesis plays a critical role during CL formation, but also the inhibition of 
apoptotic action during vessel sprouting. Progesterone, bFGF and VEGF seem to inhibit 
an increased expression of apoptotic factors like p53 and Bax, while progesterone also 
inhibits Fas and caspase3. Addtitionally to the suppression of apoptotic factors an up-
regulation of anti-apoptotic factors like Bcl-XL. and Survivin occurs. TNFα, produced by 
invading macrophages during CL formation, acts not only as an apoptotic factor, but is 
also able to enhance the production of PGE2 in endothelial and luteal cells, which 
stimulates together with TNFα the proliferation of endothelial cells during luteal 
angiogenesis. 
 
During regression of the CL the inhibitory action of progesterone, VEGF and bFGF vanish. 
PGF2α as luteolytic agents leads to the expression of MCP-1 on luteal endothelial cells. 
Thereupon monocytes and cytotoxic T cells migrate into the regressing CL and also start 
to express MCP-1 to recruite further mononuclear cells. For these migration into the 
stroma of the CL monocytes express uPA, uPAR and PAI-2. Macrophages are necessary 
for the phagocytosis of apoptotic cells and the degradation of ECM components in the CL 
during luteolysis. They are able to express different MMPs like MMP-1, MMP-9 and MMP-
2. These MMPs degrade collagen I, the main structur collagen in the stroma of the CL, 
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which might enhance the migration abilities of these macrophages. MMP-2 is also up-
regulated in microvascular endothelial cells by TNFα, which is produced by macrophages. 
At the same time a decrease of TIMP-2 occurs, so that no inhibition of MMP-2 happens 
and a detachment of the endothelial cells from the basement membrane follows. This 
leads to apoptosis of the endothelial cells, which seem to be the first cells to undergo cell 
death during luteolysis of the CL.  
Endothelial cells express TNFR1 and TNFR2 on there surface during luteolysis, which 
leads to the activation of the extrinsic apoptotic pathwas by binding of TNFα. INFγ 
enhances these apoptotic action on endothelial cells. It seems possible that apoptosis of 
luteal cells occurs after the degradation of capillaries, which leads to an undersupply with 
oxygen and an increase of ROSs. These reactive oxygen spieces up-regulate p53 and 
Bax as apoptotic factors of the intrinsic pathway, which leads to an activation of the 
caspases and apoptosis of luteal cells. These apoptotic action is further enhanced by the 
activation of the extrinsic pathway. Luteal cells stimulated by TNFα and INFγ express Fas 
on their cell surface when the progesterone level declines. Cytotoxic T cells, which also 
migrate into the CL during luteolysis, express FasL and promote luteal cell death by 
activation the extrinsic pathway. This happens only when the progesterone level is 
decreased, which is known to happen at the end of the functional luteolysis (fig. 39). 
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Figure 39: Survey of the procedures during luteolysis of the CL concerning apoptotic factors, MMPs 
and PA system members. 
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7 Summary 
 
The study is subdivided into two different parts: the first part deals with the development of a 
method to gain uterus milk in vivo during the preimplantation periode in cattle for the investigation 
of regulatory factors. The second part investigates different proteases in bovine follicles 20 hours 
after GnRH (Gonadotropin releasing hormone) injection (shortly bevor ovulation) for comparable as 
well as in the corpus luteum (CL) during oestrous cycle and induced luteolysis. In addition apoptotic 
as well as anti-apoptotic factors were evaluated in the CL during oestrous cycle and induced 
luteolysis. 
For the development of a method for gaining uterus milk in vivo during the first 24 days of gravidity 
in cattle, nine heifers were cycle synchronised using the Ovsynch method and artificially 
inseminated. Before flushing an epiduralanaesthesia was given and both uterus horns were flushed 
with 13ml 0.9% NaCl using a balloon embryo transfer catheter at day 5, 7, 12, 17 and 24 of 
gravidity. The catheter was placed 1cm cranial to the bifurcatio uteri in both horns. It was possible 
to retrive between 3ml and 13ml of the used flushing fluid. The uterus milk from the ipsilateral horn 
was inspected for an embryo and an EDTA-stabilisator was given to the uterus milk of both horns. 
An infection of the uterus occured in three heifers after the second and in five heifers after the third 
flushing. In one heifer no infection was found. Between day 17 and day 24 all heifers showed clear 
signs of oestrus. It was possible to detect progesterone, oestradiol-17β, PGF2α and VEGF via 
enzyme immunoassay (EIA) and radio immunoassay (RIA), respectively. Because of the occurred 
infection no statistic analysis was made. But it could be seen that the level of progesterone ranged 
between <0.1 and 0.4ng/ml, whereas no correlation to the inflammation was found. The values of 
the native uterus milk should be about 10-fold higher, because of the diluting effect of the flushing 
fluid. The pattern of oestradiol-17β was erratic, because the oestradiol levels of the flushing fluid 
from heifers with no infection till day 12 of gravidity could not be related to each other. It could be 
shown in further tests that high oestradiol-17β levels were measured via EIA in 0.9% NaCl with 
EDTA-stabilisator compared to 0.9% NaCl without the stabilisator. VEGF revealed levels between 
0.08 and 2.58ng/ml, whereas the higher levels were seen during inflammation. The level of PGF2α 
showed a clear correlation to the infection. But there were also differences seen between the 
different heifers or even between the two uterus horns of one animal during the first flushing, which 
might be due to the massage of the uterus horns while flushing, which can induce prostaglandin 
secretion. The method of gaining uterus milk in vivo should be changed as follows: to prevent an 
endometritis just one flushing should be done per gravidity with gaining of the embryo, so that the 
heifer can be inseminated again after two oestrous cycle. Again both horns should be flushed, 
whereas one sterile disposable catheter should be used for each horn and the flushing should be 
devided into two parts: first flushing with 13ml of sterile 0.9% NaCL for biomolecular methodes, 
then flushing of the embryo using 5 x 50ml sterile PBS buffer. The embryo should be frozen in 
RNA-Later at -80° for further investigations. The received flushing fluid should be separated in two 
aliquotes, whereas one is used for the oestradiol-17β measurement and must not contain the 
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EDTA-stabilisator. These two aliquotes should be centrifugated and the fluid should be stored 
seperatly at –20° from the received cell pellet. Part of the cell pellet can be used for the 
identification of the cells found in the uterus lumen and the rest stored in RNA-Later at –80° for 
further biomolecular investigations. For the evaluation of prostaglandins in the uterus milk it should 
be considered to treat the heifers with a prostaglandin synthetase inhibitor shortly before flushing.  
For the investigations of different extracellular matrix proteases and apoptotic as well as anti-
apoptotic factors in bovine follicles and CL, RNA samples of a previous experiment were taken. In 
these experiment 26 cows received luteolytic dosis of a PGF2α-analogon and the CLs were 
removed by transvaginal ovaryectomy 0, 2, 4, 12, 24, 48 and 64 hours after induction of luteolysis. 
Additionally to these experiment five more cows were ovarectomised and the CLs were taken 0.5 
hours after PGF2α treatment. For the investigation during oestrous cycle CL samples were 
collected at the slaughter house. For comparable reasons also follicles 20 hours after GnRH 
injection were taken using a superovulation model. The mRNA quality was inspected using the 
Bioanalyzer and good to very good results were seen for all samples. The mRNA expression levels 
were detected using quantitativ real time PCR (Rotor-Gene with SYBR Green I). The expression 
datas were normalised with the Bestkeeper index of four housekeeping genes using the ΔΔ CP 
method. The matrix metalloproteases (MMP-1, MMP-2, MMP-9, MMP-14, MMP-19), their tissue 
inhibitors (TIMP-1, TIMP-2), the plasminogen activator (PA) system (tissue –PA (tPA), urokinase-
PA (uPA), urokinase-PA-receptor (uPAR), PA-inhibitor–1(PAI-1), PA-inhibitor-2 (PAI-2)), which are 
able degradate the extracellular matrix were investigated in follicles 20h after GnRH injection and in 
the CL during oestrous cycle and induced luteolysis. Furthermore the mRNA expression of the  
monocyte chemoattractant protein-1 (MCP-1), factors of the extrinsic apoptotic pathway (Tumor 
necrosis factor alpha (TNFα), TNF-Receptor-1 (TNFR1), TNF-Receptor-2 (TNFR2), Fas, Fas-
Ligand (FasL)) and intrinsic apoptotic pathway (p53, Bax, Bcl-XL, Smac, Survivin) as well as the 
caspses 3, -6 and 7 were evaluated in the CL during oestrous cycle and induced luteolysis. During 
the first seven days of the oestrous cycle angiogenesis plays a critical role in the development of 
the CL. Basal membranes of blood vessels have to be removed to enable endothelial cell 
migration, which is necessary for the formation of new capillaries. MMP-1, MMP-2 and MMP-14 
were not regulated, but TIMP-2, MMP-9, MMP-19 and TIMP-1 showed an increasing expression 
from 20h after GnRH till day 8-12 of the oestrous cycle in the CL. VEGF and bFGF seem to be able 
to stimulate the expression of MMP-1 and MMP-2 in luteal endothelial cells, which enable these 
cells to degrade the vascular basement membranes for sprouting new capillaries. MMP-19 is also 
expressed by these cells and has the same action like MMP-2 on basement membranes. The 
action of MMP-2 is not only regulated by VEGF and bFGF, but also by TIMP-2, which is lower 
expressed during angiogenesis in the CL and therefore might not block the action of MMP-2. TIMP-
1 and TIMP-2 seem to be not only necessary for the inhibition of MMPs, but they are also able to 
enhance the proliferation of endothelial cell during angiogenesis. VEGF and bFGF also stimulate 
the expression of uPA in endothelial cells during angiogenesis. By forming a complex with uPAR 
and PAI-1 on the outer cell membrane these cells might be now able to detach from the vitronectin 
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rich perivascular region and migrate towards the fibronection rich stroma of the CL in order to form 
new capillaries. Not only angiogenesis plays a critical role during CL formation, but also the 
inhibition of apoptotic action during vessel sprouting. Progesterone, bFGF and VEGF seem to 
inhibit an increased expression of apoptotic factors like p53 and Bax, while progesterone also 
inhibits Fas and caspase3. Addtitionally to the suppression of apoptotic factors an up-regulation of 
anti-apoptotic factors like Bcl-XL. and Survivin occurs. TNFα, produced by invading macrophages 
during CL formation, acts not only as an apoptotic factor, but is also able to enhance the production 
of PGE2 in endothelial and luteal cells, which stimulates together with TNFα the proliferation of 
endothelial cells during luteal angiogenesis.  
During induced luteolysis all investigated MMPs showed an increased expression as well as TIMP-
1. Only TIMP-2 was down-regulated till 64h after PGF2α. PGF2α as luteolytic agents leads to the 
expression of MCP-1 on luteal endothelial cells. Thereupon monocytes and cytotoxic T cells 
migrate into the regressing CL and also start to express MCP-1 to recruite further mononuclear 
cells. For these migration into the stroma of the CL monocytes express uPA, uPAR and PAI-2. 
Macrophages are necessary for the phagocytosis of apoptotic cells and the degradation of ECM 
components in the CL during luteolysis. They are able to express different MMPs like MMP-1, 
MMP-9 and MMP-2. These MMPs degrade collagen I, the main structur collagen in the stroma of 
the CL, which might enhance the migration abilities of these macrophages. MMP-2 is also up-
regulated in microvascular endothelial cells by TNFα, which is produced by macrophages. At the 
same time a down-regulation of TIMP-2 occurs, so that no inhibition of MMP-2 happens and a 
detachment of the endothelial cells from the vessel basement membrane follows. This leads to 
apoptosis of the endothelial cells, which seem to be the first cells to undergo cell death during 
luteolysis of the CL. Apoptosis seems to play an important role during luteolysis of the CL. The 
extrinsic pathway mediated by TNFα, its two receptors, Fas and FasL seem to be more important 
than the intrinsic pathway, due to the massiv up-regulation of these factors seen during induced 
luteolysis. TNFα and FasL show a high increased expression from the beginning of induced 
luteolysis onwards, which might by due to the infiltration of T cells and macrophages expressing 
these factors. Endothelial cells express TNFR1 and TNFR2 on their surface during luteolysis, 
which leads to the activation of the extrinsic apoptotic pathwas by binding of TNFα. INFγ enhances 
these apoptotic action on endothelial cells. It seems possible that apoptosis of luteal cells occurs 
after the degradation of capillaries, which leads to an undersupply with oxygen and an increase of 
ROS. These reactive oxygen spieces up-regulate p53 and Bax as apoptotic factors of the intrinsic 
pathway, which leads to an activation of the caspases and apoptosis of luteal cells during induced 
luteolysis. These apoptotic action is further enhanced by the activation of the extrinsic pathway. 
Luteal cells stimulated by TNFα and INFγ express Fas on their cell surface when the progesterone 
level declines. Cytotoxic T cells, express FasL and promote luteal cell death by activation the 
extrinsic pathway. This happens only when the progesterone level is decreased, which is known to 
happen at the end of the functional luteolysis.  
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The results of these study show that ECM degrading proteases have two different roles in the life 
span of the CL: first they enable the sprouting of capillaries during angiogenesis in the developing 
CL, but during induced luteolysis their role seems to be to degrade ECM components of the CL 
stroma, which detaches endothelial cells from vessel basement membranes. These leads together 
with the infiltration of macrophages and cytotoxic T cells to apoptosis of endothelial and luteal cells.  
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8 Zusammenfassung 
Untersuchungen zu extrazellulären Matrix Proteasen sowie apoptotischen und anti-
apoptotischen Faktoren im bovinen Corpus Luteum 
 
Die Arbeit wurde in zwei Teile unterteilt, wobei sich der erste Teil mit der Entwicklung einer 
Methode zur Gewinnung von boviner Uterus Milch in vivo während der Prä-Implantationsphase für 
die Erforschung regulativer Faktoren beschäftigt. Im zweiten Teil wurden zwei verschiedene 
Proteasesysteme zum Vergleich in Follikeln 20 Stunden nach GnRH (Gonadotropin releasing 
hormon) Applikation (kurz vor Ovulation) als auch während des Östrus Zyklus und der induzierten 
Luteolyse im bovinen Corpus Luteum (CL) untersucht. Desweiteren wurde die Expression von 
apototischen als auch anti-apoptotischen Faktoren während des Östrus Zyklus und der induzierten 
Luteolyse im bovinen CL evaluiert. 
Für die Entwicklung einer Methode zur Gewinnung von Uterus Milch in vivo während der ersten 24 
Graviditätstage im Rind wurden 9 Kalbinnen mit Hilfe des Ovsynch Verfahrens synchronisiert und 
künstlich besamt. Eine Epiduralanästhesie wurde vor Beginn der Uterusspülung gegeben und alle 
zwei Uterus Hörner wurden mit 13ml 0,9% NaCl gespült, wobei ein Embryokatheter mit Ballon 
verwendet wurde. Die Spülungen erfolgten bei allen Kalbinnen am 5., 7., 12., 17. und 24. 
Graviditätstag. Der Katheter wurde in beiden Hörnern 1cm cranial der Bifurcatio uteri placiert. Es 
konnten zwischen 3ml und 13ml Spülflüssigkeit zurückgewonnen werden. Die Uterus Milch des 
ipsilateralen Hornes wurde nach einem Embryo durchsucht und ein EDTA-Stabilisator wurde zu 
der Uterus Milch beider Hörner gegeben. Eine Infektion des Uterus trat bei drei Kalbinnen nach der 
zweiten Spülung und bei fünf Kalbinnen nach der dritten Spülung auf. Eine Kalbin zeigte keine 
Anzeichen einer Infektion. Zwischen dem 17. und 24. Trächtigkeitstag zeigten alle neuen 
Kalbinnen deutlich Anzeichen einer Brunst. Es war möglich Progesteron, Östradiol-17β, PGF2α 
und VEGF mittels Enzym Immunassay (EIA) und Radio Immunassay (RIA) in der Uterus Milch 
nachzuweisen. Wegen der Infektion des Uterus konnte keine statistische Auswertung 
vorgenommen werden. Es konnte jedoch festgestellt werden, daß sich das Progesteron Level 
zwischen <0,1 und 0,4ng/ml bewegte und keine Korrelation zur Entzündung zeigte. Durch den 
Verdünnungseffekt der Spülflüssigkeit sollten die Werte der nativen Uterus Milch um das ca. 10-
fache höher liegen. Die Werte der Östradiol-17β Expression schwankten sehr stark, was daran zu 
erkennen war, daß die Werte der Kalbinnen ohne Infektion bis zum 12. Trächtigkeitstag nicht 
miteinander in Beziehung gesetzt werden konnten. Es konnte in einer Testreihe gezeigt werden, 
das in mit EDTA-Stabilisator versetztes 0,9% NaCl hohe Östradiol-17β Werte mittels EIA im 
Vergleich zu 0,9% NaCl ohne Stabilisator messbar sind. Das Level von VEGF lag zwischen 0,08 
und 2,58ng/ml, wobei eine höhere Expression während der Infektion gemessen wurde. Der Verlauf 
der PGF2α Expression zeigte eine deutliche Korrelation zur Infektion. Allerdings zeigten sich auch 
Unterschiede zwischen einzelnen Kalbinnen und auch zwischen beiden Uterus Hörnern einer 
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Kalbin während der ersten Spülung. Dies könnte durch die unterschiedliche Massagestärke oder 
Sensitivität der Uterus Hörner während der Spülung verursacht sein, die eine Freisetzung von 
PGF2α verursachen kann. Folgende Änderungen sollten bei der Methode zur Gewinnung von 
Uterus Milch in vivo vorgenommen werden: um eine Endometritis zu verhindern, sollte nur eine 
Spülung per Gravidität durchgeführt werden, wobei auch der Embryo gewonnen werden sollte. Es 
sollten wieder alle zwei Hörner gespült werden, wobei für jedes Horn ein Katheter verwendet 
werden und sich die Spülung in zwei Abschnitte teilen sollte: zuerst sollte eine Spülung zu 
Gewinnung von Uterusmilch mit 13ml 0,9% NaCl durchgeführt werden, danach sollte der Embryo 
mit 5x50ml sterilem PBS Puffer ausgespült werden. Der gewonnene Embryo kann dann in RNA-
Later bei -80° eingeforen werden. Die gewonnene Uterus Milch sollte in zwei Aliquots unterteilt 
werden, wobei das Aliquot für die Östradiol-17β Untersuchung keinen EDTA-Stabilisator enthalten 
darf. Außerdem sollte eine Zentrifugation erfolgen, um die zellulären Bestandteile der Uterus Milch 
abzutrennen. Die verbleibende Flüssigkeit kann bei –20° aufbewahrt werden. Ein Teil der 
gewonnen Zellen kann zur Zellidentifikation herangezogen werden, der Rest sollte bei –80° für 
weitere molekular-biologische Untersuchungen aufgewahrt werden. Für die Untersuchung des 
Prostaglandin Gehaltes in der Uterus Milch, sollte eine mögliche Behandlung der Kalbinnen mit 
einem Prostaglandin Synthese Hemmer kurz vor der Spülung erwogen werden. 
Für die Untersuchung von verschiedenen extrazellulären Matrix Proteasen and apoptotischen als 
auch anti-apoptotischen Faktoren im bovinen Follikel und CL wurden RNA Proben eines 
vorhergehenden Experimentes verwendet. In diesem Experiment wurden 26 Kühe mit einer 
luteolytischen Dosis eines PGF2α-Analogs behandelt und die CLs wurden mittels transvaginaler 
Ovariektomie zu folgenden Zeitpunkten entnommen: 0, 2, 4, 12, 24, 48 und 64 Stunden (h) nach 
Induktion der Luteolyse. Zusätzlich zu diesem Experiment wurden noch weitere fünf Kühe 0,5h 
nach PGF2α Applikation ovariektomiert. Für die Untersuchungen während des Östrus Zyklus 
wurden CLs vom Schlachthof gesammelt. Aus Vergleichsgründen wurden Follikel 20 Stunden nach 
GnRH Injektion im Rahmen einer Superovulation entnommen. Die mRNA Qualität wurde mittels 
Bioanalyzer untersucht und zeigte eine gute bis sehr gute Qualität aller Proben. Die mRNA 
Expressions Level wurden mittels quantitativer real time PCR (Rotor-Gene mit SYBR Green I) 
untersucht. Die erhaltenen Expressionsdaten wurden mit dem Bestkeeper Index aus vier 
verschiedenen Housekeeping Genen normalisiert, indem die ΔΔ CP Methode verwendet wurde. Es 
wurden folgende Faktoren im Follikel 20h nach GnRH Injektion und im bovinen CL während des 
Östrus Zyklus und der induzierter Luteolyse untersucht: Matrixmetalloproteinasen (MMP-1, MMP-2, 
MMP-9, MMP-14, MMP-19), deren Gewebe Inhibitoren (TIMP-1, TIMP-2), das Plasminogen 
Aktivator (PA) System (Tissue–PA (tPA), Urokinase-PA (uPA), Urokinase-PA-Rezeptor (uPAR), 
PA-Inhibitor–1(PAI-1), PA-Inhibitor-2 (PAI-2)), welche in der Lage sind extrazelluläre Matrix (ECM) 
abzubauen. Desweiteren wurden folgende Faktoren im CL während des Östrus Zyklus und der 
induzierten Luteolyse evaluiert: Monocyte chemoattractant protein-1 (MCP-1), Faktoren des 
extrinsischen apoptotischen Weges (Tumor necrosis factor alpha (TNFα), TNF-Rezeptor-1 
(TNFR1), TNF-Rezeptor-2 (TNFR2), Fas, Fas-Ligand (FasL)) und des intrinsischen Weges (p53, 
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Bax, Bcl-XL, Smac, Survivin) als auch die Caspasen 3, -6 and 7. Während der ersten sieben Tage 
des Östrus Zyklus spielt die Angiogenese eine entscheidende Rolle in der Entwicklung des CL. 
Basal Membranen der Blutgefäße müssen durchbrochen werden, um Endothelzellen die Migration 
zu ermöglichen, welche für die Bildung neuer Kapillaren wichtig ist. MMP-1, MMP-2 und MMP-14 
waren nicht reguliert, aber TIMP-2, MMP-9, MMP-19 und TIMP-1 zeigten eine zunehmende 
Exprimierung von 20h nach GnRH Applikation bis Tag 8-12 des Östrus Zyklus im CL. VEGF und 
bFGF können eine Stimulierung der Expression von MMP-1 und MMP-2 in lutealen Endothelzellen 
bewirken. Diese Proteasen ermöglichen es diesen Zellen während der Sprossung von neuen 
Kapillaren die vaskuläre Basalmembranen zu degradieren. MMP-19 wird auch von diesen Zellen 
exprimiert und hat die gleiche Wirkung auf Basalmembranen wie MMP-2. Die Wirkung von MMP-2 
wird nicht nur von VEGF und bFGF reguliert, sondern auch von TIMP-2, welches während der 
Angiogenese im CL niedriger exprimiert wird. Dadurch könnte die MMP-2 Wirkung nicht inhibiert 
werden. TIMP-1 und TIMP-2 scheinen nicht nur für die Inhibierung der MMPs wichtig zu sein, 
sondern sie sind auch in der Lage die Proliferation von Endothelzellen während der Angiogenese 
zu stimulieren. Eine weitere Protease die von VEGF und bFGF während der Gefäßbildung 
stimuliert wird ist uPA. Dieser Faktor bildet zusammen mit uPAR und PAI-1 einen Komplex an der 
äußeren Zellmembran und ermöglicht es nun der Zelle sich von der vitronektin-reichen 
perivaskulären Region abzulösen und in das fibronektin-reiche Stroma des CL zu wandern, um 
neue Kapillaren zu bilden.  Nicht nur die Angiogenese spielt eine kritische Rolle in der Formierung 
des CL, sondern auch die Inhibierung von apoptotischen Vorgängen während der 
Blutgefäßsprossung. Progesteron, bFGF und VEGF scheinen eine erhöhte Expression von 
apoptotischen Faktoren, wie p53 und Bax, zu inhibieren. Progesteron unterdrückt außerdem noch 
die Expression von Fas und Caspase3. Zusätzlich zur Supression von apoptotischen Faktoren 
findet eine Aufregulierung von anti-apoptotischen Faktoren, wie Bcl-XL und Survivin, statt. TNFα 
wird während der Entwicklung des CL von einwandernden Makrophagen produziert und kann nicht 
nur als apoptotischer Faktor wirken, sondern erhöht auch die Produktion von PGE2 in Endothel- 
und Lutealzellen. PGE2 stimuliert zusammen mit TNFα die Proliferation von Endothelzellen 
während der lutealen Angiogenese.  
Während der induzierten Luteolyse zeigten alle untersuchten MMPs und TIMP-1 eine erhöhte 
Expression. Nur TIMP-2 wurde bis 64h nach PGF2α Injektion abreguliert. PGF2α wirkt als 
luteolytisches Agens und führt zur Expression von MCP-1 auf lutealen Endothelzellen. Daraufhin 
migrieren Monozyten und zytotoxische T-Zellen in den regressierenden CL und beginnen auch 
MCP-1 auf ihrer Oberfläche zu expremieren, welches zu weiteren Anlockung von mononukleären 
Zellen führt. Monozyten exprimieren uPA, uPAR und PAI-2, um in das Stroma des CL einwandern 
zu können. Makrophagen werden während der Luteolyse für die Phagozytose von apoptotischen 
Zellen und für die Degradierung von ECM Komponenten benötigt. Sie sind in der Lage 
verschiedene MMPs, wie MMP-1, MMP-9 und MMP-2, zu expremieren. Diese MMPs degradieren 
Kollagen I, welches den größten Teil der Strukturkollagene im CL Stroma bildet, um 
möglicherweise die Migrationsfähigkeit der Makrophagen zu erhöhen. MMP-2 wird auch durch von 
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Makrophagen produziertes TNFα in mikrovaskulären Endothelzellen aufreguliert. Zur selben Zeit 
findet eine Abregulierung von TIMP-2 statt, so dass es zu keiner Inhibierung von MMP-2 kommt 
und eine Ablösung der Endothelzellen von der Gefäßbasalmembran erfolgt. Dies führt zur 
Apoptose von diesen Zellen, welche während der Luteolyse scheinbar als erste der Apoptose 
anheimfallen. Der Zelltod scheint eine wichtige Rolle während der Luteolyse des CL zu 
übernehmen. Der extrinsische Weg, der durch TNFα, dessen beiden Rezeptoren, Fas und FasL 
vermittelt wird, scheint während der induzierten Luteolyse aufgrund der massiven Aufregulierung 
dieser Faktoren eine größere Rolle als der intrinsische Weg zu spielen. TNFα und FasL zeigen 
eine stark erhöhte Expression von Beginn der induzierten Luteolyse, welche man auf die Infiltration 
von T-Zellen und Makrophagen, die diese Faktoren expremieren, zurückführen kann. 
Endothelzellen exprimieren TNFR1 und TNFR2 auf ihrer Oberfläche während der Luteolyse. Dies 
führt durch die Bindung von TNFα zur Aktivierung des extrinsischen apoptotischen Weges. INFγ 
verstärkt diese apoptotische Wirkung auf Endothelzellen. Es scheint möglich zu sein, dass die 
Apoptose von Lutealzellen erst nach der Degradierung von Kapillaren, welche zu einer 
Unterversorgung mit Sauerstoff und der Bildung von ROS führt, stattfindet. Diese reaktiven 
Sauerstoff Radikale führen zu einer Aufregulierung von p53 und Bax als apoptotische Faktoren des 
intrinsischen Weges. Daraufhin folgt die Aktivierung der Caspasen und die Apoptose der 
Lutealzellen. Dieser apoptotische Prozess wird außerdem noch durch die Aktivierung des 
extrinsischen Weges verstärkt, wobei mit TNFα und INFγ stimulierte Lutealzellen Fas auf ihrer 
Oberfläche exprimieren sobald der Progesteronspiegel abfällt. Zytotoxische T-Zellen exprimieren 
FasL und fördern den Tod der Lutealzellen durch die Aktivierung des extrinsischen Weges. Dies 
findet allerdings nur nach Abfall des Progesteronlevels am Ende der funktionellen Luteolyse statt.  
Die Ergebnisse dieser Studie zeigen, dass ECM degradierende Proteasen verschiedene Rollen 
während der Lebensspanne des CL übernehmen: zum einen ermöglichen sie die Sprossung von 
Kapillaren während der Angiogenese im sich formierenden CL, zum anderen scheinen sie eine 
wichtige Rolle während der induzierten Luteolyse durch Degradierung von ECM Komponenten zu 
spielen. Diese Degradierung führt zur Ablösung der Endothelzellen von den vaskulären 
Basalmembranen, welches zusammen mit der Einwanderung von Makrophagen und zytotoxischen 
T-Zellen zur Apoptose von Endothel-  und Lutealzellen führt.  
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